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Abstract 
The amyloidoses are a group of debilitating disorders which include neurodegenerative 
diseases such as Alzheimer’s disease and systemic diseases such as dialysis-related amyloidosis 
(DRA). Amyloidoses are associated with the aggregation of proteins into amyloid fibrils with a 
highly organised cross-β structure. Amyloid fibrils are formed by a variety of proteins and 
peptides despite differences in sequence and native structure. Amyloid formation occurs by a 
nucleated growth mechanism and proceeds via oligomeric intermediates into mature fibrils.  
Despite intense research, the molecular mechanisms involved in disease pathogenesis remain 
unclear. This thesis discusses the mechanism by which amyloid fibrils cause cellular disruption. 
Chapter 3 describes work performed to validate the use of β2-microglobulin (β2m), the protein 
that self-associates into amyloid fibrils found in DRA deposits, as a model to study amyloidosis. 
Fragmentation of mature β2m fibrils, increased their internalisation and access to intracellular 
compartments, and were therefore used to investigate mechanisms of cellular disruption. 
Building on previous work in the laboratory showing trafficking of β2m fibrils to the lysosome, 
chapter 4 examined the effect of fragmented fibrils on lysosomal function and demonstrates 
that fragmented fibrils impair lysosome-mediated degradation of endocytosed proteins. 
Following on from this, chapter 5 discusses the effect of fragmented fibrils on membrane 
trafficking. Fragmented fibrils perturbed the trafficking of lysosomal membrane proteins and 
also reduced the trafficking of endocytosed cargo to lysosomes. This may rationalise the 
impairment in degradation of endocytosed proteins. The molecular chaperone, heat shock 
protein 70 (Hsp70) has been shown to be protective in amyloid disease. The role of Hsp70 in 
fibril-mediated cell disruption was investigated in chapter 6. Hsp70 protected fibril-treated 
cells from impairment in degradation of endocytosed protein but not from membrane 
trafficking defects. This work demonstrates that fragmented fibrils are nanoparticles which 
target lysosomes and implicates the lysosome in the pathogenesis of amyloidosis.  
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1 Introduction 
1.1 Amyloidosis 
The amyloidoses are a class of protein conformational diseases that are associated with the 
conversion of proteins/peptides from their soluble, functional forms into highly ordered β-
sheet rich aggregates, known as amyloid, that deposit as extracellular plaques or intracellular 
inclusions [1]. The amyloidoses include a variety of diseases from severe debilitating 
neurodegenerative conditions such as Alzheimer’s, Parkinson’s, Huntington’s and Creutzfeldt-
Jacob diseases; to localised non-neurodegenerative diseases such as type II diabetes and light 
chain amyloidosis; and chronic systemic diseases such as dialysis-related amyloidosis [1]. With 
5 million people currently estimated to be suffering from Alzheimer’s disease in the United 
States alone and a prediction of increased prevalence to 13.8 million by 2050, the high 
prevalence of these diseases in the population has major implications for the economic burden 
on society as the population ages [2].  
The ability to adopt the amyloid conformation is an inherent property of polypeptide chains, 
although the propensity to form such a structure can vary dramatically with sequence [3]. To 
date there are at least 30 known human extracellular fibril proteins (and 7 proteins found in 
intracellular inclusion bodies) associated with amyloidosis [4](Table 1). Interestingly, some 
organisms, including humans have been found to convert one or more of their endogenous 
proteins into amyloid fibrils that have functional, rather than disease-associated properties [1].  
Remarkably, the disease-associated amyloid proteins have no evident similarity in the amino 
acid sequence, native conformations or biological functions [1]. Amyloid diseases target a 
variety of tissues and are accompanied by a variety of pathological symptoms (Table 1). To 
highlight the consequences of amyloid formation, the neurodegenerative diseases, Alzheimer’s 
disease and Parkinson’s disease will be discussed in detail in the following section, as will the 
non-neurodegenerative disorder type II diabetes mellitus. Dialysis-related amyloidosis (DRA), 
the chronic systemic disease associated with β2-microglobulin (β2m) will also be discussed.  
Finally, examples where the amyloid structure is exploited for functional uses are briefly 
discussed.  
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Disease Aggregating protein 
or peptide 
Extracellular amyloid 
deposits/ intracellular 
inclusions 
Systemic or Organ-
specific; Involved 
organ(s) 
Alzheimer’s Disease Amyloid β peptide Extracellular amyloid 
deposits 
Organ-specific; 
Brain 
Alzheimer’s Disease Tau Intracellular inclusions Organ-specific; 
Brain 
Parkinson’s Disease α-synuclein Intracellular inclusions Organ-specific; 
Brain 
Spongiform 
encephalopathies 
Prion protein Extracellular amyloid 
deposits 
Organ-specific; 
Brain 
Huntington’s Disease Huntingtin with 
polyglutamine 
expansion 
Intracellular inclusions Organ-specific; 
Brain 
Amyloid Light-chain 
(AL) amyloidosis 
Immunoglobulin light 
chain or fragments 
Extracellular amyloid 
deposits 
Systemic 
Dialysis related 
amyloidosis 
β2-microglobulin Extracellular amyloid 
deposits 
Systemic; Joints 
Lysozyme amyloidosis Lysozyme Extracellular amyloid 
deposits 
Systemic 
Senile systemic 
amyloidosis 
Transthyretin Extracellular amyloid 
deposits 
Systemic 
Transthyretin 
amyloidosis 
Transthyretin Extracellular amyloid 
deposits 
Systemic 
Fibrinogen 
amyloidosis 
Fibrinogen α-chain Extracellular amyloid 
deposits 
Systemic 
Type II Diabetes Amylin Extracellular amyloid 
deposits 
Organ-specific; 
Pancreas (Islets of 
Langerhans) 
AA amyloidosis Serum amyloid A 
protein 
Extracellular amyloid 
deposits 
Systemic 
Medullary carcinoma 
of the thyroid 
Calcitonin Extracellular amyloid 
deposits 
Organ-specific; 
Thyroid 
Atrial amyloidosis Atrial natriuretic 
factor 
Extracellular amyloid 
deposits 
Organ-specific; 
Heart 
Cataract γ-Crystallins Extracellular amyloid 
deposits 
Organ-specific; Eye 
Table 1: Examples of amyloid diseases, their associated proteins, location of deposits and affected 
organs. Adapted from [1] and [4].  
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1.1.1 Alzheimer’s disease 
Owing to its high prevalence, Alzheimer’s disease has been well studied. Since it was first 
described in 1906, substantial progress has been made in terms of understanding the etiology 
of disease; however a cure is still unavailable [5, 6].   
Alzheimer’s disease patients experience an inevitable loss of control over thought and 
behaviour, leading to relentless cognitive decline [7]. This is accompanied with behavioural 
and psychological symptoms such as delusions, hallucinations, apathy, depression, anxiety and 
agitation; inescapably leading to a gradual loss of daily activities [7]. Accurate early diagnosis of 
Alzheimer’s disease is difficult as patients not only present with varying degrees of these 
symptoms, but these symptoms are also shared with a variety of other disorders [8]. Despite a 
strong push in biomarker discovery research, biomarkers are still insufficient for a differential 
and unambiguous diagnosis between different dementia types, and the biological tools that do 
exist are not available to clinicians as they require expert knowledge for interpretation [8].  
Alzheimer’s disease is an organ-specific neurodegenerative disease and involves two major 
protein aggregates [9]. The amyloid β (Aβ) peptide, a proteolytic cleavage product of the 
amyloid precursor protein (APP), is found in extracellular aggregates known as amyloid 
plaques [10]. The microtubule-associated protein, tau, is found in intracellular aggregates 
called neurofibrillary tangles [11]. Amyloid plaques and neurofibrillary tangles are considered 
the pathological hallmarks of Alzheimer’s disease [12](Figure 1.1).  
The normal physiological function of APP is still not fully understood, however it is thought to 
relate to cell-cell interactions and cell-substrate adhesion [13, 14]. APP is required for 
migration of neuronal precursor cells in the developing brain as well as neuronal cell migration 
in the mature brain [14, 15]. It plays a part in neuronal calcium homeostasis which is essential 
for synaptic transmission [14]. Mutations in APP and in presenilins involved in the cleavage of 
APP are linked to familial Alzheimer’s disease, implicating them in the pathogenesis of disease 
[16]. Aβ is generated by the sequential cleavage of APP by β-secretase and γ-secretase [17]. 
The size of Aβ can be 39-43 residues in length depending on the γ-secretase cleavage site. The 
longer moieties are more amyloidogenic, with Aβ1-40 and Aβ1-42 being the focus of most 
research efforts, as these peptides are found at high levels in amyloid plaques [18]. Aβ1-40 is 
thought to be less aggregation prone and less toxic than Aβ1-42, but is more prevalent than Aβ1-
42 [19]. The α-secretase mediated cleavage of APP followed by γ-secretase cleavage yields non-
amyloidogenic peptide products [17].   
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Tau is a neuronal microtubule-associated protein mainly found in axons. It interacts with 
tubulin and stimulates its assembly into microtubules stabilising their structure [20]. Tau 
modulates microtubule-dependent axonal anterograde and retrograde transport of organelles 
and biomolecules [21]. It is also involved in programmed apoptosis as tau phosphorylation 
stabilises β-catenin to halt apoptotic death [22]. Hyperphosphorylation of Tau has been 
implicated in the pathogenesis of Alzheimer’s disease, both due to loss of normal physiological 
function and enhanced aggregation propensity into neurofibrillary tangles [20]. Despite the 
prominent role of Tau in the pathogenesis of Alzheimer’s disease, research efforts have mainly 
focused on Aβ. However, it is becoming increasingly clear that Alzheimer’s disease therapies 
will have to recognise both Tau and Aβ as molecular players driving Alzheimer’s disease [20]. 
Although there have been numerous clinical trials testing drugs that either modify the disease 
or relieve symptoms, there are few current U.S. Food and Drug Administration (FDA) approved 
therapies. Approved therapies currently include acetylcholinesterase inhibitors and N-methyl-
D-aspartic acid (NMDA) receptor antagonists [6].  However, these current therapies do not 
target the underlying pathogenesis of Alzheimer’s disease, but limit disease progression after 
neuronal damage has occurred [6]. Therapeutic strategies currently in development include 
those that modulate neurotransmission; alter Tau post-translational modifications and levels 
as well as APP processing and Aβ levels; target intracellular signalling cascades, oxidative stress 
and mitochondrial damage; and modulate calcium homeostasis and inflammation (reviewed in 
[6]). 
1.1.2 Parkinson’s disease 
Parkinson’s disease is the second most common neurodegenerative disease after Alzheimer’s 
disease, affecting 1 % of the population over 65 and 5 % of the population over the age of 85 
[23, 24]. Parkinson’s disease is a chronic, slowly progressive disorder with an average life 
expectancy of about 15 years after diagnosis; however some patients live 20 years or longer 
post-diagnosis [25].  
Parkinsonism is clinically described as a syndrome comprising combinations of motor problems 
such as bradykinesia, resting tremor, rigidity, postural instability and loss of postural reflexes 
[26].  Parkinson’s disease is the major cause of parkinsonism, and it begins with parkinsonism 
usually affecting one side of the body before inevitably spreading to the other side [26]. 
Secondary symptoms include anxiety, depression, confusion, memory loss and dementia [26].  
Mutations in SNCA, the gene encoding α-synuclein, are strongly associated with familial 
Parkinson’s disease, whereas sporadic Parkinson’s disease is associated with both single 
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nucleotide polymorphisms at the SNCA locus as well as mutations not associated with familial 
Parkinson’s disease historically [25]. α-synuclein is a small, 140 residue protein, widely 
expressed throughout the nervous system and particularly enriched at presynaptic nerve 
terminals [27]. Although the precise function of α-synuclein is unknown, it is thought to be 
involved in synaptic vesicle trafficking, in particular the fast kinetics of synaptic vesicle 
endocytosis [28]. α-synuclein is thought to promote Parkinson’s disease pathogenesis via gain-
of-function mechanisms; through dominantly inherited mutations or via increased expression 
due to gene-multiplication or gene-promoter polymorphisms [25]. Mutations in the LRRK2 
gene encoding the leucine-rich repeat kinase 2 (LRRK2) protein are also associated with 
Parkinson’s disease. LRRK2 is widely expressed in both neuronal and non-neuronal tissues [25]. 
GBA, the gene encoding glucocerebrosidase, a lysosomal hydrolase, is mutated in patients with 
Gaucher’s disease. There’s a strong association between Gaucher’s disease and Parkinson’s 
disease and GBA mutations are commonly found in patients with Parkinson’s disease [25]. The 
relationship between Gaucher’s disease and Parkinson’s disease is discussed in Section 
1.5.4.2.4.  
A pathological loss in dopaminergic neurons within the substantia nigra pars compacta and the 
resultant dysfunction of the basal ganglia (responsible for the initiation and execution of 
movements) is associated with Parkinson’s disease [29]. Neuronal cell loss is accompanied with 
the accumulation of intracellular, cytoplasmic, protein-rich inclusions called Lewy bodies which 
contain numerous proteins, including the fibrillar form of α-synuclein [30](Figure 1.1). Clinical 
diagnosis of Parkinson’s disease relies on the identification of motor features associated with 
the disease as outlined above. However, non-motor symptoms such as a diminished sense of 
smell, disrupted sleep and constipation are thought to precede the diagnostic motor 
symptoms by as much as 20 years [31]. Motor symptoms of Parkinson’s disease are 
manageable with dopamine replacement therapy such as levodopa which has been widely 
used since the late 1960’s [32].  Although the therapies currently available delay disability and 
extend life expectancy, none of them are capable of significantly altering the 
neurodegenerative process and therefore targeted disease altering therapies are urgently 
needed [25].  
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Figure 1.1: Amyloid deposits in neurodegenerative diseases. Post-mortem neuropathological analysis 
of patients suffering from Alzheimer’s disease (left), Parkinson’s disease (centre) and Huntington’s 
disease (right) reveals amyloid deposits. Extracellular amyloid plaques (left, white arrows) and 
intracytoplasmic neurofibrillary tangles (left, yellow arrows) are the pathological hallmarks of 
Alzheimer’s disease. Lewy bodies (centre, white arrows) are observed in the neurons of Parkinson’s 
disease patients. Intranuclear inclusions (right, white arrows) are observed in Huntington’s disease 
patients. Adapted from [33]. 
1.1.3 Type II diabetes mellitus 
Type II diabetes is  one the most common metabolic diseases, with 346 million diabetic people 
worldwide at present, and with a doubling of diabetes-related deaths from 2009 and 2030 
predicted [34]. Secondary complications such as heart attacks, strokes, blindness and renal 
failure are attributed to type II diabetes [35]. The increasing prevalence of type II diabetes in 
modern society combined with the debilitating secondary complications demonstrates an 
urgent need for investigation into the underlying mechanisms of this devastating disease. 
The amyloidogenic protein amylin, also referred to as islet amyloid polypeptide (IAPP), is 
strongly associated with type II diabetes [36, 37]. IAPP is expressed exclusively in the 
pancreatic islet β-cells, the same cells responsible for insulin production [38]. IAPP and insulin 
are under the same regulatory elements and are co-expressed and co-secreted at a 20 to 1 
molar ratio of insulin to amylin [39, 40]. Due to their co-regulation, an increased insulin 
requirement which occurs in states of insulin resistance, will inevitably lead to increased 
production of both IAPP and insulin. As high protein concentrations can induce aggregation of 
amyloidogenic proteins, resulting in amyloid fibril formation, insulin resistance is thought to 
promote islet amyloidosis leading to apoptotic death of β-cells [41].  Whether islet amyloid 
deposition is a cause or consequence of type II diabetes has long been debated, however 
evidence from in vivo experiments using transgenic mice with the human IAPP gene 
incorporated into their chromosomal DNA indicates that IAPP is an important pathogenic 
factor in the development of type II diabetes [41, 42]. 
There are a wide variety of U.S Food and Drug Administration (FDA) approved diabetes 
therapies, however they have limited efficacy, undesirable side-effects and are associated with 
24 
 
extortionate costs [43]. Although there are several classes of new drugs in development, these 
approaches involve lowering blood glucose, enhancing insulin sensitivity and insulin release 
and do not target amyloid fibril formation [43]. Developing therapies that target amyloid fibril 
formation could circumvent β-cell loss altogether and could thus prove to be more effective in 
halting disease progression [44].  
1.1.4 Dialysis related amyloidosis 
Another well-studied amyloid disease is the chronic systemic disease, dialysis related 
amyloidosis (DRA). β2m is the all β-sheet protein that self-associates to form the amyloid fibrils 
that are found in DRA [45]. β2m forms the non-covalently bound light chain of the major 
histocompatibility complex I (MHC I) which is expressed on the surface of all nucleated cells 
[46]. The role of MHC I is to present antigenic peptides to cytotoxic T cells. These antigenic 
peptides are typically 8 – 10 residues long and generated from a cytosolic pool of proteins by 
proteasomal proteolysis [47]. These peptides are trafficked to the endoplasmic reticulum 
where they associate non-covalently with the heavy chain (α-chain) and β2m, thus forming the 
fully assembled MHC I complex which is transported to the cell surface [46]. 
Significant quantities (2.4 ± 0.7 mgkg-1day-1) of β2m are synthesised in vivo, and upon 
dissociation from the MHC I complex, β2m is dispersed in the extracellular space prior to 
transport to the kidneys via the serum [48]. In healthy individuals, the kidney eliminates β2m 
from the vasculature. This is achieved by glomerular filtration, followed by proximal tubular 
resorption and proteolytic cleavage [49]. However, efficient clearance of β2m from the blood is 
not achieved in disease states where the kidney function is reduced. This is because dialysis 
therapy, which is designed to function in the place of the kidney, does not effectively eliminate 
β2m [50].  This results in an increase of serum β2m concentration from 25 – 60 fold above 
normal levels (1.2 ± 0.6 mgl-1), depending on the residual kidney function [50]. Different types 
of dialysis procedures are able to reduce serum β2m concentrations to different extents; 
however none of them are able to efficiently remove all β2m and thus serum β2m 
concentrations remain at least 10-fold greater than in healthy individuals [51]. 
Elevated β2m concentration over many years of renal insufficiency is thought to result in the 
self-association of β2m into amyloid fibrils, which deposit mainly in osteoarticular tissues due 
to their affinity for collagen [52, 53](Figure 1.2 and Figure 1.3). The major component of DRA 
amyloid deposits is full-length β2m, however truncated and modified versions of β2m have 
been observed in ex vivo amyloid fibrils. These include, amongst others, truncation of the N-
terminal six residues to generate highly amyloidogenic ΔN6 β2m and modification of β2m with 
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advanced-glycation end-products (AGE) (reviewed in [54]). Other components of DRA deposits 
include glycosaminoglycans, proteoglycans, collagen, apoliporotein E, serum amyloid protein 
(SAP) and Cu2+ ions; these are thought to help stabilise fibril deposits and be involved in 
disease pathogenesis (reviewed in [54]). 
 Clinical symptoms usually present after 5 years of dialysis therapy; beginning with carpal 
tunnel syndrome and later progressing to chronic and destructive arthropathy, which can 
result in bone lesions and fractures as well as periarthritis in multiple joints including knee, hip, 
shoulder and ankle [55]. Currently treatment of DRA mainly focuses on the alleviation of 
symptoms such as chronic pain and inflammation [49]. Symptoms can also be alleviated by 
surgery to reduce fibril bulk thereby reducing nerve compression [54]. Kidney transplantation 
is the only curative procedure which prevents further fibril deposition but does not diminish 
existing fibril deposits [56]. Transplantation, however, is not always possible for all DRA 
patients due to limited availability of kidneys for transplant and the advanced age of patients 
[54]. Advances in dialysis membranes and filters, and incorporation of β2m adsorption columns 
in series with dialysis membranes to reduce circulating levels of β2m, may have some benefit in 
preventing DRA or alleviating symptoms, however the long term impact of these is currently 
unknown [57].  
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Figure 1.2: β2m deposits in the joints in DRA. Scintograph of patient suffering from DRA using a 
111
In-
β2m tracer. Accumulation of β2m is observed in the wrists and elbows (left), shoulders (top right) and 
knees (bottom right).  Accumulation in the liver (top right) results from uptake by the hepatic reticulo-
endothelial system and does not indicate fibril deposition. Figure from [53].  
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Figure 1.3: Model for the pathogenesis of DRA. (1) β2m dissociates from the MHC I complex found on 
the surface of nucleated cells. (2) β2m is transported in the vasculature to the kidneys. (3) In healthy 
individuals, β2m is eliminated by glomerular filtration followed by proteolytic cleavage in the proximal 
tubules. Other waste products are also eliminated by the kidneys. (4) However, in patients with renal 
failure, dialysis replaces kidney function. (5) Waste products are removed by dialysis. (6) β2m, however, 
is not removed by dialysis and plasma concentration increases 25-60 fold. (7) β2m aggregates into 
amyloid fibrils. (8). Amyloid fibrils deposit in osteoarticular tissues. Figure adapted from [54].  
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1.2 Amyloid as a functional element 
Although originally associated with disease, the amyloid structure has been employed by a 
range of organisms for functional roles. For example, by bacteria for protective and invasive 
purposes, by yeast to communicate epigenetic information and by mammals to control 
melanin biosynthesis [58]. Indeed, the amyloid fold is thought to have existed for as long as 
proteins have [59]. It therefore appears that organisms have evolved to exploit the canonical 
amyloid fold which confers proteolytic and detergent resistance, mechanical strength, self-
replicative properties and molecular memory [58, 60]. 
1.2.1 Exploitation of the mechanical strength of amyloid fibrils  
Amyloid fibrils have a high mechanical strength, with a yield-strength comparable to steel [61]. 
This mechanical strength has been exploited by bacteria such as Escherichia coli and 
Salmonella spp., via the formation of extracellular amyloid fibres known as curli [62, 63]. 
Amyloid formation is carefully controlled by two operons, the csgBAC and csgDEFG operons 
encoding 7 Csg proteins [64, 65]. CsgA, the major subunit of curli fibres is secreted to the cell 
surface before amyloid formation is catalysed by the nucleator, Csg B; thereby restricting 
amyloid formation to the extracellular milieu and preventing potential toxicity associated with 
both the intermediates formed during amyloid formation and the mature fibres [60, 65]. CsgG 
forms the outer membrane pore that facilitates secretion of CsgA and CsgB whereas CsgE and 
CsgF are chaperones that assist in secretion and attachment of curli fibres to the cell surface 
[65-68].  The role of CsgC is still unclear, however it is thought to regulate subunit secretion 
[65]. CsgD is a transcriptional regulator that positively regulates curli production [64]. Careful 
regulation of amyloid formation therefore results in the production of curli fibres at the cell 
surface which are involved in biofilm formation, host-cell adhesion and pathogenesis [58, 65].  
1.2.2  Amyloid fibrils as self-replicative transmissible elements 
Prions were initially identified as the causative agent of transmissible spongiform 
encephalopathies (TSEs) such as Creutzfeld-Jacob disease and kuru [69, 70]. Prion proteins 
usually exist in a soluble conformation but are capable of refolding and assembling into highly 
ordered, self-replicating prion polymers [71]. Although associated with disease in mammals, 
several amyloid-based prions with functional properties have been identified in unicellular 
organisms such as those formed by the proteins Sup35p and Ure2p in Saccharomyces 
cerevisiae [72-75]. Like their mammalian counterparts, prion proteins in lower eukaryotes are 
also capable of forming insoluble, self-perpetuating amyloid-like polymers both in vitro and in 
vivo [76]. Both Sup35p and Ure2p reversibly form cytoplasmic amyloid, conferring a particular 
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phenotype which is passed either vertically from mother to daughter cell during cell division or 
horizontally during mating [60, 71].  
Soluble Sup35p is a translational termination factor that ensures termination of protein 
translation at nonsense (stop) codons [73]. Aggregated Sup35p, however, prevents translation 
termination, allowing stop codon read-through. This results in the extension of the C-termini of 
proteins and thus creates phenotypic diversity [73]. Clues to the biological importance of 
Sup35p, and its associated phenotype, are provided by its conservation across a diverse array 
of Saccharomyces spp. and the positive selection of the Sup35 prion domain [77]. Yeast 
populations with the aggregated form of Sup35p carry certain growth advantages [73]. Ure2p 
is another yeast prion protein, found in Saccharomyces cerevisiae. Soluble Ure2p controls 
nitrogen catabolism through its repressive action on the transcription factor, Gln3. Gln3 
regulates genes required for the uptake of poor nitrogen sources. Aggregated Ure2p is unable 
to repress the activation of Gln3, thereby making it constitutively active and allowing the 
organism to grow in nitrogen poor conditions [78]. Like Sup35p, Ure2p also confers growth 
advantages which are epigenetically heritable [60]. 
1.2.3 Functional amyloid fibrils in mammalian systems  
Examples of functional amyloid have also been identified in mammalian systems [79]. For 
example, amyloid formation plays a functional role in the biosynthesis of melanin in lysosome 
related organelles called melanosomes, in melanocytes found in skin [80]. The protein Pmel17 
forms the amyloid fibres found in melanosomes [81]. Full-length Pmel17 is a transmembrane 
protein which is proteolytically degraded into two subunits, a transmembrane fragment (Mβ) 
and a luminal fragment (Mα) [82]. Mα rapidly self-assembles into amyloid fibres which catalyse 
melanin formation by providing a scaffold. The scaffold acts as a template for the 
polymerisation of highly reactive melanin precursors [81]. Mα amyloid fibres, by sequestering 
toxic melanin precursors, are thought to reduce the toxicity associated with melanin synthesis 
[60, 81]. Mα amyloid formation is carefully controlled by the requirement of the cleavage of 
the full length protein prior to amyloid formation in the melanosome thus protecting cellular 
compartments such as the ER and Golgi  [60, 81]. This, along with the rapid rate of fibril 
formation is thought to minimise toxicity associated with amyloidogenesis [81]. 
Another example of functional amyloid in mammals is as a natural store for peptide hormones 
in pituitary secretory granules [83]. In a particular study, out of a total of 42 tested, 31 protein 
and peptide hormones found in secretory granules of the endocrine system were shown to 
form amyloid fibrils in vitro [83]. These in vitro-formed amyloid fibrils were shown to release 
functional monomer when the pH was increased from secretory granule pH to that 
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encountered upon secretion [83]. Furthermore, secretory granules containing amyloid-like 
material were identified in a mouse pituitary tumour neuroendocrine cell line as well as 
primary mouse and rat pituitary tissue. The amyloid-like material was shown to contain 
hormones such as adrenocorticotropic hormone, β-endorphin, prolactin and growth hormone 
[83]. Amyloid formation is thus proposed as a method of sorting protein and peptide 
hormones into secretory granule cores, and concentrating hormones to the highest density 
possible thus separating them from non-aggregation prone secretory proteins [83]. Toxicity 
associated with such a storage tactic is thought to be contained by storage in membrane 
bound granules and via careful regulation of amyloid formation [83]. 
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1.3 Amyloid 
The term ‘amyloid’ was first coined by Rudolph Virkchow in 1854 to describe the deposits in 
human tissue of protein that had starch-like tinctorial properties (reviewed in [84]). The 
definition of amyloid has since been adapted to describe highly ordered, insoluble, protein 
assemblies which are β-sheet rich and are characterised by their specific binding to dyes such 
as Congo Red and Thioflavin T as well as their characteristic X-ray diffraction patterns [1, 84-
88]. Rather than being a rare phenomenon associated with a few diseases, the amyloid state is 
now recognised as being a well-defined structural conformation and is an alternative to the 
native state which can be adopted, in principle, by all polypeptide sequences [1, 79, 89, 90].  
1.3.1 Structure of amyloid fibrils 
Amyloid fibrils formed from different amino acid sequences share a striking resemblance at a 
nanometre scale [1, 88]. When observed by transmission electron microscopy (TEM) or atomic 
force microscopy (AFM), amyloid fibrils appear as long, unbranched, polymeric assemblies 
often a few microns in length [1, 79]. Fibrils usually consist of a number (2-6) of 
protofilaments, individually about 2-5 nm in diameter, which either twist together to form 
rope-like fibres typically 7-13 nm wide; or associate laterally to form long ribbons 
approximately 2-5 nm thick and up to 30 nm wide [1, 91-94] (Figure 1.4).  
There are subtle differences in fibril structures formed from different precursor proteins and 
peptides due to the influence of side chains [95, 96]. Nevertheless, the core structure is 
remarkably similar in all fibrils, consisting of parallel or anti-parallel β sheets propagating along 
the fibril with β-strands perpendicular to the fibril axis. This gives rise to a cross-β arrangement 
with a distinctive and characteristic ‘cross-β’ X-ray diffraction pattern [88, 97] (Figure 1.5). This 
pattern shows an intense reflection at 4.7 - 4.8 Å in the meridional direction and a broader 
reflection at 8 - 10 Å in the equatorial direction indicating a spacing of 4.7 – 4.8 Å between β-
strands within β-sheets and 8 - 10 Å between β-sheets [88, 97]. 
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Figure 1.4: Electron micrographs showing different fibril morphologies. Negatively stained amyloid 
fibrils assembled from amyloidogenic peptides display different morphologies such as twisted ribbons, 
tapes, robes and tubes when analysed by electron microscopy. Adapted from [98]. 
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Figure 1.5: Amyloid fibrils have a cross-β architecture. Aligned islet amyloid polypeptide (IAPP) fibrils 
have been shown to display a characteristic cross-β diffraction pattern (left) with reflections (single 
headed white arrows) at 4.7 Å in the meridional direction and 10 Å in the equatorial direction [99]. The 
direction of the fibril axis is shown by single headed black arrows. A representation of the generic cross-
β structure inferred from the X-ray diffraction pattern is shown (right) with the spacing between β-
strands determined by the meridional reflections and that between β-sheets determined by equatorial 
reflections. Adapted from [99] and [100].  
A detailed view of the molecular structure of amyloid fibrils has been made possible by 
developments in cryo-electron microscopy and solid-state nuclear magnetic resonance 
(ssNMR) spectroscopy [79, 101] (Figure 1.6). X-ray microcrystallography of amyloid fibril 
segments formed from small peptides provides further evidence for a common core structure, 
but also demonstrates how side-chains interlock between β-sheets [95]. This compatibility in 
side-chain interactions within β-sheets has also been shown by high resolution ssNMR studies 
as well as by X-ray fibre diffraction [102-107]. A combination of experimental techniques 
spanning five orders of magnitude in length was used to demonstrate at a molecular level the 
hierarchical assembly of a small peptide into mature polymorphic fibrils via protofilaments and 
filaments [100]. These studies support earlier work demonstrating a common core structure 
which can be attributed to the polypeptide backbone as well as explain the packing of side-
chains and the basis of fibril polymorphism. An understanding of amyloid fibrils at the 
molecular level, and the species formed en route to mature fibrils, will undoubtedly aid the 
development of effective compounds that impede or accelerate fibril formation which could 
inform future targeted therapies. 
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Figure 1.6: Amyloid fibril structure at atomic resolution. The structure of a polymorph of a mature fibril 
from a transthyretin fragment has been determined at atomic resolution [100]. Transmission electron 
microscopy (TEM) imaging (top left) in combination with cryo-electron microscopy allowed visualisation 
of fibril structure by cryo-electron microscopy reconstruction (top right). Cryo-electron microscopy 
imaging in combination with ssNMR analysis allowed the determination of an atomic level structure 
(bottom), demonstrating the hierarchical organisation of a mature fibril. Three individual filaments twist 
together to form the mature fibril. The filaments are composed of pairs of individual protofilaments 
which in turn are made up of pairs of β-sheets. β-sheets are shown in a ribbon representation and 
oxygen, carbon and nitrogen atoms are shown in red, grey and blue respectively. Figure adapted from 
[100]. 
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1.3.2 Amyloid fibril formation pathway 
Characterisation of the fibril formation process is challenging due to the heterogeneous nature 
of intermediate species formed en route to mature fibril formation, and the existence of 
polymorphisms in amyloid fibrils formed from the same starting protein [96, 108]. There is a 
potential discrepancy between in vitro studies performed on purified protein solutions, which 
are achievable on the timescale of days, compared to the crowded microenvironment in which 
fibrillation occurs in vivo over the course of decades [108]. Nevertheless, advances have been 
made in understanding the oligomerisation process with the aid of in vitro macroscopic 
techniques such as the use of amyloid-dyes for example, Congo Red and Thioflavin T, to follow 
the kinetics of fibril formation [86, 87]. As amyloid structures typically have a high β-sheet 
content, the use of spectroscopic techniques such as Circular Dichroism (CD) and Fourier 
Transform Infrared Spectroscopy (FTIR) has been exploited to monitor progression of fibril 
formation over time [86]. Despite the limited resolution of these techniques, a picture of the 
fibril formation pathway is beginning to form and is continuously being refined by the 
development of single molecule methods, advances in theoretical studies and the 
development of imaging techniques in living systems [79, 108-113]. 
Amyloid fibril growth is a hierarchical process, starting with monomers which are unfolded or 
have aggregation prone segments exposed [114, 115]. These monomers coalesce in solution 
resulting in the formation of short-lived, unstable, globular or tubular entities referred to as 
oligomers [115-117]. Oligomers are heterogeneous in size and conformational properties and 
have been described as frequently associating into beaded chains, curvy protofibrils, large 
enclosed rings and/or ribbons, collectively termed protofibrils [115, 117-120]. 
The oligomerisation process involves the formation of thermodynamically stable intermediates 
en route to mature fibril formation, which have been visualised by transmission electron 
microscopy and atomic force microscopy [121, 122]. Fibril formation proceeds via a rate-
dependent formation of a nucleus, with the lag-phase thought to involve the conversion of 
monomers into a nucleus, which is followed by a rapid elongation phase as individual 
monomers add to fibril ends [109, 110, 123]. Monomers adopt the cross-β conformation upon 
addition to fibril ends, and fibrils thus function as templates [114]. Indeed, the addition of pre-
formed fibrils as seeds significantly reduces and ultimately eliminates the lag phase [124]. 
When the amount of protein is limited, as is the case of in vitro fibril kinetics studies, the 
growth phase is followed by a plateau phase where the rate of reaction diminishes due to the 
depletion of monomer species (Figure 1.7).  
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Some protofibrils can be off-pathway intermediates, whereas others which are on-pathway 
intermediates are precursors of longer ribbons or protofilaments that ultimately assemble into 
mature fibrils [120]. Oligomeric species are thought to contain more exposed hydrophobic 
clusters than the native monomers or mature fibrils [117, 125]. A11 is a conformation-specific 
antibody which binds to a shared epitope found on soluble oligomers independent of protein 
sequence [18]. A11 does not bind to monomer or fibrils. OC is another antibody which also 
binds in a sequence-independent fashion; however it recognises a conformation found on both 
fibrils and soluble oligomers [126]. These oligomers are characterised as fibrillar oligomers as 
they are distinct from the pre-fibrillar oligomers recognised by A11. The aggregation pathway 
can therefore be simplified using conformation-dependent antibodies [127] (Figure 1.7). 
Monomer can follow one of two pathways depending on the conformation it adopts. One 
pathway involves the formation of pre-fibrillar oligomers recognised by A11 but not by OC. 
These pre-fibrillar oligomers may undergo a concerted conformation change ‘en bloc’ to form 
fibrils [127]. An alternate pathway involves the aggregation of amyloidogenic monomer to 
fibrillar oligomers, recognised by OC but not A11, which may represent nuclei or seeds that 
elongate by monomer addition to their ends [127]. Pre-fibrillar oligomers may also form off-
pathway intermediates that do not mature into fibrils. The simplified model (Figure 1.7) 
describes two of an infinite number of possible pathways of amyloid formation.  
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Figure 1.7: Schematic representation of two possible amyloid formation pathways: Monomer can 
either coalesce in solution to form fibrillar oligomers (OC-positive, A11-negative), or form pre-fibrillar 
oligomers (A11-positive, OC-negative). Fibrillar oligomers mature into amyloid fibrils by monomer 
addition (top pathway). Pre-fibrillar oligomers may undergo a concerted conformation change to form 
mature fibrils (bottom pathway) or form off-pathway intermediates (not shown in this schematic).  
Figure adapted from [127].  
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1.4 Association of amyloid with cell death and disease progression 
The close association between the appearance of amyloid deposits and the beginning of 
pathological events in Alzheimer’s disease has been established for many years [12]. The 
amyloid cascade hypothesis, put forward over 20 years ago, was based on neuropathological, 
genetic and biophysical information and implicates the deposition of Aβ as the primary insult 
driving pathogenesis in Alzheimer’s disease [12]. This hypothesis has evolved over the years to 
account for the role of soluble Aβ species due to the lack of quantitative correlation between 
the number of insoluble amyloid deposits and the extent of cognitive decline [128]. The 
hypothesis has also been generalised over the years to include other amyloidoses as it has 
become clear that they are all characterised by amyloid protein aggregates, although of 
varying composition [129](Figure 1.1).  Despite this long standing association, the specific 
mechanisms underlying pathogenesis remain unclear [79].  
Originally, the observation of fibrillar deposits in the organs of patients suffering from 
amyloidosis led to the postulation that these deposits where the causative agents of disease 
[12]. Further evidence for this postulation came from the toxicity of amyloid fibrils assembled 
from Aβ1-42, to cultured neuronal cells [130]. The incorporation of animal models provided 
additional proof as the injection of amyloid fibrils assembled from Aβ1-40, into the cerebral 
cortex of aged rhesus monkeys led to microglia activation and neuronal loss [131]. In addition, 
amyloid fibrils generated from IAPP, implicated in type II diabetes, were also found to be toxic, 
in this case to insulin-producing beta-cells of the adult pancreas of rats and humans [132]. This 
combined with the observed neurotoxicity of Aβ amyloid fibrils, suggested a common cytotoxic 
effect of amyloid fibrils as a contributing factor to the pathogenesis of amyloid diseases [133]. 
The observation that the severity of cognitive decline in Alzheimer’s disease correlated better 
with soluble Aβ compared to insoluble Aβ plaques (containing fibrillar Aβ), drew focus to the 
role of soluble low-molecular weight species in the pathogenesis of disease [134-137]. 
Transgenic mice models showing cognitive decline as well as impairments in cell function and 
synaptic plasticity prior to the accumulation of significant detectable quantities of amyloid 
plaques provided further support to the role of low-molecular weight species in disease 
pathogenesis [138]. The presence of amyloid plaques throughout the cortex of many healthy 
70 year-olds unaccompanied by cognitive decline, further detracted the field from amyloid 
plaques being central to disease progression [139]. Extensive extracellular deposition of 
insoluble amyloid material, through its sheer bulk is likely to cause organ failure by disrupting 
tissue architecture, especially in systemic diseases where kilograms of amyloid deposits can 
accumulate in vital organs such as the liver and kidney [1]. However, in non-systemic 
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conditions such as neurodegenerative diseases and organ-specific diseases like type II 
diabetes, the soluble low-molecular weight species are thought to play a greater role in 
disease progression [79, 120, 140-142]. 
1.4.1 The role of oligomers in cell death and disease progression 
The lack of correlation between fibrillar deposits and disease severity, sometimes even 
observed as an anti-correlation, led to the investigation of pre-fibrillar aggregates [135, 143-
145]. Due to difficulties in extraction of non-fibrillar aggregates from the brains of patients 
with Alzheimer’s disease, the first non-fbrillar Aβ aggregates were prepared from synthetic Aβ 
in vitro [146-148]. As discussed in section 1.3.2, oligomerisation is a heterogeneous process 
and a variety of pre-fibrillar aggregates, collectively referred to as oligomers have been 
described. Oligomers have been observed and described for a variety of disease-associated 
proteins such as α-synuclein, huntingtin and IAPP as well as for fibril forming proteins not 
associated with disease [141, 149-152].  
Oligomer extraction methods have evolved over the years and this has enabled the purification 
of oligomers isolated from cell culture, brains of animal models and from diseased human 
brains [153-160]. It is important to note that the extraction and analysis methods used to 
study these oligomers utilise techniques that dissociate, or at least destabilise fibrillar proteins 
such as homogenisation and boiling as well as addition of reagents such as sodium dodecyl 
sulphate (SDS), β-mercaptoethanol and urea; thus making the occurrence of oligomers in the 
tissue of interest potentially unclear [129, 161].  However, bearing this limitation in mind, 
several reports have implicated oligomers in disease pathogenesis.  
Oligomeric Aβ species have demonstrated toxicity to cultured neurons, inhibited hippocampal 
long-term potentiation (LTP), impaired synaptic function as well as disrupted cognition and 
learned behaviour in rats [120, 140, 157, 158, 162-165]. Oligomeric α-synuclein species also 
demonstrate toxicity via oxidative stress, Golgi fragmentation, synaptic loss and inhibition of 
proteasomal activity [166-169]. Toxicity has also been associated with oligomeric assemblies 
from other proteins such as huntingtin, IAPP, transthyretin, and lysozyme as well as non-
amyloidosis associated proteins such as stefin B, hypF-N and p53 [141, 170-175]. The 
remarkable observation of toxicity associated with oligomers prepared from proteins that are 
not associated with amyloidosis implies an inherent toxicity of oligomeric species [142]. 
Interestingly, the conformation-specific, sequence-independent antibody, A11, binds to 
oligomers generated from amyloidogenic proteins and peptides such as Aβ1-42, Aβ1-40, α-
synuclein, IAPP, polyglutamine and lysozyme and protects against their observed cytotoxicity; 
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providing further support for both the role of oligomeric species in disease pathogenesis and 
the inherent toxicity associated with oligomers [18] (Figure 1.8).   
1.4.2 The role of amyloid fibrils in cell death and disease progression 
Following the original formulation of the amyloid cascade hypothesis, evidence suggesting 
toxicity associated with the Aβ fibril began to appear, as discussed in section 1.4. Due to the 
lack of established characterisation methods, many of these early studies do not contain 
biophysical evidence of the presence of fibrils and the absence of oligomers in amyloid 
preparations; and therefore strictly speaking, do not exclude oligomer toxicity [176]. However, 
more recent studies with biophysical characterisation of amyloid aggregates show that fibrils 
do play a role in disease pathogenesis.  
Fibril-associated toxicity has been reported for fibrils assembled from amyloid disease 
associated proteins or peptides such as Aβ, lysozyme, recombinant mammalian prion protein 
(rPRP) and IAPP as well as from proteins not associated with disease such as the yeast prion 
proteins Sup35 and Ure2p [173, 177-186]. In some instances toxicity has been associated with 
both oligomeric species and fibrils by side by side comparison of both entities [173, 179, 182, 
185, 186]. Interestingly, oligomer and fibril have been shown to initiate cell death via distinct 
pathways. For example, oligomers and fibrils assembled from Aβ1-42 were both shown to 
initiate cell death via apoptosis, however fibrils induced apoptosis via a mechanism involving 
caspase 8 activation and oligomers via caspase 9 activation [179]. Studies on lysozyme amyloid 
oligomers and fibrils demonstrated a detrimental effect on cell viability associated with both 
species. In this instance, oligomers were shown to induce an apoptosis-like death in contrast to 
the necrosis-like death induced by fibrils [173]. These studies proposed that the widespread 
polymorphism observed in amyloid species, is indicative of a continuum of cross-β-sheet 
containing amyloid structures as perpetuators of disease progression, as opposed to a single 
uniform oligomer or fibril species [173] (Figure 1.8). 
One observation that challenged the original amyloid cascade hypothesis was that the decline 
in cognition, cell function and synaptic plasticity was independent of the accumulation of 
significant detectable quantities of amyloid plaques [138]. This was supported by the 
observation of morphological abnormalities and alterations in axonal trafficking preceding 
plaque detection [187]. Developments in temporally resolved longitudinal in vivo multiphoton 
microscopy in combination with the availability of sensitive in vivo amyloid dyes have provided 
a different perspective. Although collectively, plaques take months to accumulate in 
Alzheimer’s disease mouse models; individually, each plaque was shown to represent an acute 
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event and formed extraordinarily rapidly. Plaque formation preceded microglia recruitment 
and activation as well as the appearance of dysmorphic neurites. The authors propose that 
plaques act as critical mediators of neuritic pathology and the lengthy, sometimes decades-
long degenerative process of Alzheimer’s disease is marked by infinite acute changes in the 
cortex [188]. 
 Amyloid polymorphism is a widely accepted phenomenon and there are several examples of 
fibrils formed from the same starting peptide or protein with different stabilities, 
morphologies and/or molecular structure [96, 117]. In some cases, these polymorphisms carry 
different biological activities. One example of this is the polymorphism observed in fibrils 
assembled from Aβ1-40, where differences in both morphology and molecular structure are 
apparent. These differences are associated with differences in their toxicities in neuronal cell 
cultures [177]. Amyloid fibrils from lysozyme that differ in molecular structure, stability and 
size of the cross-β core also demonstrate differences in the degree of cytotoxicity to neuronal 
cultures [180]. Another example is the variation in fibril morphology observed in fibrils 
assembled from β2m [189]. Depending on the assembly conditions, β2m has been shown to 
assemble via competing pathways into rigid amyloid fibrils or semi-flexible worm-like fibrils. 
These fibrils have also been shown to differ in their biological activity [190]. These studies 
demonstrate that cytotoxic potential is governed by molecular structure and stability. 
Indeed, the stability of amyloid fibrils and in particular, their disassembly process is an 
important factor [101, 161].  Fibrils have been shown to disaggregate and release oligomeric 
species and have thus been proposed to act as a reservoir of cytotoxic species [117, 166, 191, 
192]. For example, natural lipids have been shown to destabilise and rapidly disaggregate 
mature Aβ1-42 fibrils, releasing oligomers which demonstrate potent toxicity to primary 
neurons, and memory impairment in mouse models [191]. This phenomenon is not exclusive 
to Aβ fibrils, as α-synuclein fibrils have also been shown to disaggregate into stable oligomers 
with toxic potential [166]. The mechanical stability of amyloid fibrils may also play an 
important role in pathogenesis. Indeed, previous work in our laboratory has shown that 
amyloid fibrils assembled from β2m disrupt artificial lipid membranes and also inhibit the 
cellular reduction of the tetrazolium dye, 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium 
bromide (MTT), a substrate commonly used to assay cell viability. Interestingly, mechanical 
fragmentation of amyloid fibrils enhanced their ability to disrupt lipid membranes and inhibit 
MTT reduction, thus suggesting that particle size plays an important role in determining 
biological activity [190]. 
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In light of this accumulating evidence, the role of amyloid fibrils in disease pathogenesis is 
being reappraised [176]. It is important to appreciate the limitation of the correlative studies 
conducted so far. These studies reduce a complex disease process which develops over years, 
perhaps decades, to a single, measurable phenotype; for example cognitive decline in 
Alzheimer’s results from impairment in long term potentiation [129]. Although this 
oversimplification is essential to draw conclusions; it is worthwhile to remember that amyloid 
diseases probably result from an amalgamation of biochemical, cell biological and systemic 
events, each of which may be aggravated by one or more aggregated species [129] (Figure 
1.8). 
 
Figure 1.8: Model of pathogenicity: A number of factors have been proposed to trigger protein 
aggregation into amyloid fibrils [129]. A large body of evidence supports the role of oligomers in disease 
progression as discussed in section 1.4.1. Accumulating evidence also points to a role of fibrils in 
pathogenicity either directly or indirectly as discussed in section 1.4.2. It is therefore possible that the 
perpetuator of disease pathogenesis is not a single uniform species, but rather a continuum of species.  
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1.5 Mechanisms and consequences of cell death and disruption of 
cellular functions 
The underlying mechanism of cell disruption in the pathogenesis of amyloid diseases is poorly 
understood. In light of the intense research focused on this, several models have been 
proposed. These models along with the evidence that led to their proposal will be discussed. 
1.5.1 Disruption due to aberrant interactions via hydrophobic surfaces 
A prominent hypothesis is one that focuses on the misfolded nature of aggregates, in 
particular the heterogeneous, soluble, oligomers. These misfolded aggregates expose on their 
surfaces a variety of groups and hydrophobic patches that would normally be either buried in 
globular proteins or dispersed in intrinsically disordered proteins and peptides [1, 125, 193, 
194].  It is possible that these aggregates mediate aberrant interactions with other cellular 
components thus causing cell disruption via abnormal exposure of hydrophobic surfaces and 
reactive groups [141, 193-195]. Indeed, a study using 1-anilinonapthalene 8-sulphonate (ANS), 
a dye widely used to measure exposed hydrophobic patches, showed an increase in exposure 
during the course of fibril formation of three different amyloid systems. Interestingly, the 
increase in hydrophobic exposure was shown to correlate with cell death, measured by the 
incorporation of propidium iodide in the neuronal cell line, SH-SY5Y; thus suggesting that the 
exposure of hydrophobic surfaces during amyloid aggregation is a generic toxic feature of 
amyloid proteins [194]. The role of hydrophobic interactions is further supported by studies on 
oligomer toxicity. Interestingly, when polymorphic oligomers are compared, where the 
fundamental differences lie in the degree of hydrophobic packing and exposure; toxicity was 
associated with the oligomer species which had a greater exposure of hydrophobic surfaces 
and a lower degree of hydrophobic packing [141, 195]. 
Exposed hydrophobic surfaces have been proposed to mediate aberrant interactions and 
studies have been conducted to identify these interaction partners with the aim of 
understanding the mechanisms of toxicity [193, 196]. A large number of proteins (324 out of 
8100 tested) were identified to interact with oligomeric Aβ in an in vitro protein array based 
study, where the most highly impacted cellular system identified was the protein translation 
machinery [196]. Another study revealed a much larger set of proteins, approximately 2000, as 
interaction partners for amyloid-like aggregates formed from model proteins designed de novo 
and expressed in the cytosol [193]. The de novo design allowed for complete removal of bias 
from naturally occurring proteins and thus allowed investigation of interaction partners based 
on the amyloid conformation in human cells transfected with the de novo model amyloid 
construct. Co-aggregating proteins identified were found to occupy essential ‘hub’ positions in 
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cellular protein networks with important roles in protein quality control, chromatin 
organisation, transcription, translation and maintenance of cell architecture [193]. The authors 
propose that these aberrant interactions with amyloid aggregates can impair the normal 
functioning of the identified essential proteins by sequestering them, thereby causing the 
collapse of cellular functions and inevitably resulting in multifactorial toxicity [193].  
1.5.2 Disruption via saturation of the central protein quality control and clearance 
systems 
Protein homeostasis, also known as proteostasis, refers to the tight regulation that ensures 
that each protein in the cellular proteome is properly synthesised, folded, sub-
compartmentalised and degraded [197, 198]. Proteostasis is maintained by a network of 
cellular systems and components, collectively referred to as the proteostasis network [197, 
199]. The ubiquitin-proteasome system (UPS) is one pathway of the proteostasis network [197, 
199]. Molecular chaperones play multiple key roles in the proteostasis network due to their 
ability to recognise misfolded proteins [199]. The capacity to maintain proteostasis is found to 
decline with age as well as in various neurodegenerative conditions [197]. The role of two 
aspects of the proteostasis network, the UPS and molecular chaperones will be discussed here; 
however many branches of the proteostasis network are thought to be affected in aging and 
disease and is the focus of intense research [197]. Molecules that regulate the network as a 
whole (proteostasis regulators) as well as those that control individual protein fates such as 
pharmacological chaperones and kinetic stabilisers are currently under development as 
therapeutic agents [197]. 
The normal role of the UPS is cellular quality control by degrading misfolded, unassembled or 
damaged proteins that could otherwise form potentially toxic aggregates [200]. Proteins 
tagged for degradation display poly-ubiquitin chains and are rapidly degraded by cellular 
proteasomes. The presence of elevated ubiquitin conjugates in the intracellular deposits of 
protein aggregates within diseased neurons in most sporadic and inherited neurodegenerative 
diseases has led to a long established link between UPS dysfunction and pathogenesis [201]. 
Indeed, mutations in genes encoding components of the UPS pathway such as parkin and 
ubiquitin carboxy-terminal hydrolase L1 (UCHL1) are associated with Parkinson’s disease [202]. 
Importantly, protein aggregation of a pathogenic variant of huntingtin was shown to 
completely inhibit the UPS [201]. The injection of proteasome inhibitors into adult rats was 
shown to cause parkinsonian features, including Lewy body aggregates [203]. This suggests 
that protein aggregates are simultaneously inhibitors of the UPS as well as products that result 
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from its inhibition and this positive feedback mechanism may rationalise the neuronal loss 
characteristic of neurodegenerative diseases [201].  
Despite the amino acid sequence containing all the necessary information required to facilitate 
proper folding into a functional three-dimensional structure, the highly crowded 
macromolecular environment in vivo promotes misfolding and aggregation [204, 205]. This has 
led to the evolution of highly conserved molecular chaperones [206]. Molecular chaperones 
function by preventing inappropriate interactions both within and between non-native 
polypeptides; as well as by increasing the efficiency of de novo protein folding; and refolding of 
existing proteins that have misfolded [207]. They were first discovered due to their increased 
synthesis in response to mild elevations in temperature, and were therefore named heat shock 
proteins (Hsps). Hsps are rapidly produced in response to stress such as elevated temperature, 
ischemia, oxidation; but a subset are constitutively expressed and are involved in 
conformational maintenance [207, 208]. Primary or secondary impairments in molecular 
chaperone function have been associated with a host of age-related pathologies [198].  
Changes in chaperone content are indicative of the cellular attempt to overcome a pathogenic 
condition and preserve proteostasis [198]. For example, a stress inducible small Hsp, Hsp27, 
was detected at high levels in degenerating areas of brains from patients with Alzheimer’s 
disease [209]. In addition, aging is associated with impairment in stress-induced synthesis of 
molecular chaperones [210-212]. Interestingly, in a study using Caenorhabditis elegans 
polyglutamine aggregation models, polyglutamine aggregates were shown to globally stress 
the cellular folding capacity by overwhelming it; resulting in the aggregation of several 
unrelated metastable proteins; which in turn further aggravated the aggregation of 
polyglutamine proteins [213]. This has led to the concept of protein ‘metastasis’ which 
describes a condition when initial aggregation events elicit a cascade of pathological events 
[79]. And finally, multiple lines of evidence demonstrate that pharmacological or genetic 
enhancement of molecular chaperones is protective in amyloid disease models [214-218]. 
1.5.3 Disruption via membrane permeation 
Cellular membranes, in particular the plasma membrane, have been implicated as a target for 
amyloid cell disruption [117, 219, 220]. Amyloidogenic proteins and peptides, either as 
monomers or higher order aggregates have been shown to interact with membranes [184, 
221-223]. The presence of lipids has been shown to modulate the fibril formation process. 
Fibril growth from α-synuclein, IAPP and Aβ is accelerated in a membrane environment when 
compared to growth in solution [221-223].  
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Amyloid aggregates have also been shown to permeabilise membranes and this has been 
proposed as a mechanism of cell disruption [117]. It is important to note that the ability of 
amyloid proteins to fibrillate on, interact with and to permeabilise cell membranes critically 
depends on the biophysical features of the membrane such as curvature, compactness, rigidity 
and charge density [117]. Various models have been put forward to explain membrane 
destabilisation and cell toxicity (Figure 1.9) [219, 220]. These include carpeting effects, 
detergent effects, pore formation, raft-like insertion and fibrillogenesis on the membrane 
[219, 220, 224].     
The carpeting model suggests that the carpeting of the peptide on one edge of membrane 
applies asymmetric pressure between membrane leaflets resulting in the leakage of small 
molecules [225]. Evidence for this model comes from in vitro experiments showing dye leakage 
from model liposomes after incubation with human IAPP [226]. Incubation with non-
amyloidogenic rat IAPP also resulted in membrane disruption leading to leakage and therefore 
this model is unlikely to explain the membrane perturbations associated with amyloid 
structures [184, 226]. Fibril formation of IAPP on the membrane, however, has been shown to 
damage membranes leading to their leakage; and the amyloid fibril formation process has 
been shown to be crucial to this disruption as manipulations that retard or accelerate fibril 
formation, retard or accelerate membrane disruption respectively [184].  
The raft-like insertion model describes the extensive insertion of amyloid in the membrane 
resulting in a ‘protein raft’ inside the membrane [219]. Studies on a yeast toxic mutant of HET-
s support the raft-like insertion model as amyloid aggregation was shown to result in a large 
insertion of amyloid in the membrane to form a ‘protein raft’ [227]. Whether amyloid 
aggregation occurs prior to membrane interaction, or as a result of membrane interaction as in 
the case of Aβ; both result in a raft-like insertion of amyloid material which leads to membrane 
destabilisation [219, 227, 228]. 
Amyloid species are also proposed to have detergent like effects which may rationalise the 
potential to disrupt membranes. The model based on detergent-like effects is based on an 
initial electrostatic interaction allowing the peptide or aggregate to bind the charged 
phospholipid head group or membrane surface receptors and thus permitting the peptide or 
aggregate to orientate its hydrophobic residues in proximity to the hydrophobic core of the 
membrane [229]. This results in disruption of the bilayer curvature and thus leads to 
membrane disintegration. Human IAPP has been shown to extract lipids from cellular 
membranes in such a fashion [230]. β2m fibrils have also been shown to interact with and 
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distort artificial lipid membranes. Distortion, mainly by fibril ends, was shown to coincide with 
the extraction of lipids from the membranes into tiny lipid vesicles [231].   
Ca2+ is a universal intracellular messenger, and cytosolic Ca2+ regulates a multitude of cellular 
functions and reactions [232]. Disruptions to cytosolic Ca2+ concentrations could lead to 
apoptosis through caspase activation and cytochrome-c release [233]. Disruption of Ca2+ 
homeostasis following the formation of stable pores or ion channels in the membrane is 
perhaps the model with the most supporting evidence [219].  This model is based on 
observations of a certain type of annular amyloid oligomeric species which has a central cavity 
and resembles a pore or channel within model liposomes [224]. Remarkably, this type of 
oligomer has been observed in amyloid aggregates from disease associated amyloid proteins 
or peptides such as Aβ, α-synuclein and huntingtin amongst others [121, 224, 234-236]. 
Furthermore, a large body of evidence supporting pore or channel formation has been 
associated with Aβ, α-synuclein and polyglutamine proteins and implicates a disruption in Ca2+ 
homeostasis as the main mechanism of toxicity [224, 237-239].  
Cell disruption due to membrane permeation need not be exclusively via one of the above 
proposed models [220]. It is possible that a combination of these proposed models are 
responsible for pathogenesis [219, 220]. Indeed, the biophysical properties of the membrane 
in question as well as the structure of the amyloid species will ultimately determine the nature 
of disruption [117].  
 
Figure 1.9: Schematic description of the proposed models of interactions resulting in membrane 
destabilisation and disruption. Pore formation may lead to the leakage of ions and small molecules 
depicted by pink spheres.  
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1.5.4 Disruption via organelle dysfunction 
Increasing evidence points towards intracellular damage by amyloid aggregates. Extracellular 
amyloid aggregates either occurring in vivo or applied exogenously in vitro utilise the endocytic 
pathway to access intracellular compartments as demonstrated for Aβ, α-synuclein, 
polyglutamine and β2m [240-248]. Once in the intracellular milieu, amyloid aggregates have 
been reported to induce ER stress, inhibit proteasomes, cause autophagic dysfunction and 
Golgi fragmentation [167, 201, 249-256]. Oxidative stress and mitochondrial damage have also 
been implicated [251, 257-259]. Lysosomal damage either via perturbation of the lysosomal 
membrane or accumulation of amyloid aggregates in the lysosome has also been reported 
[242, 245, 260-265]. The role of mitochondrial damage in amyloid disease will be briefly 
discussed. The role of lysosomes in amyloid disease including lysosomal membrane damage, 
lysosomal dysfunction and autophagy impairment will be discussed in more detail due to its 
prominence in this project.  
1.5.4.1 Mitochondrial dysfunction in amyloid disease 
The complex biosynthesis of mitochondria combined with their vital function of energy 
production contributes to their vulnerability to damage accumulation over their life cycles 
[266]. Neurons are particularly susceptible to mitochondrial damage as they require high levels 
of ATP to fuel transport of macromolecules and organelles across a range of distances along 
axons, and maintain ionic gradients, Ca2+ homeostasis and membrane potentials [266]. Due to 
their complex morphology and high energetic demand, mitochondria have to be transported 
away from the cell body (where most mitochondrial biogenesis occurs) along axons to regions 
with high energy and Ca2+ buffering requirements  thus extending their life-span when 
compared to other post-mitotic cells [267-270]. This longer life-span results in accumulation of 
damage [266]. Most newly synthesised mitochondrial proteins are imported in to the 
mitochondria at the cell body  and therefore the older mitochondria at the cell periphery may 
be less efficient at coping with misfolded proteins or Ca2+ overload [271, 272]. Removal of 
damaged mitochondria from the cell periphery by mitophagy can be an energetically 
demanding task in neurons as autophagosomes from the axons would need to travel the 
length of the axon to fuse with lysosomes at the cell body [273]. Therefore, although neurons 
share the same mitochondrial quality control (QC) systems as other cells they are faced with 
more arduous challenges [266]. Any mutations or accumulation of aggregates that affect 
mitochondrial QC capacity will thus preferentially affect neurons  and are implicated in 
neurodegenerative diseases such as Parkinson’s disease and Alzheimer’s disease [251, 266, 
274-276]. One example is the association of mutations in PINK1 and parkin with Parkinson’s 
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disease. Mounting evidence points to the concerted involvement of PINK1 and parkin in 
mitophagy thus validating the role of mitochondria in disease pathogenesis [276, 277].  Mutant 
PINK1 and parkin disrupt mitophagy at several different steps [277].  
1.5.4.2 Role of lysosomes in amyloid disease 
Increasing evidence points towards lysosomal and autophagy dysfunction as one of the 
underlying mechanisms in amyloidoses such as Alzheimer’s, Parkinson’s and Huntington’s 
diseases [278]. Amyloid aggregates accumulate in the endolysosomal system, making it the 
focus of many studies [242, 261, 263, 265].  
1.5.4.2.1 Lysosomal membrane damage 
Lysosomes, first described by Christian de Duve in 1955, are membrane-bound acidic 
organelles that house approximately 60 different lysosomal hydrolases responsible for the 
degradation and recycling of cellular waste [278, 279]. Lysosomes, however, are much more 
than just a cell waste disposal system, they are central organelles involved in secretion, plasma 
membrane repair, signalling, energy metabolism, antigen presentation, cholesterol 
homeostasis, cell death and autophagy pathways [278, 280]. Extracellular material targeted for 
degradation reaches the lysosome mainly via the endocytic pathway whereas intracellular 
material is targeted via autophagy [280, 281].  
The acidic milieu of lysosomes is crucial for their function and is maintained by a vacuolar 
ATPase [282]. It is also crucial for the lysosomal membrane to remain intact, both to maintain 
an acidic lysosomal lumen and to protect the cell from the hydrolytic contents of the lysosome 
[283]. Lysosomal membrane permeabilisation (LMP) refers to the activation of controlled cell 
death via leakage of lysosomal proteases from the lysosomal lumen [283]. The lysosomal 
proteases that remain active at neutral pH such as cathepsins B, D and L have been implicated 
in activating cell death via caspase or mitochondria-dependent pathways [283]. 
Accumulating evidence supports lysosomal membrane damage as one of the main causes of 
cytotoxicity associated with amyloid aggregates. In Alzheimer’s disease, Aβ1-42 has been 
reported to insert tightly into the lysosomal membrane and this has been suggested to cause 
lysosomal membrane instability leading to LMP [264]. Others have found that the 
accumulation of Aβ1-42 aggregates in the lysosome results in the rapid generation of free 
radicals which disrupt the lysosomal proton gradient resulting in cell death [263]. Enzyme 
leakage following damage to lysosomes culminating in cell death has also been described for 
exogenously applied Aβ42 oligomers [242]. Mouse models of Alzheimer’s disease containing 
the aggressive Osaka mutation show lysosomal leakage in combination with ER stress and 
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mitochondrial dysfunction [251]. Lysosomal membrane rupture is also observed in studies 
involving α-synuclein. This rupture is particle size dependent such that α-synuclein oligomers 
are more efficient at causing damage than larger α-synuclein fibrillar assemblies [245].  
1.5.4.2.2 Disruption of lysosomal function 
Undoubtedly, damage to the lysosomal membrane mediated by amyloid aggregates would 
result in disruption to lysosomal function. Further evidence supporting the role of the 
lysosome in amyloid cytotoxicity comes from elegant studies looking at the effect of enhancing 
or disrupting lysosomal function [284, 285]. Interestingly, inhibition of lysosomal function in 
the absence of amyloid aggregates results in the same phenotype as observed in amyloid 
disease [284]. For example, inhibition of lysosomal proteolysis either by cathepsins or 
suppression of lysosomal acidification, retarded transport of late endosomes, lysosomes and 
autolysosomes along axons and resulted in their accumulation on dystrophic axonal swellings, 
as observed in Alzheimer’s disease. These swellings resembled, in morphology and 
composition, those observed in mouse models of Amyloid disease [284]. Scyllo-Inositol inhibits 
accumulation of Aβ and Huntingtin aggregates by promoting proteasomal and lysosomal 
degradation, and thus inhibits toxicity [285, 286].  
Further evidence is provided by fibroblasts from patients suffering from Kufor-Rakeb 
Syndrome. This disease is characterised by juvenile-onset Parkinsonism and dementia. These 
patients carry a mutation in PARK9 which results in a reduced ability to maintain Zn2+ 
homeostasis resulting in lysosomal dysfunction [287]. This disruption leads to accumulation of 
α-synuclein and inhibition of glucocerebrosidase, which is reminiscent of the pathogenic 
association observed between Parkinson’s disease and Gaucher’s disease [287, 288]. And 
lastly, disruption of lysosomal function is also observed in non-neurodegenerative diseases. 
Human-IAPP disrupts lysosome-dependent degradation which in turn impairs autophagy in 
mouse models of type II diabetes [289].  
1.5.4.2.3 Autophagy dysfunction 
As alluded to in section 1.5.4.1 above, neurons are particularly sensitive to accumulation of 
damaged organelles due to their unusual morphology and high energy demands. It is 
unsurprising therefore, that autophagy plays a crucial role in neurons and autophagic 
dysfunction is reported across a host of neurodegenerative diseases. Gathering evidence 
points to lysosomal and autophagy dysfunction as the central underlying mechanisms in 
common neurodegenerative diseases such as Alzheimer’s, Parkinson’s and Huntington’s 
disease [278]. Autophagy is a complex process requiring several different steps and the 
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involvement of many molecular players. Understanding the reasons behind autophagic failure 
in neurodegenerative diseases thus requires identification of the pathway(s) affected in each 
disease [255]. Differences in pathways involved may explain differences in disease pathology 
and progression. Identification of these differences is therefore crucial to developing targeted 
therapies [255]. 
Altered autophagy is a common theme in neurodegenerative diseases and the first clue to this 
alteration is the accumulation of autophagosomes in diseased neurons in Alzheimer’s, 
Parkinson’s and Huntington’s diseases [255, 261, 290, 291]. However, accumulation of 
autophagosomes does not necessarily signify increased degradation through autophagy, as 
cells could accumulate autophagosomes when autophagy is upregulated (due to increased 
autophagosome formation) or when clearance of autophagosomes is disrupted [255, 292, 
293]. Disrupted autophagic clearance via autophagosome accumulation uncoupled with 
increased autophagic flux, has been reported for an increasing number of neurodegenerative 
diseases [255]. This perturbation could be due to disrupted autophagosome trafficking, 
decreased fusion with endosomes/lysosomes or decreased proteolysis inside lysosomes [255]. 
Decreased proteolysis could be attributed to altered lysosomal pH, accumulation of 
undigested by-products or impaired activity and/or expression of lysosomal hydrolases; thus 
drawing striking parallels between amyloid diseases and the neurodegenerative symptoms 
observed in lysosomal storage disorders [255, 294].  
There are different types of autophagy and three of the main sub-types are macroautophagy, 
microautophagy and chaperone-mediated autophagy (CMA). The main difference between 
them is the method of delivery of cargo to the lysosome [295, 296]. In the case of 
microautophagy and macroautophagy, whole areas of the cytosol are directly engulfed either 
by invagination at the lysosomal membrane (microautophagy) or by formation of a membrane 
that seals around the cargo to form an autophagosome (macroautophagy) [255]. CMA involves 
selective recognition of cargo and direct delivery to the lysosome by specific cytosolic 
chaperones [297]. All three pathways function simultaneously alongside other proteolytic 
mechanisms in a co-ordinated manner, for example, macroautophagy is upregulated during 
blockage of both UPS and CMA [298, 299]. Mutated pathogenic variants of α-synuclein bind 
tightly to the CMA translocation complex but are not delivered to the lysosome; thus 
interfering with the CMA translocation complex by sequestering it and preventing degradation 
of other CMA substrates [300]. Mutated forms of Tau, but not wild-type Tau, are targeted to 
the lysosomes via CMA where they are abnormally cleaved into amyloidogenic peptides; some 
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of these peptides form oligomeric structures at the lysosomal membrane which interfere with 
normal CMA functioning [301].  
Connections between macroautophagy and non-autophagic lysosomal pathways such as 
endocytosis also exist. ESCRT-III dysfunction in the late endosomal membrane disrupts the 
formation of multi-vesicular bodies (MVBs), which reduces autophagic flux and results in 
autophagosome accumulation in models of frontotemporal dementia [302]. Disruption of 
endosome biogenesis causing autophagic failure leads to accumulation of poly-ubiquitinated 
amyloid proteins such as Huntingtin and TDP-43 [303].  
In summary, identification of the nature of the autophagic defect and the cellular response to 
that defect will inform targeted therapies [255]. An ideal approach would involve enhancing 
autophagosome clearance by upregulating the lysosome, as demonstrated by upregulating 
lysosomal biogenesis via overexpression of the transcription factor EB (TFEB) [255, 304]. 
1.5.4.2.4 Parallels between lysosomal storage diseases and amyloid disease 
Lysosomal storage diseases (LSDs) are a group of over 40 metabolic disorders attributed to 
mutations in lysosomal proteins such as hydrolases and integral membrane proteins as well as 
proteins involved in modification and trafficking of lysosomal proteins  [305, 306]. Over 65 % of 
LSDs have defects in the central nervous system (CNS) leading to progressive cognitive and 
motor decline [305]. LSDs exist in infantile, juvenile and adult forms [307].  
Over the years, an increased interest in the involvement of autophagy in LSD pathogenesis has 
developed. Indeed, in mouse models of two LSDs (Multiple Sulfatase Deficiency and 
Mucopolysaccharidosis type IIIA) striking parallels with Alzheimer’s disease are drawn such as 
an accumulation of autophagosomes [294], reduced degradation of endogenous and 
exogenous autophagic substrates [308] and defective organelle turnover [306]. Also, 
autophagic impairment leading to pathological protein aggregate accumulation was detected 
in LSD neurons [309]. In combination, these observations show similarities between LSDs and 
amyloid diseases such as Alzheimer’s, Parkinson’s and Huntington’s disease [306]. The 
similarities between LSDs and neurodegenerative diseases not only suggest a potential central 
role of lysosomes in amyloid disease, but in some cases are informative of the pathogenesis of 
the amyloid disease. In particular, the similarities between Parkinson’s and Gaucher’s diseases, 
as well as Niemann-Pick Type C and Alzheimer’s will be briefly discussed. 
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Parkinson’s and Gaucher’s diseases 
Gaucher’s disease is an autosomal recessive disorder that results from loss-of-function 
mutations in GBA1, the gene encoding glucocerebrosidase, a lysosomal enzyme that cleaves 
the β-glucosyl linkage of glucoceramide [288]. Gaucher’s disease has three subtypes which are 
based on the aggressiveness of the disease and neurological involvement [310]. Gathering 
clinical, pathological and genetic evidence points to an association between Gaucher’s and 
Parkinson’s diseases [311].  
The clinical presentation of parkinsonism in type 1 Gaucher’s disease patients, further 
supported by genetic evidence, suggests a strong link [312-314]. α-synuclein aggregation was 
implicated in the pathogenesis of Gaucher’s disease upon discovery of α-synuclein positive 
Lewy bodies in the brains of Gaucher’s disease patients [315]. The discovery that parkinsonism 
patients had an increased incidence of GBA1 mutations from genetic studies in large patient 
cohorts makes GBA1 the most common genetic risk factor for Parkinson’s disease known to 
date [288, 316]. And finally, accumulation of toxic α-synuclein species has been shown to 
deplete lysosomal glucocerebrosidase, leading to accumulation of glucocerebroside which in 
turns stabilises α-synuclein aggregates. This self-propagating positive feedback loop has been 
proposed as a mechanism that connects the two diseases [288]. 
Niemann-Pick type C and Alzheimer’s diseases 
Niemann-Pick type C is also an autosomal recessive disorder, involving disruption in 
cholesterol trafficking within the endolysosomal pathway [317]. Although fundamentally 
different from Alzheimer’s disease, Niemann-Pick type C disease draws some interesting 
parallels with it. Endosomal abnormalities reminiscent of those observed at the earliest stage 
in Alzheimer’s disease are observed in neuronal populations in Niemann-Pick type C disease 
[317]. Strikingly, this is also combined with endosomal accumulation of APP and Aβ peptides 
[317-319]. Also of remarkable interest, is the observation of neurofibrillary tangles in the 
brains of NPC patients in the absence of mutations in tau or abnormal Aβ deposition [320, 
321]. Cholesterol is another common theme between the two diseases, cholesterol trafficking 
disruption being the primary pathogenic cause in Niemann-Pick type C disease and elevated 
cholesterol being a risk factor in Alzheimer’s disease [317, 322]. 
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1.6 Aims 
The first aim of the thesis was to analyse the effect of β2m amyloid fibrils on lysosomal 
function, with particular focus on lysosomal proteolysis. This was based on the large body of 
literature implicating lysosomes as key cellular targets of amyloid pathogenesis (discussed in 
1.5.4.2) as well as emerging evidence from our laboratory.  The second aim was to analyse the 
effect on membrane trafficking. The precedence for this comes from genome wide association 
studies implicating endocytic trafficking and observations of impaired endolysosomal 
trafficking [323, 324]. The third aim was to investigate the role of the molecular chaperone, 
Hsp70, in fibril-mediated cell disruption based on the increased incidence of amyloid disease 
with diminished proteostasis (discussed in 1.5.2).   
1.7 Objectives 
1.7.1 Chapter 3 objectives 
The objective of this chapter was to validate the use of β2m as a model to study amyloid-cell 
interactions. β2m amyloid fibrils were generated and subsequently characterised based on 
their biophysical, tinctorial and immunological characteristics. In addition, the effect of β2m 
fibrils on the cell viability assay, the MTT assay was analysed.  
1.7.2 Chapter 4 objectives 
Building on previous work in the laboratory which shows that fragmentation of β2m fibrils 
enhances their internalisation and trafficking to the lysosome, the objective of chapter 4 was 
to investigate the effect of fragmented β2m fibrils on lysosomal function. This included analysis 
of lysosomal proteolysis and autophagy, as well as the activity of the lysosomal hydrolases β-
glucocerebrosidase and β-galactosidase.  
1.7.3 Chapter 5 objectives 
The objective of chapter 5 was to investigate the effect of fragmented β2m fibrils on 
membrane trafficking. This was based on literature precedence as well as observations from 
experiments described in chapters 3 and 4. Investigation of membrane trafficking involved the 
analysis of the localisation of the lysosomal membrane proteins, LAMP-1 and CD63, and 
analysis of fluid-phase endocytosis.  
1.7.4 Chapter 6 objectives 
The objective of chapter 6 was to investigate the role of Hsp70 in fibril-mediated cellular 
disruption. Building on observations in chapters 3, 4, and 5, this involved analysis of the effect 
of Hsp70 on cellular reduction, lysosomal proteolysis and LAMP-1 trafficking in fibril-treated 
cells.   
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2 Materials and methods 
All materials used were from Sigma-Aldrich unless otherwise stated in the text. 
2.1 Expression and purification of β2m 
2.1.1 Expression of β2m 
β2m was expressed in BL21 (DE3) pLysS cells  transformed with the designated pINK plasmid 
containing the gene for human β2m [325]. 10 µl of a glycerol stock of BL21 (DE3) pLysS cells 
transformed with pINK was streaked out onto a fresh Lysogeny Broth (LB)-agar plate 
containing 100 µg/ml carbenicillin (Melford). The LB-agar plate was incubated at 37 ⁰C for 16 
h. A single colony was picked and used to inoculate a starter culture of 100 ml LB containing 
100 µg/ml carbenicillin. The starter culture was incubated in an orbital shaker (Stuart S150) at 
37 ⁰C for 16 h whilst shaking at 200 rpm. 
11 l of pre-warmed LB were inoculated with the starter culture (5 ml of starter culture per litre 
of LB containing 100 µg/ml carbenicillin). The bacterial cultures were incubated at 37⁰C whilst 
shaking at 200 rpm. The OD600 was monitored regularly and when an OD of 0.6 was reached, 
the cultures were induced by the addition of isopropyl β-D-1-thiogalactopyranoside (IPTG) at a 
final concentration of 1 mM. The bacterial cultures were incubated at 37⁰C whilst shaking at 
200 rpm for 16 h, after which the cells were harvested using a continual action centrifuge 
(Heraeus Contifuge Stratos # 3049 with a continuous flow rotor) at 15,000 rpm. The 
supernatant was discarded and the pellet was resuspended as described below. 
2.1.2 Inclusion body isolation 
The cell pellet was resuspended in 100 ml lysis buffer (25 mM Tris.HCl pH 8.0 containing 100 
µg/ml lysozyme, 50 µg/ml PMSF, 20 µg/ml DNaseA and 1 mM EDTA) by stirring at room 
temperature for 30 min. The cells were homogenised by passing through a small blunt needle 
and then further lysed using a cell disrupter (Constant Systems Cell Disrupter). Cell lysates 
were centrifuged for 30 min at 4 °C (Beckman Coulter, JLA 16.250 rotor, 15,000 rpm). The cell 
pellet containing the protein as inclusion bodies was washed five times with 100 ml wash 
buffer (25 mM Tris.HCl pH 8.0).  The pellet was then solubilised in 200 ml solubilisation buffer 
(25 mM Tris.HCl pH 8.0 containing 8 M urea) by stirring at 25 °C for 16 h. 
2.1.3 Refolding by dialysis 
Solubilised protein was then dialysed six times against 5 l of 25 mM Tris.HCl pH 8.0 using 3500 
molecular weight cut off (MWCO) dialysis tubing at 4 °C. The dialysed protein was centrifuged 
for 1 h at 4 °C (Beckman Coulter, JLA 16.250 rotor, 15,000 rpm) to remove any precipitate. 
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2.1.4 Anion exchange chromatography 
The refolded protein was further purified by anion exchange chromatography using a XK50 
column (GE Healthcare) containing 200 ml (bed volume) fast-flow Q-Sepharose (GE 
Healthcare) previously equilibrated with 25 mM Tris.HCl pH 8.0 and connected to an AKTA 
prime chromatography system (GE Healthcare). The resolubilised protein was loaded onto the 
column, and washed with five column volumes of 25 mM Tris.HCl pH 8.0. The protein was 
eluted with a linear gradient of 0-400 mM NaCl in 25 mM Tris.HCl pH 8.0 over 1 l. The fractions 
containing β2m, as judged by the elution profile and sodium dodecyl sulphate polyacrylamide 
gel electrophoresis (SDS-PAGE) analysis, were pooled and dialysed five times against 5 l of 18 
MΩ purite water before lyophilising for storage at -20⁰C. 
2.1.5 Size exclusion chromatography 
The protein was further purified by size exclusion chromatography using a Superdex 75 HiLoad 
26/60 size exclusion column (GE Healthcare) mounted on an AKTA prime chromatography 
system (GE Healthcare). The lyophilised protein was dissolved in 20 ml of 10 mM sodium 
phosphate buffer pH 7.2 and filtered using a 0.2 µm filter (Sartorius). The protein was loaded 
onto the column (5 ml of ~10 mg/ml per run) and the following program (Table 2.1) on the 
AKTA prime system was used to purify the protein. 
Breakpoint 
(ml) 
% B Flow 
rate 
Fraction 
size 
Buffer 
valve 
position 
Inject 
valve 
position 
Set 
peak 
collect 
Auto 
zero 
Event 
mark 
0 0 2ml/min 0ml 1 Load No No No 
10 0 2ml/min 0ml 1 Inject No Yes Yes 
20 0 2ml/min 0ml 1 Load No No Yes 
110 0 2ml/min 3ml 1 Load No No Yes 
360 0 2ml/min 0ml 1 Load No No No 
Table 2.1: Details of the AKTA program used for size exclusion chromatography of β2m.  
The fractions corresponding to monomeric β2m as judged by SDS-PAGE analysis were pooled 
and dialysed five times against 5 l of 18 MΩ purite water before lyophilising for storage at -
20°C. The precise molecular weight of the protein was determined using electrospray 
ionisation mass spectrometry (ESI-MS) performed by James Ault (Astbury mass spectrometry 
facility manager).  
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2.2 Sodium dodecyl sulphate polyacrylamide gel electrophoresis 
(SDS-PAGE) 
Tris-tricine or Tris-glycine buffered SDS-PAGE gels were used to separate proteins according to 
their molecular weight. Two glass plates were assembled according to the manufacturer’s 
instructions using a 1.5 mm spacer (Bio-Rad for Tris-tricine gels and Hoefer for Tris-glycine 
gels). A two-layered gel system consisting of a stacking and resolving gel was made using the 
components in Table 2.2 or Table 2.3. 
Solution Component Resolving gel 
Volume to add (ml) 
Stacking gel 
Volume to add (ml) 
30% (w/v) Acrylamide: 0.8% (w/v) bis-acrylamide 7.5 0.83 
3 M Tris.HCl, 0.3% (w/v) SDS pH 8.45 5.0 1.55 
H2O 0.44 3.72 
Glycerol 2.0 - 
10% (w/v) ammonium persulphate 0.05 0.10 
Tetramethylethylenediamine (TEMED) 0.005 0.005 
Table 2.2: Components of a Tris-tricine buffered gel. 
Solution Component Resolving gel 
Volume to add (ml) 
Stacking gel 
Volume to add (ml) 
30% (w/v) Acrylamide: 0.8% (w/v) bis-acrylamide 3.33 0.83 
3 M Tris.HCl, 0.8% (w/v) SDS, pH 8.8 1.35 - 
1 M Tris.HCl, 0.8% (w/v) SDS, pH 6.8 - 0.63 
H2O 5.31 3.4 
10% (w/v) ammonium persulphate 0.05 0.10 
 TEMED 0.005 0.005 
Table 2.3: Components of a Tris-glycine buffered gel. 
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For Tris-tricine gels: 
The resolving gel mixture was made and rapidly poured to within 2 cm of the top of the glass 
plates. The stacking gel mixture was made and then poured on top of the resolving gel.  A 
comb was inserted to create wells for sample loading. The gels were left for a minimum of 1 h 
to set.  
Gel samples were diluted two-fold into 2X modified Laemmli buffer (100 mM Tris.HCl pH 6.8 
containing 20 % (v/v) glycerol, 4 % (w/v) SDS, 0.2 % (w/v) bromophenol blue and 100 mM 
dithiothreitol (DTT)) and incubated at 95 °C for 5 min before loading onto the gel. To obtain 
comparative loadings of bacterial cell lysates, 100 μl of the modified Laemmli buffer was added 
to the cell pellet (obtained from the volume of bacterial culture corresponding to 1.0 OD600 
units) and 15 μl was loaded per lane.  A lane containing 15 μl of protein marker (Invitrogen 
Mark 12) was included.  
The proteins were electrophoresed using a cathode buffer (200 mM Tris-HCl, 200 mM Tricine, 
0.2% (w/v) SDS pH 8.25) and an anode buffer (400 mM Tris-HCl pH 8.8).  A constant current of 
30 mA was applied until the samples entered the resolving gel, and then the current was 
adjusted to 60 mA until the dye front reached the bottom of the gel. Gels were stained, de-
stained and imaged as described below. 
For Tris-glycine gels: 
The resolving gel mixture was made and rapidly poured to within 2 cm of the top of the glass 
plates. A layer of water-saturated butan-1-ol was applied onto the surface of the first layer to 
exclude oxygen and to aid polymerisation. Once the resolving gel had set, the surface was 
rinsed with water before the stacking gel mixture was poured on top of it. A comb was 
inserted immediately after pouring the stacking gel. The stacking gel was allowed to set for 
approximately 45 min.  
Samples were prepared for loading as described above. A lane containing 15 µl protein marker 
(ColorPlus Prestained Protein Marker, New England Biolabs) or 5 µl protein marker (Precision 
Plus Dual Xtra Pre-stained Standards, Bio-Rad) was included. 
The gels were electrophoresed in running buffer (25 mM Tris-HCl, pH 8.0, 192 mM glycine, 0.1 
% (w/v) SDS) through the stacking gel at 15 mA and through the resolving gel at 25 mA. The 
gels were stained, de-stained and imaged as described below or western blotted (Section 0). 
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For both gel types: 
The gels were stained in 50% methanol (v/v), 10% acetic acid (v/v) and 0.25% (w/v) Coomassie 
Brilliant Blue for 1 h at room temperature whilst rocking. After staining, the gels were rinsed 
and destained in 50% methanol (v/v) and 10% acetic acid (v/v) for approximately 16 h or until 
the bands were clearly visible and the background stain diminished. The gels were 
photographed using the InGenius gel documentation system (Syngene). 
2.3 Statistical analysis 
Where appropriate, statistical analysis was performed using the two-tailed, independent, two-
sample t test between sample pairs. Where appropriate, p values of <0.05, <0.01 and <0.001 
are indicated by (*), (**) and (***) respectively. When p > 0.05, p values are not quoted and 
the lack of significant difference is indicated in the text.  
2.4 Generation and characterisation of β2m fibrils 
2.4.1 Production of β2m fibrils 
β2m fibrils were generated using an established protocol [190]. The lyophilised protein was 
dissolved in 10 mM sodium phosphate buffer pH 2.0 containing 50mM NaCl to a concentration 
of approximately 5 mg/ml. The protein solution was filtered using a 0.2μm filter (Sartorius).  10 
μl of the protein solution was unfolded in 20 mM sodium phosphate buffer pH 6.5 containing 6 
M guanidine.HCl and the OD280 was measured spectrophotometrically. The extinction 
coefficient of 20065M-1cm-1 was used to calculate the concentration of the protein solution 
[326].  The protein concentration was adjusted to 120 μM. Fibrils were generated by seeding 
with 0.1% (v/v) fragmented fibrils and quiescent incubation at room temperature for 72 h.    
2.4.2 Fragmentation of β2m fibrils 
Fragmented β2m fibrils were generated by stirring 500 µl of β2m fibrils in a 1.5 ml glass vial 
containing a 3 x 8 mm polytetrafluoroethylene-coated magnetic stirring bar, using a custom-
made precision stirrer (custom built by the workshop of the School of Physics and Astronomy, 
University of Leeds). 
2.4.3 Thioflavin T fluorescence 
The end point Thioflavin T (ThT) fluorescence of fibril samples was measured. Each sample 
(β2m monomer, unfragmented fibrils or fragmented fibrils) was diluted to a final monomer 
equivalent concentration of 1.2 µM in ThT buffer (0.5 M Tris.HCl pH 8.5 containing 10 µM ThT).  
Samples were excited at 440 nm and fluorescence was measured immediately after dilution 
for 60 s by recording emission at 480 nm (slit widths of 3 nm each, acquisition temperature of 
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37 °C). Fluorescence was measured on a fluorimeter (Quantamaster, Photon Technology 
International). An average fold increase in fluorescence of fibril samples over β2m monomer 
was calculated. 
2.4.4 Immunoblotting of fibril samples  
Fibril samples or controls (2 µl) were applied to nitrocellulose membrane (Hybond-Enhanced 
Chemiluminescence, GE Healthcare) and allowed to dry at room temperature. Controls 
included, Hsp70 as a negative control for anti-β2m, β2m monomer as a negative control for 
WO1 and A11 and as a positive control for anti-β2m, and Aβ1-40 oligomer (kind gift from Charles 
Glabe, University of California, Irvine) as a positive control for A11. The membranes were 
blocked with 10 % (w/v) skimmed milk powder (Marvel) in immunoblot buffer (Table 2.4) for 
16 h at 4 °C (β2m and A11 blots) or 1 h at 25 °C (WO1 blots). For WO1 blots, samples were 
incubated with primary antibody in immunoblot buffer containing 3 % (w/v) bovine serum 
albumin (BSA) for 16 h at 4 °C. For A11 and anti-β2m dot blots, samples were incubated with 
primary antibody in immunoblot buffer containing 5 % (w/v) skimmed milk powder for 1 h at 
25 °C. The membranes were washed three times in immunoblot buffer before incubation with 
horseradish peroxidase (HRP) conjugated secondary antibody, in the same buffers as the 
primary antibodies, for 1 h at 25 °C (Table 2.5). The membranes were washed three times with 
immunoblot blot buffer, before visualisation of antibody binding using Supersignal West Pico 
chemiluminescent substrate (Perbio) and medical imaging film (Fujifilm), developed on the 
Konica SRX-101A developer.  
Antibody Host, 
clonality 
Supplier/source Concentration 
used 
Immunoblot 
buffer 
Anti-β2m Rabbit,  
Polyclonal 
DakoCytomation 11 µg/ml PBS containing  0.2 
% (v/v) Tween 20 
Anti-
oligomer 
(A11) 
Rabbit, 
polyclonal 
Charles Glabe, 
University of California, 
Irvine [18] 
0.5 ng/ml PBS containing 
0.05 % (v/v) Tween 
20 
Anti-fibril 
(WO1) 
Mouse, 
monoclonal 
Ronald Wetzel, 
University of Pittsburgh 
[327] 
1 µg/ml PBS containing 0.2 
% (v/v) Tween 20 
Table 2.4: Primary antibodies used in the immunoblotting protocol.  
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Antibody Supplier Concentration used 
Anti-rabbit HRP BD Biosciences 0.4 µg/ml 
Anti-mouse HRP BD Biosciences 0.4 µg/ml 
Table 2.5: Secondary antibodies used in the immunoblotting protocol.  
2.4.5 Transmission electron microscopy 
20 µl of unfragmented or fragmented β2m fibril samples at a final monomer equivalent 
concentration of 12 µM was applied to  carbon coated copper grids and allowed to dry for 30 
s. Excess fibril sample was blotted using filter paper.  The grids were then stained with 20 µl of 
4% (w/v) uranyl acetate for 30 s. Excess uranyl acetate was blotted using filter paper. The fibril 
samples were imaged using a Phillips CM10 electron microscope (100 KeV).  
2.4.6 Fibril length determination by atomic force microscopy (AFM) 
Fibril length distribution was determined by Kevin Tipping, University of Leeds. Samples were 
prepared for tapping-mode AFM by dilution in 18 MΩ purite water to a final monomer 
equivalent concentration of 0.4 µM. Samples were diluted to ensure good sample dispersion 
and uniform distribution on the imaging surface. 20 µl of diluted sample was applied to a 
freshly cleaved mica surface and allowed to dry for 5 min at room temperature. Mica surfaces 
were then washed with 1 ml of 18 MΩ purite water and dried under a gentle stream of N2 gas.  
Samples were imaged using a Dimension 3100 scanning probe microscope (Veeco Instruments) 
and PPP-NCLR silicon cantilever probes (Nanosensors) with a nominal force constant of 48 
N/m. Typically, 10 µm2 images at a pixel ratio of 1024 x 1024 were collected for analysis. Image 
analysis was performed using scripts generated in Matlab (MathWorks) by Wei-Feng Xue 
(University of Kent) [328]. Fibrils were selected automatically using the script to avoid 
subjective bias in analysis.  
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2.5 Cell culture 
RAW 264.7 and SH-SY5Y cells were cultured in Dulbecco’s modified eagle’s medium (DMEM) 
with 10 % (v/v) foetal bovine serum (Biosera), 2 mM L-glutamine, 100 IU/ml1 penicillin and 100 
µg/ml streptomycin in 75 cm3 flasks (OrFlask, Orange Scientific). Cells were incubated at 37 °C, 
5 % CO2. SH-SY5Y cells were passaged using 1 % Trypsin-EDTA solution and RAW 264.7 cells 
with a cell scraper (Grenier Bio-one) when they reached 60–80 % confluency.  
2.5.1 3-(4,5-Dimethylthiazol-2yl)-2,5-diphenyltetrazolium bromide (MTT) assay  
Cells were plated out at 5,000 cells/well (RAW 264.7) or 10,000 cells/well (SH-SY5Y) in 96 well 
plates (RAW 264.7 in Corning Costar plates and SH-SY5Y in NUNC plates) and cultured for 16 h. 
Cells were then incubated with 1.2 µM (monomer equivalent) β2m fibril samples, or controls 
(1.2 µM β2m monomer, fibril growth buffer or 0.1 % (w/v) sodium azide) for 24 h.   20μl of 5 
mg/ml MTT solution was added to the cells and incubated for 1.5 h. The media was then 
discarded and the resulting formazan crystals were resuspended in dimethyl sulfoxide (DMSO). 
Absorbance was measured spectrophotometrically (PowerWave HT Microplate 
Spectrophotometer, BioTek) at 570 nm with absorbance due to background cell debris 
subtracted at 650 nm. Results were normalised to 0.1 % (w/v) sodium azide (0 %) and fibril 
growth buffer (100 %).   
2.5.2 Phase contrast microscopy of cells incubated with MTT 
RAW 264.7 cells were plated out at 500,000 cells/well and SH-SY5Y cells at 1,000,000 cells/well 
in 6 well plates (Corning Costar) and cultured for 16 h. Cells were incubated with 1.2 µM 
(monomer equivalent) β2m fibril samples or controls (1.2 µM β2m monomer or fibril growth 
buffer) for 24 h. Cells were then incubated with MTT at a final concentration of 0.5 mg/ml for 
1.5 h. The cell culture medium was replaced with PBS and cells were imaged with an inverted 
contrasting microscope (Leica DM IL connected to a Leica DC 300F camera, Leica 
Microsystems).     
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2.6 Western blotting analysis  
2.6.1 Preparation of cell lysates 
RAW 264.7 and SH-SY5Y cells were plated out at 500,000 cell/swell and 1,000,000 cells/well 
respectively in 6 well plates (Corning Costar) and cultured for 16 h. Cells were incubated with 
either fragmented β2m fibrils at a final monomer equivalent concentration of 1.2 µM or 1.2 µM 
β2m monomer as a control for 2 h or 24 h. Cells were then washed three times with PBS, prior 
to lysis in lysis buffer (50 mM Tris.HCl pH 7.6 containing 150 mM NaCl, 1 % (v/v) nonidet P-40 
(NP-40) and EDTA-free complete protease inhibitor cocktail (Roche, as described in 
manufacturer’s instructions)) for 30 min on ice. Cell lysates were centrifuged at 500 g for 10 
min at 4 °C (Microcentrifuge 5415R, Eppendorf) and the supernatant was retained. Protein 
concentration in the supernatant was determined by an adapted version of the Lowry assay, 
the DC protein assay (Bio-Rad), as described in the manufacturer’s instructions. Protein 
concentration was assayed for all samples in the experiment at the same time. All sample 
concentrations were adjusted with lysis buffer to match the lowest sample concentration. All 
samples were further diluted in an equal volume of 2X modified Laemmli buffer (100 mM 
Tris.HCl pH 6.8 containing 20 % (v/v) glycerol, 4 % (w/v) SDS, 0.2 % (w/v) bromophenol blue 
and 100 mM dithiothreitol (DTT)) and incubated at 95 °C for 5 min. Samples were then 
resolved by SDS-PAGE and immunoblotted as described below.  
2.6.2 Immunoblotting 
Tris-glycine SDS-PAGE was carried out as described in section 2.2. 10 % Tris-glycine SDS-PAGE 
gels were transferred onto polyvinylidene fluoride (PVDF) membranes (GE Healthcare) using a 
trans-blot semi-dry electrophoretic Transfer cell (Bio-Rad) as described in the manufacturer’s 
instructions, with transfer buffer (15 mM Tris-HCl, 150 mM glycine, 0.02 % (w/v) SDS, 20 % 
(v/v) methanol) at 12 V for 1 h. Membranes were blocked with 5 % (w/v) skimmed milk 
powder (ovalbumin, LC3B and GAPDH blots) or 3 % (w/v) BSA (LAMP-1, CD63 and cathepsin D 
blots) for 16 h rocking at 4 °C. Membranes were incubated with primary antibody for the times 
specified (Table 2.6). Membranes were then washed three times for 5 min whilst rocking with 
PBS containing 0.2 % (v/v) Tween20. This was followed by incubation with secondary 
antibodies (Table 2.5) for 1 h whilst rocking at room temperature. Membranes were washed 
three times for 5 min whilst rocking with PBS containing 0.2 % (v/v) Tween 20. Excess buffer 
was blotted and membranes were developed by chemiluminescence detection using 
Supersignal West Pico chemiluminescent substrate (Perbio) and medical imaging film (Fujifilm), 
on a Konica SRX-101A developer.  
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Antibody Host,  
clone 
Supplier Incubation 
period 
Concentration 
used 
Ovalbumin-
HRP 
Rabbit, 
polyclonal 
GeneTex 16 h, 4 °C 1 in 2000 
Anti-LC3B Rabbit, 
polyclonal 
Abcam 16 h, 4 °C 0.5 µg/ml 
Anti-LAMP-1 Mouse,  
H4A3 
Santa Cruz 
Biotechnology 
16 h, 4 °C 0.4 µg/ml 
Anti-CD63 Rabbit, 
EPR5702 
Abcam 16 h, 4 °C 1 in 200 
Cathepsin D Mouse,  
CTD-19 
GeneTex 16 h, 4 °C 1 in 500 
GAPDH Mouse,  
6C5 
Abcam 1 h, 25 °C 0.4 µg/ml 
Table 2.6: Primary antibodies used for probing western blots. 
Antibody Supplier Incubation period  Concentration used 
Anti-mouse HRP BD Biosciences 1 h, 25 °C 0.4 µg/ml 
Anti-rabbit HRP DakoCytomation  1 h, 25 °C 0.4 µg/ml 
Table 2.7: Secondary antibodies used for probing western blots. 
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2.7 Assays on lysosomal function 
2.7.1 Analysis of lysosomal degradation of fluorescent protein substrates 
2.7.1.1 Preparation of fluorescent protein substrates 
β2m was fluorescently labelled as described below. Pumilio-GFP was a kind gift from Thomas 
Edwards (University of Leeds). Alexa Fluor® 647 ovalbumin was purchased from Molecular 
Probes.  
2.7.1.1.1 Labelling of β2m monomer with tetramethylrhodamine.  
A ten-fold molar excess of 5-(and-6)-carboxytetramethylrhodamine-succinimidyl ester (TMR, 
Molecular Probes) over β2m was dissolved in DMSO at a concentration of 1 mg/ml, and added 
drop wise to β2m (10 mg/ml in 1 M sodium bicarbonate buffer) whilst stirring in the dark for 1 
h. A PD10 desalting column (GE Healthcare) was equilibrated using 25 ml of 100 mM Tris.HCl 
pH 8.0. 2.5 ml of the TMR-β2m conjugate was loaded onto the column and eluted using 3.5 ml 
of 100 mM Tris.HCl pH 8.0. The eluted TMR-β2m conjugate was dialysed against 18 MΩ purite 
water, lyophilised and stored at -20 °C. β2m monomer was labelled with 2, 3, 4 or 5 TMR 
molecules per monomer with a ratio of ≈1:2:2:1 as determined by electrospray ionisation mass 
spectrometry performed by James Ault (University of Leeds, Astbury mass spectrometry 
facility manager).  
2.7.1.2 Analysis by flow cytometry 
RAW 264.7 and SH-SY5Y cells were plated out at 25,000 and 150,000 cells/well respectively in 
12 well plates (Corning Costar) and cultured for 16 h. Cells were incubated with either 
fragmented β2m fibrils at a final monomer equivalent concentration of 1.2 µM, or controls (1.2 
µM β2m monomer and/or fibril growth buffer) for 24 h. Following fibril incubation, cells were 
pulsed with fluorescent protein substrate (Table 2.8) for 4 h (RAW 264.7 cells) or 6 h (SH-SY5Y 
cells). At the end of the pulse, cells were washed thoroughly and either analysed for cell-
associated fluorescence immediately (0 h chase) or cultured for a further 24 h in the absence 
of fluorescent protein substrate and then analysed (24 h chase). The cell population was gated 
to exclude dead cells and debris and 10,000 gated events were recorded. Because SH-SY5Y 
cells have a tendency to clump, SH-SY5Y cells were gated further to exclude cell clumps. 
Results were corrected for background fluorescence using cells incubated in the absence of 
fluorescent protein substrate. Results were normalised to 0 h chase (100 %) for each condition 
and the percentage remaining fluorescence of protein substrate was determined (background 
corrected fluorescence at 24 h chase/background corrected fluorescence at 0 h chase). Cells 
were analysed using a BD LSRFortessa analyser (Becton Dickinson).     
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Protein Fluorophore Concentration used Excitation 
laser 
β2m Tetramethylrhodamine 
(TMR) 
14 µg/ml (RAW 264.7) or 28 µg/ml 
(SH-SY5Y); 10 % labelled: 90 % 
unlabelled 
488 nm 
Pumilio-
GFP 
Green fluorescent protein 
GFP 
20 µg/ml 488 nm 
Ovalbumin Alexa Fluor® 647 15 µg/ml; 40 % labelled: 60 % 
unlabelled 
640 nm 
Table 2.8: Fluorescent protein substrates used for analysis of lysosomal degradation. 
2.7.1.2.1 In vitro measurement of GFP-fluorescence variation with pH 
Pumilio-GFP was diluted to a final concentration of 150 µg/ml into a citrate-phosphate buffer 
(50 mM citric acid, 50 mM sodium phosphate, 100 mM NaCl, 1 mM EDTA) at pH 4.5, 5.5 or 7.4 
respectively. Diluted Pumilio-GFP was excited at a wavelength of 395 nm and emission spectra 
were collected on a fluorimeter (Quantamaster, Photon Technology International). Excitation 
and emission slit widths were set to 3 nm. Background correction was applied by subtracting 
the fluorescence spectra acquired from a citrate-phosphate buffer control. 
2.7.1.3 Analysis by live cell confocal microscopy 
RAW 264.7 and SH-SY5Y cells were seeded at 50,000 and 250,000 cells/well respectively in 3 
cm glass bottomed imaging dishes (Iwaki) and cultured for 16 h. Cells were incubated with β2m 
fibril samples at a final monomer equivalent concentration of 1.2 µM, or controls (1.2 µM β2m 
monomer or fibril growth buffer) for 24 h. Cells were then washed and pulsed with 15 µg/ml 
Alexa Fluor® 647 ovalbumin (40 % labelled, 60 % unlabelled) for 4 h (RAW 264.7) or 6 h (SH-
SY5Y). Following thorough washing, cells were either imaged by live cell confocal microscopy 
immediately (0 h chase) or cultured for a further 24 h and then imaged (24 h chase). Cells were 
stained with 50 nM (RAW 264.7) or 75 nM (SH-SY5Y) LysoTracker Green (Molecular Probes) 30 
min prior to imaging. Images were acquired on an inverted confocal microscope (Zeiss 
LSM700) with a heated stage (37 °C).   
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2.7.2 Analysis of lysosomal proteolysis using Magic Red™ 
2.7.2.1 Live cell confocal microscopy analysis of Magic Red™ cathepsin B substrate 
cleavage 
SH-SY5Y cells were plated at 1,000,000 cells/well in 3 cm imaging dishes (Iwaki) and were 
cultured for 16 h. Following thorough washing, cells were incubated with Magic Red™ 
cathepsin B substrate (ImmunoChemistry Technologies) according to the manufacturer’s 
protocol (Magic Red™ cathepsin B substrate was re-constituted in DMSO and diluted 260-fold 
into cell culture media before incubation with cells at 37 °C for 1 h). Cells were then washed 
and stained with 75 nM LysoTracker Green (Molecular Probes) 30 min prior to imaging, and 
Hoescht (Immunochemistry Technologies) immediately before imaging. Images were acquired 
on an inverted confocal microscope (Zeiss LSM700) with a heated stage (37 °C).   
2.7.2.2 Flow cytometric quantification of cathepsin B activity using Magic Red™ 
RAW 264.7 and SH-SY5Y cells were plated at 250,000 and 500,000 cells/well in 12 well plates 
(Corning Costar) and cultured for 16 h. Cells were incubated with either fragmented β2m fibrils 
at a final monomer equivalent concentration of 1.2 µM, or controls (1.2 µM β2m monomer or 
fibril growth buffer) for 24 h. Cells were washed and incubated in the presence or absence of 
Magic Red™ cathepsin B substrate as described in 2.7.2.1. Cells were washed prior to analysis 
for cell-associated fluorescence by flow cytometry. The cell population was gated to exclude 
dead cells and debris and 10,000 gated events were recorded. Because SH-SY5Y cells have a 
tendency to clump, SH-SY5Y cells were gated further to exclude cell clumps. Results were 
corrected for background fluorescence using cells incubated in the absence of Magic Red™ 
cathepsin B substrate. Results were normalised to controls incubated with fibril growth buffer 
(100 %). Cells were analysed using a BD LSRFortessa analyser (Becton Dickinson).  
2.7.3 Analysis of β-glucocerebrosidase and β-galactosidase activity 
SH-SY5Y cells were plated at 500,000 cells/well in 12 well plates (Corning Costar) and cultured 
for 16 h. Cells were incubated with either fragmented β2m fibrils at a final monomer 
equivalent concentration of 1.2 µM, or controls (1.2 µM β2m or fibril growth buffer) for 24 h. 
Cells were then washed and incubated with either 50 µg/ml 5-
(pentafluorobenzoylamino)fluorescein di-β-D-glucopyranoside (PFB-FDGlu, Molecular Probes) 
or 50 µM  fluorescein di-β-D-galactopyranoside (FDG, Molecular Probes) respectively for 1 h at 
37 °C. β-glucocerebrosidase cleaves the non-fluorescent substrate PFB-FDGlu to yield the 
green-fluorescent PFB-F dye. β-galactosidase cleaves the non-fluorescent substrate FDG to 
yield highly fluorescent fluorescein. For analysis of β-glucocerebrosidase activity, the inhibitor 
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conduritol B epoxide (CBE) was included as an additional control. Cells were pre-incubated 
with 1 µM CBE for 2 h prior to incubation with PFB-FDGlu. Cells were then washed and cell-
associated fluorescence was quantified by flow cytometry. The cell population was gated to 
exclude dead cells and debris and 10,000 gated events were recorded. As SH-SY5Y cells have a 
tendency to clump, SH-SY5Y cells were gated further to exclude cell clumps. Results were 
corrected for background fluorescence using cells incubated in the absence of PFB-FDGlu or 
FDG. Results were normalised to controls incubated with fibril growth buffer (100 %). Cells 
were analysed using a BD LSRFortessa analyser (Becton Dickinson). 
2.8 Analysis of membrane trafficking 
2.8.1 Analysis of the cell surface levels of LAMP-1 and CD63 
SH-SY5Y cells were plated at 1,000,000 cells/well in 6 well dishes (Corning Costar) and cultured 
for 16 h. Cells were incubated with either 1.2 μM (monomer equivalent) fragmented β2m fibril 
samples or controls (1.2 μM β2m monomer or fibril growth buffer) for 2 h or 24 h. To inhibit 
protein synthesis, cells were pre-incubated for 1 h with 100 µg/ml cycloheximde prior to the 
addition of β2m.  After incubation with β2m, cells were washed and then blocked by 
resuspension in PBS with 0.2% (w/v) BSA containing 10% Mouse Seroblock FcR (AbD Serotec) 
and incubation for 30 min on ice. 
 To detect cell surface expression of LAMP-1 and CD63, cells were stained with fluorescently 
labelled anti-LAMP-1 or anti-CD63 antibodies at the recommended concentrations (Table 2.9). 
To measure non-specific background antibody staining, isotype controls were included in 
which cells were stained with the relevant isotype matched antibodies (Table 2.9).  The cell 
population was gated to exclude dead cells and debris, and 10,000 gated events were 
recorded. Due to the tendency of SH-SY5Y cells to clump, an additional gate to exclude cell 
clumps was included. The geometric mean fluorescence for the isotype controls was 
subtracted from the geometric mean fluorescence for the samples for each respective 
treatment. The corrected geometric mean fluorescence was then normalised to buffer treated 
controls (100 %).  Cell-associated antibody fluorescence was quantified by flow cytometry with 
a BD-LSRFortessa analyser (Becton Dickinson). 
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Antibody Host, 
clone 
Isotype Supplier Fluorescent label 
Anti-LAMP-1 Mouse, 
H4A3 
IgG1 κ BD Biosciences PE-Cy5 
Mouse IgG1 κ isotype control 
(control for anti-LAMP-1) 
Mouse, 
MOPC-21 
IgG1 κ BD Biosciences PE-Cy5 
Anti-CD63 Mouse, 
MEM-259 
IgG1 κ GeneTex FITC 
Mouse IgG1 κ isotype control 
(control for anti-CD63) 
Mouse, 
15H6 
IgG1 κ Genetex FITC 
Table 2.9: Antibodies used for flow cytometric analysis of LAMP-1 and CD63 cell surface expression. 
2.8.2 Immunofluorescence microscopy analysis of the intracellular distribution of 
LAMP-1 and CD63 
SH-SY5Y cells were plated on to coverslips (pre-treated with 0.01 % poly-L-lysine) at 75,000 
cells/well in 24 well plates (Nunc) and cultured for 16 h. Cells were then incubated with either 
fragmented β2m fibrils at a final monomer equivalent concentration of 1.2 µM, or fibril growth 
buffer as a control for 2 h or 24 h. Cells were then washed and fixed with 4 % formaldehyde for 
10 min. Following three washes with PBS, cells were incubated with PBS containing 15 mM 
glycine for 10 min. Cells were then washed with PBS and were simultaneously blocked and 
permeabilised for 3 h in blocking buffer (PBS containing 1 % (w/v) fish skin gelatin and 0.2 % 
saponin). This was followed by three washes with PBS. Cells were incubated with primary 
antibody (Table 2.10) in blocking buffer for 1 h at 37 °C. Following three washes with PBS, cells 
were incubated with secondary antibody in blocking buffer for 1 h at 37 °C in the dark. After 
incubation with secondary antibody (Table 2.11), cells were washed three times with PBS prior 
to mounting on to glass slides with mounting medium (VectaShield containing DAPI, Vector 
Laboratories). Images were acquired on an inverted confocal microscope (Zeiss LSM700).      
Antibody Host, clone Supplier Concentration used 
Anti-LAMP-1 Rabbit, polyclonal Sigma-Aldrich 1 in 50 
Anti-CD63 Mouse, MEM-259 GeneTex 1 in 50 
Table 2.10: Primary antibodies used for immunofluorescence microscopy. 
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Antibody Host, clonality Supplier Concentration used 
Anti-rabbit Alexa 
Fluor® 546 
Goat, polyclonal Molecular Probes 1 in 200 
Anti-mouse Alexa 
Fluor® 546 
Donkey, polyclonal Molecular Probes 1 in 200 
Table 2.11: Secondary antibodies used for immunofluorescence microscopy. 
2.8.3 Analysis of the effect of fibrils on fluid phase endocytosis 
2.8.3.1 Analysis by flow cytometry 
SH-SY5Y cells were plated at 150,000 cells/well in 12 well plates (Corning Costar) and were 
cultured for 16 h. Cells were incubated with either fragmented β2m fibrils or controls (1.2 µM 
β2m monomer or fibril growth buffer) for 24 h. Cells were then washed prior to incubation 
with Alexa Fluor® 680 10,000 molecular weight (MW) dextran (Molecular Probes) at a final 
concentration of 0.25 mg/ml for 24 h. Following incubation with labelled dextran, cells were 
washed thoroughly and analysed for cell-associated fluorescence by flow cytometry. The cell 
population was gated to exclude dead cells and debris and 10,000 gated events were recorded. 
Because SH-SY5Y cells have a tendency to clump, SH-SY5Y cells were gated further to exclude 
cell clumps. Results were corrected for background fluorescence using cells incubated in the 
absence of labelled dextran. Cell-associated dextran (%) was normalised to cells incubated 
with fibril growth buffer (100 %).  Cells were analysed using a BD LSRFortessa analyser (Becton 
Dickinson).     
2.8.3.2 Analysis by live cell confocal microscopy 
SH-SY5Y cells were plated at 500,000 cells/well in 3 cm imaging dishes (Iwaki) and cultured for 
16 h. Cells were then washed and incubated with Alexa Fluor® 568 10,000 MW dextran 
(Molecular Probes) at a final concentration of 0.5 mg/ml for 24 h. Following incubation with 
labelled dextrans, cells were washed thoroughly prior to incubation with either fragmented 
β2m fibrils at a final monomer equivalent concentration of 1.2 µM or fibril growth buffer as a 
control for 24 h. This was followed by incubation with a second labelled dextran, Alexa Fluor® 
680 10,000 MW dextran (Molecular Probes) at a final concentration of 0.5 mg/ml for 24 h. 
Cells were then washed thoroughly prior to analysis by live cell confocal microscopy. Images 
were acquired on an inverted confocal microscope (Zeiss LSM700) with a heated stage (37 °C).   
Images were analysed for colocalisation of the two labelled dextrans with Image J using the 
JACoP plugin [329]. Colocalisation analysis was performed by following established guidelines 
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[330]. Background fluorescence which would result in over-estimation of correlation, was 
subtracted using the Costes’ threshold method using the Costes’ subtraction feature in JACoP 
[329, 331]. Correlation was quantified by calculating Manders’ colocalisation coefficients 
(MCC) [332]. MCC allows quantification of the fraction of one fluorophore that colocalises with 
a second fluorophore [332]. For example, for two probes, denoted as R and G, two different 
MCC values, M1 and M2 are derived. M1 represents the fraction of R in compartments 
containing G. M2 represents the fraction of G in compartments containing R. M1 and M2 
values were calculated for 20 images per condition.  
2.9 Expression and purification of Hsp70 
2.9.1 Expression of Hsp70 
Hsp70 (UniProtKB P08107.5) was expressed in BL21 (DE3) pLysS cells transformed with the 
designated pET28b-Hsp70(1A) plasmid containing the gene for human, stress-inducible, 
cytosolic Hsp70 (kind gift from Nunilo Cremades, University of Cambridge). Hsp70 was 
expressed and purified using a previously described protocol [333]. 10 µl of a glycerol stock of 
BL21 (DE3) pLysS cells transformed with pET28b-Hsp70(1A) was streaked out onto a fresh LB-
agar plate containing 50 µg/ml kanamycin. The LB-agar plate was incubated at 37 °C for 16 h. A 
single colony was picked and used to inoculate a starter culture of 100 ml LB containing 50 
µg/ml kanamycin. The starter culture was incubated in an orbital shaker (Stuart S150) at 37 °C 
for 16 h whilst shaking at 200 rpm. 
11 l of pre-warmed LB were inoculated with the starter culture (5 ml of starter culture per litre 
of LB containing 50 µg/ml kanamycin). The bacterial cultures were incubated at 37 °C whilst 
shaking 200 rpm. The OD600 was monitored regularly and when an OD of 0.7 was reached, the 
cultures were induced by addition of IPTG at a final concentration of 1 mM. The bacterial 
cultures were incubated at 28 ⁰C whilst shaking at 200 rpm for 16 h, after which the cells were 
harvested by centrifugation (Beckman Coulter, JLA-10.500 rotor, 6000 rpm, 4 °C, 40 min). The 
supernatant was discarded and the cell pellet was stored at -20 °C.  
2.9.2 Cell lysis 
The cell pellet was thawed on ice and resuspended in 100 ml of lysis buffer (50 mM Tris.HCl pH 
7.4, 150 mM KCl, 2 mM MgCl2 and 10 mM imidazole) containing EDTA-free complete protease 
inhibitor cocktail (Roche, according to the manufacturer’s instructions). The cells were lysed 
further with a cell disrupter (Constant Systems Cell Disrupter). 5 mg of DNAseA was added to 
the cells post-lysis. Cell lysates were then centrifuged for 30 min at 4 °C (Beckman Coulter, JLA 
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16.250 rotor, 15,000 rpm).  The supernatant was retained and filtered through a 0.4 µM filter 
(Sartorius) prior to purification by Ni-NTA affinity chromatography. 
2.9.3 Ni-NTA affinity chromatography 
The filtered supernatant was loaded onto an XK26 column (GE Healthcare) containing 25 ml 
(bed volume) Ni Sepharose High Performance (GE Healthcare) previously equilibrated with 
lysis buffer (50 mM Tris.HCl pH 7.4, 150 mM KCl, 2 mM MgCl2 and 10 mM imidazole). The 
column was mounted on an AKTA prime chromatography system (GE Healthcare) at 4 °C. The 
column was washed with a mixture of 6 % elution buffer (lysis buffer containing 500 mM 
imidazole) and 94 % lysis buffer (final imidazole concentration of 40 mM). The protein was 
then eluted with a mixture of 40 % elution buffer and 60 % lysis buffer (final imidazole 
concentration of 200 mM). The column was finally washed with 100 % elution buffer. The 
fractions corresponding to the peak eluted with 200 mM imidazole were pooled and dialysed 
five times against 2 l of 50 mM Tris.HCl pH 7.4 containing 150 mM KCl and 2 mM MgCl2.  
2.9.4 Size exclusion chromatography 
The dialysed protein was further purified by size exclusion chromatography using a Superdex 
75 HiLoad 26/60 size exclusion column (GE Healthcare) previously equilibrated with 50 mM 
Tris.HCl pH 7.4 containing 150 mM KCl and 2 mM MgCl2, and connected to an AKTA prime 
chromatography system (GE Healthcare) at 4 °C. The dialysed protein was loaded onto the 
column (5 ml of ~12 mg/ml per run) and the following program (Table 2.1) on the AKTA prime 
system was used to purify the protein.  
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Breakpoint 
(ml) 
% 
B 
Flow 
rate  
Fraction 
size 
Buffer 
valve 
position 
Inject 
valve 
position  
Set 
peak 
collect 
Auto 
zero 
Event 
mark 
0 0 2 
ml/min 
0 1 Load No No No 
10 0 0.5 
ml/min 
0 1 Inject No Yes Yes 
20 0 2 
ml/min 
0 1 Load No No  Yes 
30 0 2 
ml/min 
2.5 1 Load No No Yes 
260 0 2 
ml/min 
0 1 Load No No Yes 
Table 2.12: Details of the AKTA program used for the size exclusion chromatography purification of 
Hsp70. 
2.9.5 Anion exchange chromatography 
Size exclusion chromatography did not successfully separate the protein as judged by SDS-
PAGE analysis, the protein was therefore further purified by anion exchange chromatography. 
The protein fractions from size exclusion chromatography were pooled and dialysed five times 
against 2 l of 20 mM Tris.HCl pH 8.0. The dialysed protein was loaded onto a ResourceQ 
column (GE Healthcare) previously equilibrated with loading buffer (20 mM Tris.HCl pH 8.0) 
and connected to an AKTA prime chromatography system (GE Healthcare) at 4 °C. The column 
was washed with 10 ml of loading buffer, and protein was eluted with a linear gradient of 0 – 
700 mM NaCl in 20 mM Tris.HCl pH 8.0 over 60 ml. Finally, the column was washed with 1M 
NaCl in 20 mM Tris.HCl pH 8.0 to remove any remaining bound protein and regenerate the 
column. The fractions corresponding to pure Hsp70 as judged by SDS-PAGE analysis were 
pooled and dialysed five times against 2 l of 50 mM Tris.HCl pH 7.4 containing 150 mM KCl and 
2 mM MgCl2, prior to storage at -80 °C.    
2.10 Analysis of the effect of Hsp70 on fibril-mediated cell disruption 
2.10.1 Analysis of intracellular localisation of recombinant Hsp70 
Purified wild-type Hsp70 was fluorescently labelled with Alexa Fluor® 405 using Alexa Fluor® 
405-succinimidyl ester (Molecular Probes) at a five-fold molar excess over Hsp70. Alexa Fluor® 
405-succinimidyl ester was dissolved in DMSO at a concentration of 1 mg/ml, and added drop 
wise to Hsp70 (12 mg/ml in 1 M sodium bicarbonate buffer) whilst stirring in the dark for 1 h. 
The reaction was quenched by addition of 500 µl 10 mM Tris.HCl pH 8.0. A PD10 desalting 
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column (GE Healthcare) was equilibrated with 25 ml of 100 mM Tris.HCl pH 8.0. The Alexa 
Fluor® 405-Hsp70 conjugate was loaded onto the column and eluted using 3.5 ml of 100 mM 
Tris.HCl pH 8.0. The eluted Alexa Fluor® 405-Hsp70 conjugate was dialysed against PBS. 
Approximately 30 % of the Hsp70 was labelled with one dye molecule per Hsp70 monomer as 
determined by electrospray ionisation mass spectrometry performed by James Ault (University 
of Leeds, Astbury mass spectrometry facility manager).   
RAW 264.7 cells were incubated with 3 µM Alexa Fluor® 405-Hsp70 for 4 h. Cells were then 
washed and stained with 50 nM LysoTracker Green prior to analysis by live cell confocal 
microscopy. Images were acquired on an inverted confocal microscope (Zeiss LSM510) using a 
heated stage (37 °C).  
2.10.2 MTT assay 
Cells were plated out at 5,000 cells/well (RAW 264.7) or 10,000 cells/well (SH-SY5Y) in 96 well 
plates (RAW 264.7 in Corning Costar plates and SH-SY5Y in NUNC plates) and cultured for 16 h. 
Cells were then pre-incubated with either Hsp70 or W90F Hsp70 at a final concentration of 0 
µM, 0.3 µM or 3 µM for 4 h (RAW 264.7) or 6 h (SH-SY5Y).  Controls cultured in the absence of 
Hsp70 were incubated with PBS instead. This was followed by incubation with either 1.2 µM 
(monomer equivalent) fragmented β2m fibrils or controls (1.2 µM β2m or fibril growth buffer) 
for 24 h. Cells were assayed for MTT reduction as described in 2.5.1.  
2.10.3 Phase contrast microscopy analysis of cells incubated with MTT 
SH-SY5Y cells were plated at 1,000,000 cells/well in 6 well plates (Corning Costar) and cultured 
for 16 h. Cells were pre-incubated with either Hsp70 at a final concentration of 3 µM or PBS as 
a control.  This was followed by incubation with either 1.2 µM (monomer equivalent) 
fragmented β2m fibrils or fibril growth buffer as a control for 24 h. Cells were then incubated 
with MTT and imaged by phase contrast microscopy as described in 2.5.2.  
2.10.4 Analysis of cell-surface expression of LAMP-1 
SH-SY5Y cells were plated at 1,000,000 cells/well in 6 well plates (Corning Costar) and cultured 
for 16 h. Cells were pre-incubated with either Hsp70 at a final concentration of 3 µM or PBS as 
control for 6 h prior to incubation with either fragmented β2m fibrils at a final monomer 
equivalent concentration of 1.2 µM or controls (1.2 µM β2m monomer or fibril growth buffer) 
for 24 h. Cell-surface LAMP-1 levels were quantified as described in 2.8.1.  
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2.10.5 Analysis of lysosomal degradation of fluorescently labelled ovalbumin 
SH-SY5Y cells were plated at 250,000 cells/well in 12 well plates (Corning Costar) and cultured 
for 16 h. Cells were pre-incubated with either Hsp70 at a final concentration of 3 µM or PBS as 
control for 6 h prior to incubation with either 1.2 µM (monomer equivalent) fragmented β2m 
fibrils or controls (1.2 µM β2m monomer or fibril growth buffer) for 24 h. Ovalbumin 
degradation was assayed as described in 2.7.1.2.  
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3 β2m as a model to study amyloid disease 
3.1 Introduction 
3.1.1 β2m structure  
β2m is a 99 residue protein which exhibits a typical immunoglobulin fold consisting of seven β 
strands arranged into a β-sandwich stabilised by a disulphide bond between residues 25 and 
80 (Figure 3.1) [334]. The β strands are arranged in an all antiparallel organisation with the 
edge strand, ‘D’ exhibiting a β-bulge as observed in crystal structures of β2m within the MHC I 
complex or as a free monomer in solution (Figure 3.2)[335, 336]. A conformation in which the 
edge ‘D’ strand does not exhibit a β-bulge but instead displays a straight D-strand has also 
been reported several times, and has been implicated in facilitating aggregation (Figure 3.2 
and reviewed in [337]). Four out of five of the proline residues found within the β2m sequence 
are in the trans conformation, whereas proline 32 is in the cis conformation in the native state. 
The isomerisation of proline 32 is thought to be important in controlling β2m aggregation into 
amyloid fibrils [338]. 
 
Figure 3.1: Structure of MHC I complex and β2m monomer. (A) Ribbon representation of human MHC I 
(PDB code 3MYJ)[339] showing the heavy chain (silver) and the light chain, β2m (gold). Hydrophobic 
residues present in β-strand E (Phe56, Trp60, Tyr62, Tyr63 and Leu65) that contact the heavy chain are 
highlighted. (B) Ribbon representation of the solution structure of native β2m monomer (PDB code 
2XJS)[340] showing β-strands A (residues 6-11), B (residues 21-28), C (residues 36-41), C’ (residues 44-
45), D (residues 50-51), E (residues 64-70), F (residues 79-83) and G (residues 91-94). Figure adapted 
from [337, 341]. 
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Figure 3.2: Structures of wild-type β2m and β2m variants displaying a β-bulge or continuous β-strand 
D.  (A) Structures displaying a β-bulge. Wild-type β2m is displayed in red (PDB code 1JNJ)[336], H31Y β2m 
in green (PDB code 1PY4)[342], W60G β2m in blue (PDB code 2VB5)[343], H13F β2m in yellow (PDB code 
3CIQ)[344] and β2m bound to the MHC I complex in magenta (PDB code 3MYJ)[339]. (B) Structures 
displaying a continuous β-strand D. Wild-type β2m  is displayed in red (PDB code 1LDS)[334], 
L39W/W60F/W95F β2m in green (PDB code 2D4D)[345], wild-type β2m  in blue (PDB code 2YXF)[345], 
wild-type β2m  in yellow (PDB code 2YXFF)[346], W60G β2m  in magenta (PDB code 2Z9T)[343], W60C 
β2m  in cyan (PDB code 3DHJ)[347], D59P β2m  in orange (PDB code 3DHM)[347], W60G β2m in wheat 
(PDB code 3EKC)[347], K58P/W60G β2m  in black (PDB code 3IB4)[348] and P32A β2m  in grey (PDB  code 
2F8O)[349].  Figure adapted from [337]. 
3.1.2 β2m amyloid formation and characterisation 
It is important to note that wild-type human β2m, does not form amyloid fibrils at physiological 
temperature and pH in vitro, without the aid of external factors such as Cu2+, SDS or 
trifluoroethanol [350-352]. In vitro studies of β2m amyloid fibril formation have been made 
possible by the finding that agitation at low pH results in rapid β2m fibril formation [189, 325, 
353]. Perturbation of the β2m sequence controls the amyloid fibril-forming propensity of the 
unfolded state at low pH, thus implicating several regions in amyloid formation [54]. Peptide 
fragments that correspond to residues 21-40 (spanning β strands B and C) have been shown to 
aggregate into amyloid fibrils in isolation [354]. Another study involving the systematic 
investigation of peptide fragments spanning the entire sequence of β2m, implicated residues 
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59-71 (encompassing β strand E) [355]. This region is highly enriched in aromatic residues and 
is capable of forming amyloid fibrils in isolation. It has also been shown to play an important 
role in nucleation and elongation of fibrils as well as the rate of fibril formation [355-357]. 
Residues in the loop connecting β strands D and E, as well as residues 83-89 (corresponding to 
the C terminal region) have also been reported to promote aggregation [343, 358]. In contrast, 
β strand A has been reported to disfavour aggregation and stabilise the native state [359].  
Accumulating evidence points to increased conformational dynamics as a common feature in 
the assembly of β2m monomers into amyloid fibrils at neutral pH, analogous to observations 
from other amyloidogenic proteins that also assemble into amyloid fibrils via conformational 
changes in their folded monomeric states (reviewed in [337]). Wild-type β2m and its variants 
such as ΔN6 β2m (a truncated variant where six N terminal residues are cleaved), ΔK58 β2m 
and ck58 β2m (variants where Lys58 is cleaved with or without removal of Lys58, respectively), 
have all been demonstrated to exhibit increased local and global unfolding events, decreased 
solubility and enhanced amyloidogenicity at pH values close to physiological pH (reviewed in 
[337]).  
ΔN6 β2m is of particular interest because it is found in ex vivo fibril deposits, of which it forms a 
significant component (~ 26 %) [360]. ΔN6 β2m is highly amyloidogenic and exhibits a greater 
affinity for collagen than wild-type β2m [360, 361]. Collagen is highly enriched in osteoarticular 
tissues, the main site of damage in DRA, thus implicating ΔN6 β2m in the pathogenesis of DRA 
[360, 361]. Proline 32 in ΔN6 β2m is in the trans conformation compared to the cis 
conformation observed in wild-type β2m; this is particularly relevant as the non-native trans 
conformation of proline 32 is thought to be the link between the native and aggregation-prone 
states [338, 362]. Although ΔN6 β2m forms a significant component of ex vivo β2m amyloid 
deposits, it is not found in the serum of DRA patients [363].  Cleavage has thus been suggested 
to occur after incorporation of full-length β2m into amyloid fibrils [364]. However, recent 
studies have demonstrated that ΔN6 β2m is not only able to nucleate fibrillogenesis efficiently 
in vitro at physiological pH, but is also able to convert wild-type β2m into an aggregation-
competent state by bimolecular collision [340]. Catalytic amounts of ΔN6 β2m (1 %) are 
sufficient to convert wild-type β2m into amyloid fibrils, therefore implicating ΔN6 β2m as an 
important initiating factor for amyloid formation in DRA [340].  
β2m fibril formation in vitro has been shown to proceed via both nucleation-dependent and 
nucleation-independent polymerisation pathways under different fibrillation conditions [189, 
365]. At low pH and low ionic strength (pH 2.0, 50 mM NaCl), β2m monomers assemble via a 
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nucleation-dependent pathway to generate amyloid fibrils of a long straight morphology with 
a characteristic periodic twist classically associated with amyloid [189](Figure 3.3). By contrast, 
at higher pH and higher ionic strength (pH 3.5, 200 mM NaCl), β2m monomers rapidly 
assemble via a non-nucleated pathway to generate shorter, ‘worm-like’ fibrils [189]. Long 
straight β2m amyloid fibrils exhibit a characteristic cross-β diffraction pattern, Congo Red 
birefringence and ThT binding [341, 366](Figure 3.3). β2m fibrils are also bound by the anti-
fibril antibody, WO1, which recognises a fibrillar epitope found on amyloid fibrils independent 
of the precursor protein sequence [327, 367](Figure 3.3). In contrast, β2m fibril samples are 
not recognised by the anti-oligomer antibody, A11 [367](Figure 3.3). A11 recognises soluble 
oligomers, and like, WO1, is also generic in that it binds independently of precursor protein 
sequence [18].  
 
Figure 3.3: Morphological, structural and tinctorial characteristics of β2m amyloid fibrils assembled at 
low pH and low ionic strength. (A) β2m amyloid fibrils have a long straight morphology when visualised 
by TEM (scale bar 100 nm). Image from [366]. (B) β2m amyloid fibrils display a characteristic cross-β X-
ray diffraction pattern. Image from [341]. (C) The characteristic red-green birefringence of Congo Red 
under polarised light is observed when bound to β2m amyloid fibrils. Image from [341]. (D) β2m amyloid 
fibril growth kinetics visualised by ThT fluorescence. Image from [366]. (E) Immunoblotting of β2m 
amyloid fibrils with anti- β2m, A11 and WO1 antibodies. Image from [367]. Adapted with permission 
from [367]. Copyright (2006) American Chemical Society. 
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3.1.3 β2m as a model to study amyloid disease 
β2m amyloid fibrils assembled at low pH and low ionic strength have been shown to share 
structural characteristics with fibrils assembled in vitro at physiological pH as well as ex vivo 
β2m amyloid fibrils [366]. In addition, β2m amyloid fibrils exhibit amyloid characteristics which 
are shared by all amyloid fibrils irrespective of the starting protein (Figure 3.3 and section 1.3). 
The β2m amyloid fibril formation pathways, the various intermediate species and amyloid 
fibrils have been well studied and characterised [125, 189, 340, 341, 368]. Indeed, β2m fibrils 
with a long straight morphology are readily formed (within 72 h) at low pH and low ionic 
strength with well characterised yield, morphology and fibril length [190, 366]. Mature β2m 
fibril preparations do not contain detectable levels of soluble oligomer species [190]. The 
starting conformation of each fibril preparation prior to addition to cells is thus known. 
Furthermore, purification of recombinant β2m is straightforward and results in a high yield of 
pure protein (approximately 40 mg per litre of bacterial culture). β2m thus serves as a useful 
model to study amyloid disease.   
3.2 Results 
3.2.1 Expression and purification of β2m 
In order to generate β2m to make amyloid fibrils for subsequent experiments, recombinant 
β2m was expressed in BL21 (DE3) pLysS cells carrying the pINK plasmid using an established 
protocol [325](Section 2.1 and Figure 3.4). Cells were lysed after induction of protein 
expression with isopropyl β-D-1-thiogalactopyranoside (IPTG) and the inclusion bodies 
containing β2m were isolated and solubilised as described (Section 2.1.2).  
β2m was purified from the inclusion bodies by anion exchange chromatography (Figure 3.5). 
β2m eluted in fractions corresponding to peak 1 as confirmed by SDS-PAGE analysis (Figure 
3.6). Fractions corresponding to peak 1 were pooled, dialysed against 18 MΩ purite water and 
lyophilised. The lyophilised protein was re-solubilised in 25 mM sodium phosphate buffer pH 
8.0 prior to further purification by size exclusion chromatography (Figure 3.7). Size exclusion 
chromatography was performed to separate monomeric β2m from dimeric β2m, higher order 
β2m aggregates and other contaminants. Peak 2 corresponds to pure β2m as confirmed by SDS-
PAGE analysis (Figure 3.8). Fractions corresponding to peak 2 were pooled, dialysed against 18 
MΩ purite water and lyophilised for storage at -20°C. 
Analytical gel filtration was used to check the purity of β2m upon reconstitution from 
lyophilised powder stored at -20 °C (Figure 3.9). A single symmetrical peak was observed and is 
consistent with a pure preparation of β2m. Electrospray ionisation mass spectrometry (ESI-MS) 
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was used to determine the molecular weight of purified protein (Figure 3.10). A molecular 
mass of 11,859.48 ± 0.66 Da is consistent with the purified protein being monomeric β2m 
(expected mass = 11,860 Da). The additional low intensity peaks correspond to mono- and bi- 
phosphate adducts.  
 
Figure 3.4: Schematic of expression and purification strategy.  
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Figure 3.5: Anion exchange chromatography purification of solubilised inclusion bodies.  After isolation 
from IPTG induced BL21 DE3 pLysS cells carrying the pINK plasmid [325], inclusion bodies were 
solubilised in 25 mM Tris.HCl pH 8.0 containing 8 M urea. β2m was refolded by dialysis into 25 mM 
Tris.HCl pH 8.0 and purified from the inclusion bodies by anion exchange chromatography using a Q-
Sepharose column. The protein was eluted with a linear gradient of 0 – 400 mM NaCl in 25 mM Tris.HCl 
pH 8.0 over 650 ml. β2m elutes in peak 1. The corresponding fractions were pooled and dialysed against 
18 MΩ purite water. Samples spanning peaks 1 and 2 were collected for analysis by SDS-PAGE. 
  
Figure 3.6: SDS-PAGE analysis of β2m expression and purification by anion exchange chromatography. 
Samples were resolved by 15% Tris-Tricine SDS-PAGE and proteins were visualised with Coomassie Blue. 
Lane 1 – Soluble fraction of cell lysate post cell-lysis; 2 and 3 – Post-wash supernatant of inclusion body 
washes; 4 – Protein loaded onto anion exchange column after refolding by dialysis; 5 and 6 - Flow-
through of anion exchange column; 7 to 11 – samples spanning first peak of anion exchange 
chromatographic purification (1 from Figure 3.5) 
83 
 
 
Figure 3.7: Further purification of β2m by size exclusion chromatography. The lyophilised protein was 
dissolved in 10mM sodium phosphate buffer pH 7.2 to a concentration of approximately 1 mg/ml. 5ml 
of protein was loaded onto a Superdex 75 HiLoad 26/60 column per run. Samples spanning both peaks 1 
and 2 were collected for SDS-PAGE analysis.   
 
Figure 3.8: SDS-PAGE analysis of purification of β2m by size exclusion chromatography. Samples were 
resolved by 15% Tris-Tricine SDS-PAGE and proteins were visualised with Coomassie Blue. Lane 1- 
marker; 2 - sample from the second anion exchange chromatography peak (2 in Figure 3.5); 3 - sample 
from the first size exclusion chromatography (1 in Figure 3.7); 4 and 5 – samples spanning the second 
size exclusion chromatography peak (2 in Figure 3.7). 
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Figure 3.9: Analytical size exclusion chromatography to determine the purity of β2m. Lyophilised β2m 
stored at -20°C was dissolved in 10 mM sodium phosphate buffer pH 7.2 and then loaded onto a 
Superdex 75 HiLoad 16/10 column. 
 
Figure 3.10: Electrospray ionisation mass spectrometry (ESI-MS) analysis of the purified protein. Mass 
profiles generated by Maximum Entropy processing of the ESI-MS m/z spectra. The peak corresponding 
to 11859.48 ± 0.66 Da represents full-length wild-type β2m. The peaks to the right correspond to β2m 
bound to sodium and potassium ions. ESI-MS analysis was performed by Dr James Ault (University of 
Leeds, Astbury mass spectrometry facility manager). 
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3.2.2 Generation and characterisation of amyloid fibrils 
β2m amyloid fibrils with the previously described long, straight morphology were generated 
from purified monomeric β2m according to an established protocol (Section 2.4.1)[190]. Pure 
lyophilised β2m was resuspended in fibril growth buffer (10 mM sodium phosphate pH 2.0, 
containing 50 mM NaCl) and passed through a 0.2 µm filter (Sartorius). Protein concentration 
was adjusted to 120 µM prior to the addition of 0.1 % (v/v) seeds (fragmented β2m fibrils). 
Fibril formation was allowed to proceed quiescently at room temperature for 72 h.  
Fragmented fibrils can be used to model fibrils that are formed early on in the polymerisation 
process or those that fragment post-assembly. Previous work in our laboratory has shown that 
fragmentation of fibrils results in fibrils of shorter length but otherwise unchanged molecular 
architecture. These fragmented fibrils inhibit the cellular reduction of a commonly used cell 
viability substrate, 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide (MTT), to a 
greater extent than their unfragmented counterparts [190]. Fragmented fibrils were generated 
by fragmentation of mature long straight β2m amyloid fibrils for 48 h using a custom built 
precision stirrer (Section 2.4.2)[190]. 
To confirm fibrils generated in this project have the same properties as described previously, 
fragmented and unfragmented fibrils were characterised based on their biophysical, tinctorial 
and immunological properties. Thioflavin T (ThT) is an amyloid dye widely used for over 50 
years to monitor amyloid formation [369]. It is a fluorescent dye that fluoresces more intensely 
when bound to amyloid fibrils in vitro [86]. Samples of fragmented and unfragmented fibrils 
were characterised based on their binding to ThT, relative to monomer control (Section 2.4.3). 
An increase in ThT fluorescence over monomer control was observed for both fragmented (60-
fold) fibrils and unfragmented (110-fold) fibrils (Figure 3.11). The enhanced increase in ThT 
fluorescence for unfragmented fibrils over fragmented fibrils is consistently observed, however 
the mechanism for this is currently unknown. Despite many studies, the exact binding 
mechanism of ThT to amyloid fibrils has not yet been determined [369]. The enhanced ThT 
fluorescence of unfragmented fibrils compared to unfragmented fibrils could be due to the 
longer length providing more ThT binding sites in close proximity to each other compared to 
fragmented fibrils. 
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Figure 3.11: Characterisation of amyloid fibrils by ThT fluorescence. Samples of 1.2 µM β2m monomer,  
1.2 µM (monomer equivalent) fragmented or unfragmented fibrils were incubated with 10 µM ThT and 
the fluorescence measured. 60 readings were taken over 1 minute and the average fold increase over 
β2m monomer calculated. Error bars represent one standard deviation (S.D). 
The development of amyloid conformation-specific antibodies has created an additional 
experimental tool to characterise amyloid material (reviewed in [127]). Monomeric β2m, as 
well as fragmented and unfragmented fibril samples were dotted onto nitrocellulose 
membrane and immunoblotted with A11, WO1 and anti-β2m antibodies (Section 2.4.4). Aβ1-40 
oligomers were used as a positive control for the A11 antibody and Hsp70 as a negative control 
for the anti-β2m antibody. Both fragmented and unfragmented fibrils were bound by WO1, but 
not by A11 (Figure 3.12). Consistent with previously published work, this confirms the 
presence of an amyloid fibril epitope in both fragmented and unfragmented fibril samples as 
well as the absence of detectable oligomers recognised by A11 [190].  
87 
 
 
Figure 3.12: Analysis of β2m fibril samples with amyloid-specific antibodies. Samples of β2m monomer, 
unfragmented, or fragmented β2m fibrils were analysed by immunoblotting with the anti-oligomer 
antibody A11 (top), the anti-fibril antibody WO1 (middle) and the anti-β2m antibody (bottom). Aβ1-40 
oligomers (kind gift from Charles Glabe, University of California, Irvine) were used as a positive control 
for the A11 antibody. Antibody binding was detected with secondary anti-rabbit IgG-HRP (A11, β2m) or 
anti-mouse IgM-HRP (WO1) respectively and visualised by chemiluminescence. Hsp70 was used as a 
negative control for the anti- β2m antibody. Each dot contains 2.8 µg (β2m and Hsp70) or 1.1 µg (Aβ1-40) 
of protein/peptide. 
Fragmented and unfragmented fibril samples were analysed by negative stain transmission 
electron microscopy (TEM) to confirm the presence of fibrils and to visualise fibril morphology. 
Carbon coated copper grids were incubated with fragmented and unfragmented fibril samples 
prior to imaging (Section 2.4.5). Images for both fibril samples show rope-like, twisted fibrils 
with fragmented fibrils being qualitatively of a reduced length compared to their 
unfragmented counterparts (Figure 3.13). 
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Figure 3.13: TEM images of fibrils generated from β2m. Fibril samples were diluted to 6 µM (monomer 
equivalent) before incubation on carbon coated copper grids for 30 s. Grids were dried after fibril 
incubation and negatively stained with 4 % (w/v) uranyl acetate. Imaging was performed with a Phillips 
CM10 electron microscope at a magnification of 52,000. The scale bars represent 200 nm. 
The effect of fragmentation on the structure of β2m amyloid fibrils has been previously 
characterised extensively [190]. However for the purpose of this chapter, the effect of 
fragmentation on fibril length was determined by atomic force microscopy (AFM) (Section 
2.4.6). Fibrils were imaged by tapping mode AFM and fibril length was quantified using 
automated scripts generated by Wei-Feng Xue (University of Kent)[328]. The fibril length 
distribution for unfragmented fibrils is broad and shallow with an average length of 1.30 ± 0.05 
µm, whilst that for fragmented fibrils is narrower with an average length of 0.30 ± 0.01 µm 
(Figure 3.14).  
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Figure 3.14: Analysis of fibril length by AFM. AFM images (top) of fragmented (left) and unfragmented 
(right) β2m fibrils. Scale bars represent 1 µm. Histograms (bottom) showing the fibril length distribution 
calculated from >200 particles. Images acquired and calculations performed by Kevin Tipping, University 
of Leeds. 
3.2.3 Analysis of the effect of fibrils on the cellular reduction of MTT 
Having generated fibrils of defined length, and biophysical and immunological characteristics, 
the next step was to analyse the effect of fibrils on cellular viability. This involved the use of 
two cell lines, the human neuroblastoma cell line, SH-SY5Y and the mouse macrophage cell 
line, RAW 264.7. SH-SY5Y cells are widely used to study amyloid-cell interactions [242, 370, 
371]. Macrophages have been implicated in disease progression in DRA and therefore RAW 
264.7 cells serve as a good model to study macrophage interactions with amyloid [247, 372]. 
Cell viability was analysed using the commonly used viability assay, the MTT assay [373-
376](Figure 3.15). The MTT assay measures the ability of viable cells to internalise the yellow 
tetrazolium salt (MTT) and reduce it to a dark blue product (formazan) [373]. MTT is thought to 
be reduced by mitochondrial dehydrogenases [377]. Spectroscopic measurement of the dark 
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blue product of reduction allows quantification of cell viability. The yellow MTT salt is 
internalised by endocytosis and the reduced formazan accumulates in intracellular-granule like 
structures prior to exocytosis to the cell surface where it accumulates as needle-like crystals 
[378].  
Cells were incubated with β2m monomer, fragmented or unfragmented β2m fibrils at a final 
monomer equivalent concentration of 1.2 µM for 24 h (Section 2.5.1). β2m monomer serves as 
control as it is the same protein however it is natively folded and lacks the cross-β architecture 
of amyloid fibrils. Additional controls were included to allow data normalisation; these were 
0.1 % (w/v) sodium azide (0 % MTT reduction) and fibril growth buffer alone (100 % MTT 
reduction). As reported previously for both RAW 264.7 and SH-SY5Y cells, fragmented fibrils 
inhibited MTT reduction to a greater extent than unfragmented fibrils (Figure 3.16)[190].  
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Figure 3.15: Schematic showing an overview of the MTT assay.  Cells were plated on to 96 well plates 
prior to incubation with fibril growth buffer (left), β2m monomer (centre left), fragmented β2m fibrils 
(centre right) or unfragmented β2m fibrils (right). Cells were then incubated with MTT which is a yellow 
salt. Reduced formazan is a dark blue product. Spectroscopic measurement of reduced formazan allows 
quantification of MTT reduction.  
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Figure 3.16: Analysis of the effect of fibrils on MTT reduction.  MTT assays were performed using β2m 
monomer, fragmented and unfragmented β2m fibrils at a final monomer equivalent concentration of 1.2 
µM. RAW 264.7 cells (A) and SH-SY5Y cells (B) were incubated with fibrils or controls for 24 h before 
being tested for MTT reduction. MTT reduction (%) was calculated by normalising the signal from cells 
incubated with fibril growth buffer as 100% and cells treated with 0.1% (w/v) NaN3 as 0%.  The error 
bars represent one standard error of mean (S.E.M.) over five independent experiments each containing 
five replicates. *** signifies a p value <0.001. 
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The use of the MTT assay in assessing the cytotoxicity of amyloid material must be approached 
with care. Previous work with Aβ peptides and amylin has shown that amyloid preparations 
inhibit MTT reduction, however, this inhibition is associated with an increase in formazan 
exocytosis [379-383]. Increased formazan exocytosis is visualised by an increased amount of 
needle-like formazan crystals at the cell surface [380] and has been proposed to impair cell 
membrane integrity [382, 383]. This inhibition in MTT reduction is uncoupled from any effect 
on cell death when assayed by alternative viability assays [380-382]. Indeed, analysis of RAW 
264.7 and SH-SY5Y cells incubated with fibrils or controls demonstrated that formazan 
accumulates primarily in intracellular granule-like structures in fibril growth buffer or β2m 
monomer controls (Figure 3.17 and Section 2.5.2). Both fragmented and unfragmented fibrils, 
however, markedly increased the deposition of formazan as extracellular needle-like crystals 
(Figure 3.17).  
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Figure 3.17: Phase contrast microscopy images of fibril treated cells incubated with MTT.  RAW 264.7 
cells (left) and SH-SY5Y cells (right) were incubated with β2m monomer or fibrils at a final monomer 
equivalent concentration of 1.2 µM for 24h. Cells were incubated with MTT 90 min prior to imaging by 
phase contrast microscopy. Reduced formazan was visualised as dark intracellular granules as observed 
in buffer and monomer treated cells (open triangle) or extracellular needles as observed in fibril treated 
cells (filled triangle). The scale bar represents 20 µm.  
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3.3 Discussion  
The thermodynamic and kinetic stability of amyloid fibrils, with particular focus on the 
reversibility of amyloid formation and fibril disassembly to release potentially cytotoxic 
species, has been implicated as an important factor in determining amyloid cytotoxicity [101, 
117, 161, 166, 177, 180, 191, 192]. The mechanical stability of amyloid fibrils may also be an 
important factor [101, 384]. Fragmentation of preformed amyloid fibrils may occur in vivo in 
the joints of DRA patients due to shear forces and mechanical stress [384]. Fibril fragmentation 
may also be caused by enzymatic action, for example, the molecular chaperone Hsp104 has 
been shown to fragment fibrils from the yeast prion protein Sup35 [385]. In addition, 
fragmented (i.e. short) fibrils may represent species that are formed during fibril elongation in 
vivo.   
Fragmentation of β2m amyloid fibrils alters their biological characteristics without changing 
their structural characteristics. Fragmented β2m amyloid fibrils display the same biophysical 
and immunological characteristics (Figure 3.12 and Figure 3.13) but have a reduced average 
length (Figure 3.14)[190]. This reduction in length is an important factor in the inhibition of 
MTT reduction (Figure 3.16). Reduced fibril length has also been shown to be an important 
factor in the disruption of artificial lipid membranes [190]. Although beyond the scope of this 
thesis, an extensive characterisation on fragmented and unfragmented β2m fibrils has been 
performed previously [190, 386]. This includes immunoblotting with WO1 and A11, of 
increasing concentrations of fragmented and unfragmented β2m fibril samples up to 2400 µM 
(20 times the concentration tested in Figure 3.12). Oligomers bound by A11 were still 
undetectable at these high concentrations. Fibril architecture and fibril height were also 
analysed by Fourier transform infrared (FTIR) spectroscopy and AFM and were shown to be 
unchanged by fragmentation [190]. This characterisation is important to aid rationalisation of 
the differences in cellular effects between oligomer and fibril populations.  
 The MTT assay is a widely used cellular viability assay, however the use of it in determining 
the cytotoxicity of amyloid preparations has been questioned [379-383]. Amyloid aggregates 
of Aβ and amylin have been shown to inhibit MTT reduction in the absence of a loss in cell 
viability as mentioned above [380-382]. The inhibition in MTT reduction is thought to be linked 
to the enhanced exocytosis of formazan needles. This increase in extracellular formazan 
needles is thought to prevent endocytosis of the MTT salt, thereby inhibiting further reduction 
of MTT into formazan [379]. Indeed, the inhibition of MTT reduction by β2m fibrils is coupled 
with an increase in extracellular formazan needles comparable to those reported with 
aggregated Aβ peptide (Figure 3.17) [380]. 
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To investigate whether the inhibition of MTT reduction by β2m amyloid fibrils was 
accompanied by a loss in cell viability, two additional viability assays were employed in our 
laboratory. Cellular ATP levels, which can be used as a measure of cell viability, were measured 
after incubation with fibrils or controls [387]. β2m amyloid fibrils were shown to have no effect 
on cellular ATP levels, suggesting that the inhibition of MTT reduction is not due to loss in cell 
viability (Morwenna Porter, personal communications and Figure 3.18). Another cellular 
viability assay using the tetrazolium salt, 2-(4-iodophenyl)-3-(4-nitrophenyl)-5-(2,4-
disulphophenyl)-2H-tetrazolium sodium salt (WST-1), employs the use of cellular reduction as 
a measure of cell viability. However, in this instance, reduction is thought to occur at the 
plasma membrane as opposed to the intracellular reduction of MTT [377]. WST-1 reduction 
was also measured after incubation with fibrils or controls. β2m amyloid fibrils were also 
shown to have no effect on WST-1 reduction indicating no impairment in the overall cellular 
reductive capacity (Morwenna Porter, personal communications and Figure 3.18). Although 
β2m amyloid fibrils do not affect cell viability, their effect on MTT reduction, in particular, the 
exocytosis of formazan needles provides clues of altered cell biology. Experiments designed to 
investigate these alterations are discussed in chapters 4 and 5. 
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Figure 3.18: Analysis of the effect of fibrils on cell viability.  ATP (A,B) and WST-1 (C,D) assays were 
performed using fragmented and unfragmented fibrils at a final monomer equivalent concentration of 
1.2 µM. RAW 264.7 cells (A,C) and SH-SY5Y cells (B,D) were incubated with fibrils or controls for 24 h 
before being assayed for cellular ATP levels or WST-1. ATP levels and WST-1 reduction (%) was 
calculated by normalising the signal from cells incubated with fibril growth buffer as 100%  and cells 
treated with 0.1% (v/v) NaN3 as 0%.  The error bars represent one S.E.M. over two to three independent 
experiments each containing five replicates. Assays performed by Morwenna Porter. 
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4 Analysis of the effect of amyloid fibrils on lysosome function 
4.1 Introduction 
Increasing evidence points towards disruption of the lysosomal compartment in amyloid 
disease, in particular, lysosome and autophagy dysfunction have been consistently reported as 
mechanisms underlying pathogenesis in Alzheimer’s, Parkinson’s and Huntington’s disease 
(reviewed in [255, 278, 388, 389]. Further evidence for lysosomal involvement comes from 
studies which demonstrate that inhibition of lysosomal function leads to neuronal dystrophy 
reminiscent of that observed in Alzheimer’s disease [284]. Indeed, amyloid aggregates have 
been reported to accumulate in the endolysosomal system and this accumulation is associated 
with lysosomal dysfunction [242, 261, 263, 265]. Accumulation of amyloid aggregates in the 
endolysosomal system has also been demonstrated for β2m. Analysis of amyloid deposits from 
DRA patients shows an accumulation of β2m fibrils in the lysosomes of surrounding 
macrophages [390]. This is further supported by previous work from our laboratory. 
Macrophages were shown to internalise β2m fibrils [247]. However, unlike β2m monomer, β2m 
fibrils were shown to be resistant to lysosomal degradation resulting in their persistence in the 
lysosome [247]. This lysosomal accumulation and persistence has also been shown for fibrils 
formed by the truncated form of β2m, ΔN6 β2m, in primary human monocytes [248]. This 
chapter examines whether β2m fibrils, upon trafficking to the lysosome, perturb lysosomal 
function.  
Interestingly, β2m fibril internalisation has been shown to be length dependent. Fragmented 
β2m fibrils are internalised to a much greater extent than their unfragmented counterparts 
(Andrew Hellewell, personal communications and Figure 4.1). Fragmented fibrils would thus 
have greater access to intracellular compartments such as the lysosome where it has been 
shown to be trafficked to. Experiments were therefore focussed on fragmented β2m fibrils. 
Unless explicitly stated otherwise, the experiments described in this chapter and subsequent 
chapters were performed with fragmented β2m fibrils.   
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Figure 4.1: Quantification of intracellular TMR labelled β2m monomer and fibrils from confocal 
images. Intracellular fluorescence from confocal images of RAW 264.7 (top) and SH-SY5Y cells (bottom) 
incubated with TMR labelled β2m monomer, fragmented or unfragmented β2m fibrils for 4 h was 
quantified using Image J. Ten images were collected for each condition and cell boundaries were 
delineated by hand using the phase contrast images. Images were acquired on a Zeiss LSM510 confocal 
microscope with a 40X objective. Representative images of cells treated with fibrils are shown on the 
left. The mean pixel intensity from the red channel (TMR) was calculated and is graphically shown on the 
right. Error bars represent one S.E.M. 158 RAW 264.7 and 60 SH-SY5Y cells were analysed. Experiment 
performed by Andrew Hellewell.  
100 
 
As degradation and recycling of macromolecules is one of the primary functions of the 
lysosome, the effect of fragmented fibrils on the ability of lysosomes to perform this crucial 
function was investigated [391]. Indeed, disruption to lysosome mediated degradation has 
been reported as a mechanism involved in the pathogenesis of amyloid disease [284, 285, 
289](Section 1.5.4.2.2). The effect of fragmented β2m amyloid fibrils on lysosome mediated 
protein degradation was studied and will be discussed here. In addition, the effect of 
fragmented β2m fibrils on the activities of two other lysosomal hydrolases, β-
glucocerebrosidase and β-galactosidase was examined.  
4.2 Results 
4.2.1 Analysis of the effect of fragmented fibrils on lysosomal proteolysis 
4.2.1.1 TMR-labelled β2m monomer as a lysosomal protease substrate 
In order to investigate the effect of fragmented β2m fibrils on lysosomal proteolysis, cells were 
incubated with fluorescently labelled substrates and their hydrolysis was followed by 
measuring cell-associated fluorescence by flow cytometry. β2m monomer labelled with 
tetramethylrhodamine (TMR-β2m) was initially selected for use as a substrate as previous work 
using RAW 264.7 cells and primary human monocytes revealed that exogenously added β2m 
monomer is trafficked to the lysosome where it is degraded by lysosomal proteases [247, 248]. 
RAW 264.7 and SH-SY5Y cells were incubated with either fragmented β2m fibrils or fibril 
growth buffer as a control for 24 h. Cells were then pulsed with fluorescent protein substrate 
(TMR-β2m) for 4 h (RAW 264.7) or 6 h (SH-SY5Y) (Section 2.7.1). At the end of TMR-β2m pulse, 
cells were either analysed for cell-associated fluorescence (0 h chase) or cultured for a further 
24 h in the absence of TMR-β2m. Cell-associated fluorescence was also measured 24 h after 
TMR-β2m pulse (24 h chase). Cell-associated fluorescence at 0 h chase gives a measure of 
uptake of fluorescent protein substrate, in this case TMR-β2m. The cell-associated fluorescence 
at 24 h chase gives a measure of the amount of fluorescent protein substrate remaining in cells 
24 h after pulse. A comparison of fluorescence at 24 h chase to that at 0 h chase would 
therefore allow an estimation of lysosome-mediated degradation of fluorescent protein 
substrate over 24 h (Figure 4.2).   
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Figure 4.2: Schematic of the lysosomal proteolysis assay.  
Cell-associated fluorescence at 24 h chase in both RAW 264.7 and SH-SY5Y cells was higher in 
cells incubated with fragmented β2m fibrils than those incubated with fibril growth buffer 
(Figure 4.3 and Figure 4.4). This suggests that β2m fibrils impair lysosomal proteolysis. 
However, as fragmented fibrils also contain β2m, the possibility that TMR-β2m is incorporated 
into proteolytically resistant fibrils in the lysosome could not be excluded [247]. The increased 
cell-associated fluorescence at 24 h chase in fibril-treated cells could therefore be due to an 
incorporation of TMR-β2m into fibrils and may not necessarily reflect disruption in lysosomal 
proteolysis.  
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Figure 4.3: Analysis of the effect of fibrils on the degradation of TMR-β2m in RAW 264.7 cells. Cells 
were incubated with either fragmented fibrils at a final monomer equivalent concentration of 1.2 µM or 
fibril growth buffer for 24 h. Cells were then pulsed with TMR-β2m and analysed for cell-associated 
fluorescence immediately after pulse (0 h) or cultured for a further 24 h in the absence of TMR-β2m and 
analysed (24 h chase). (A) Representative flow cytometry data comparing cell-associated fluorescence at 
24 h chase with that at 0 h chase for each experimental condition. (B) Quantification of flow cytometry 
data. TMR-β2m fluorescence (%) was calculated by normalising the fluorescence at 24 h chase to the 
fluorescence at 0 h chase for each treatment. Error bars represent one S.E.M. over two independent 
experiments containing three replicates each. Flow cytometry data was collected on a BD LSRFortessa 
analyser (Becton Dickinson).   
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Figure 4.4: Analysis of the effect of fibrils on the degradation of TMR-β2m in SH-SY5Y cells. Cells were 
incubated with either fragmented fibrils at a final monomer equivalent concentration of 1.2 µM or fibril 
growth buffer for 24 h. Cells were then pulsed with TMR-β2m and analysed for cell-associated 
fluorescence immediately after pulse (0 h) or cultured for a further 24 h in the absence of TMR-β2m and 
analysed (24 h chase). (A) Representative flow cytometry data comparing cell-associated fluorescence at 
24 h chase with that at 0 h chase. (B) Quantification of flow cytometry data. TMR-β2m fluorescence (%) 
was calculated by normalising the fluorescence at 24 h chase to the fluorescence at 0 h chase for each 
treatment. Error bars represent one S.E.M. over three independent experiments containing three 
replicates each. *** signifies a p value of <0.001. Flow cytometry data was collected on a BD 
LSRFortessa analyser (Becton Dickinson).  
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4.2.1.2 Pumilio-GFP as a lysosomal protease substrate 
Due to the complications associated with using TMR-β2m as a lysosomal protease substrate, an 
unrelated protein, Pumilio conjugated to GFP was selected. Pumilio, from Drosophila 
Melanogaster is a 157 KDa cytoplasmic protein [392]. Degradation of GFP is predicted to be 
coupled with a loss of fluorescence. The loss in cell-associated fluorescence can therefore be 
used as an estimate of Pumilio-GFP degradation.  RAW 264.7 cells were incubated with either 
fragmented β2m fibrils or fibril growth buffer as a control for 24 h. Cells were then pulsed with 
fluorescent protein substrate, in this case, Pumilio-GFP (Section 2.7.1). Cell-associated 
fluorescence was quantified by flow cytometry, immediately after pulse (0 h chase) or cells 
were cultured for a further 24 h in the absence of Pumilio-GFP. Cell-associated fluorescence 
was also measured 24 h after pulse (24 h chase). Cells incubated with fragmented β2m fibrils 
had a greater amount of cell-associated fluorescence at 24 h chase than buffer controls (Figure 
4.5). In combination with experiments using TMR-β2m, this suggests that fragmented fibrils 
disrupt lysosomal proteolysis. 
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Figure 4.5: Analysis of the effect of fibrils on the degradation of Pumilio-GFP in RAW 264.7 cells. Cells 
were incubated with either fragmented fibrils at a final monomer equivalent concentration of 1.2 µM or 
fibril growth buffer for 24 h. Cells were then pulsed with Pumilio-GFP and analysed for cell-associated 
fluorescence immediately after pulse (0 h chase) or cultured for a further 24 h in the absence of Pumilio-
GFP and analysed (24 h chase). (A) Representative flow cytometry data comparing cell-associated 
fluorescence at 24 h chase with that at 0 h chase. (B) Quantification of flow cytometry data. Pumilio-GFP 
fluorescence (%) was calculated by normalising the fluorescence at 24 h chase to the fluorescence at 0 h 
chase for each treatment. Error bars represent one S.D. over two replicates. Flow cytometry data was 
collected on a BD LSRFortessa analyser (Becton Dickinson).  
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Two caveats present themselves with this experiment. The first, although Pumilio-GFP is 
predicted to be internalised by fluid phase endocytosis; unlike β2m, its internalisation and 
trafficking to the lysosome as well as degradation in the lysosome has not been characterised. 
The second caveat is that GFP fluorescence varies with pH and is diminished at acidic pH. 
Indeed, when Pumilio-GFP fluorescence was measured in vitro, a significant decrease in 
fluorescence intensity was observed when pH was reduced from 7.4 (cytosolic pH) to both 5.5 
(late endosomal pH) and 4.5 (lysosomal pH) (Figure 4.6 and Section 2.7.1.2.1). The increased 
cell-associated fluorescence in fibril-treated cells could therefore also be due an increase in 
lysosomal pH. It is not possible, therefore, to distinguish between the effect of fibrils on 
lysosomal proteolysis and on lysosomal pH in these experiments.  
   
Figure 4.6: Pumilio-GFP fluorescence intensity varies with pH. Fluorescence emission spectra of 150 
µg/ml Pumilio-GFP at pH 4.5, 5.5 and 7.4. Pumilio-GFP was diluted in buffer immediately before 
fluorescence emission spectra were collected. The background corrected mean fluorescence is shown.  
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4.2.1.3 Alexa Fluor® 647 ovalbumin as a lysosomal protease substrate 
In order to overcome the limitations of using TMR-β2m and Pumilio-GFP as fluorescent protein 
substrates, a third substrate, Alexa Fluor® 647 labelled ovalbumin (AF647-ovalbumin) was 
selected for use in subsequent experiments. Ovalbumin has been shown to be trafficked via 
the endocytic pathway to the lysosome where it is degraded [393]. The fluorescence of the 
conjugated fluorophore, Alexa Fluor® 647, is pH insensitive. AF647-ovalbumin is therefore a 
better suited substrate to analyse the effect of fragmented β2m fibrils on lysosomal 
proteolysis.  
To confirm that ovalbumin is internalised and trafficked to the lysosome, cells were analysed 
by live cell confocal microscopy (Section 2.7.1.3). RAW 264.7 cells were incubated with either 
fragmented β2m fibrils or controls (fibril growth buffer and β2m monomer). Cells were then 
pulsed with AF647-ovalbumin for 4 h and imaged by live cell confocal microscopy immediately 
after pulse (0 h chase) or cultured for a further 24 h in the absence of AF647-ovalbumin and 
then imaged (24 h chase). Cells were stained with LysoTracker Green 30 min prior to imaging. 
LysoTracker Green is a fluorescent lysosomal marker used for its ability to accumulate in acidic 
vesicles.  
AF647-ovalbumin was localised to intracellular punctate structures which co-stained with 
LysoTracker Green at 0 h chase (Figure 4.7, part 1). Images taken at 24 h chase show reduced 
AF647-ovalbumin fluorescence when compared to those at 0 h chase (Figure 4.7, part 2). This 
suggests that ovalbumin is degraded in the lysosome. Interestingly, AF647-ovalbumin 
fluorescence at 24 h chase in cells treated with fragmented fibrils was greater than in buffer or 
β2m monomer controls (Figure 4.7, part 2).  
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Figure 4.7: Analysis of the internalisation, localisation and degradation of fluorescently labelled 
ovalbumin in RAW 264.7 cells (part 1 of 2). For legend, see next page.  
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Figure 4.7: Analysis of the internalisation, localisation and degradation of fluorescently labelled 
ovalbumin in RAW 264.7 cells (part 2 of 2). Cells were incubated with 1.2 µM (monomer equivalent) 
fragmented β2m fibrils or 1.2 µM β2m monomer and fibril growth buffer as controls for 24 h. Cells were 
then pulsed with 15 µg/ml AF647-ovalbumin (40 % labelled: 60 % unlabelled) for 4 h. Cells were washed 
and imaged immediately after pulse (0 h chase, part 1) or cultured in the absence of AF647-ovalbumin 
for 24 h and imaged (24 h chase, part 2). Cells were stained with 50 nm LysoTracker Green 30 min prior 
to imaging. Images were acquired with a Zeiss LSM700 confocal microscope and a 63X objective. 
Representative confocal images for each condition are shown. Scale bar represents 10 µm.    
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When the uptake and degradation of AF647-ovalbumin was analysed in SH-SY5Y cells, 
ovalbumin was also found to localise to punctate structures which co-stain with LysoTracker 
Green (Figure 4.8, part 1). As observed in RAW 264.7 cells, reduced ovalbumin fluorescence 
was observed at 24 h chase in SH-SY5Y cells. Cells treated with fragmented fibrils also showed 
greater ovalbumin fluorescence at 24 h chase than cells treated with fibril growth buffer or 
β2m monomer controls (Figure 4.8, part 2).  
 
Figure 4.8: Analysis of the internalisation, localisation and degradation of fluorescently labelled 
ovalbumin in SH-SY5Y cells (part 1 of 2). For legend, see next page. 
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Figure 4.8: Analysis of the internalisation, localisation and degradation of fluorescently labelled 
ovalbumin in SH-SY5Y cells (part 2 of 2). Cells were incubated with 1.2 µM (monomer equivalent) 
fragmented β2m fibrils or 1.2 µM β2m monomer and fibril growth buffer as controls for 24 h. Cells were 
then pulsed with 15 µg/ml AF647-ovalbumin (40 % labelled: 60 % unlabelled) for 6 h. Cells were washed 
and imaged immediately after pulse (0 h chase, part 1) or cultured in the absence of AF647-ovalbumin 
for 24 h and imaged (24 h chase, part 2). Cells were stained with 75 nm LysoTracker Green 30 min prior 
to imaging. Images were acquired with a Zeiss LSM700 confocal microscope and a 63X objective. 
Representative confocal images for each condition are shown. Scale bar represents 10 µm.    
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In order to ensure that the decrease in ovalbumin fluorescence was due to a decrease in 
protein levels and not due to photobleaching of AF674, RAW 264.7 and SH-SY5Y cells were 
pulsed with unlabelled ovalbumin and analysed by immunoblotting. Cells were lysed 
immediately after pulse with ovalbumin (0 h chase) or cultured for a further 24 h in the 
absence of ovalbumin and lysed (24 h chase). Cell lysates were immunoblotted for ovalbumin 
using an HRP-conjugated anti-ovalbumin antibody (anti-ovalbumin-HRP) (Section 0). Detection 
of ovalbumin in cell lysates was limited by the poor sensitivity of anti-ovalbumin HRP. A ten-
fold increase in concentration (over that used for confocal microscopy analysis) was required 
to enable detection by immunoblotting of cell-associated ovalbumin at 0 h chase. Ovalbumin 
was detected in 0 h chase cell lysates from cells pulsed with 150 µg/ml ovalbumin but not in 
those pulsed with 15 µg/ml ovalbumin (Figure 4.9). In cell lysates from cells pulsed with 150 
µg/ml ovalbumin, ovalbumin was no longer detected at 24 h chase. Ovalbumin levels were 
detectable by confocal live cell microscopy at 24 h chase, yet undetectable by immunoblotting 
within the same time frame. This may reflect differences in the sensitivity of techniques. 
Nevertheless, the disappearance of the ovalbumin band in cell lysates immunoblotted for 
ovalbumin at 24 h chase indicates a reduction in ovalbumin levels. This suggests that the 
decrease in ovalbumin fluorescence observed by confocal microscopy is due to a decrease in 
protein levels.  
 
Figure 4.9: Immunoblotting analysis to assess the degradation of ovalbumin in RAW 264.7 and SH-
SY5Y cells.  RAW 264.7 (top) and SH-SY5Y (bottom) cells were pulsed with ovalbumin at the indicated 
concentrations for 4 h and 6 h respectively. Cells were then washed and lysed either immediately (0 h 
chase) after pulse or cultured for a further 24 h and lysed (24 h chase). Cell lysates were analysed by 
immunoblotting with an HRP-conjugated ovalbumin-specific antibody.  
Flow cytometry was used to quantify lysosomal proteolysis of AF647-ovalbumin as described 
for TMR-β2m and Pumilio-GFP (Section 2.7.1.2). Cells were incubated with either fragmented 
β2m fibrils or controls (β2m monomer and fibril growth buffer). Cells were pulsed with AF647-
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ovalbumin and analysed for cell-associated fluorescence immediately after pulse (0h chase) or 
cultured for a further 24 h in the absence of AF647-ovalbumin and analysed (24 h chase). Cell-
associated ovalbumin fluorescence at 24 h chase was greater in fibril treated cells compared to 
controls for both RAW 264.7 and SH-SY5Y cells (Figure 4.10 and Figure 4.11). This suggests that 
ovalbumin degradation is impaired in fibril-treated cells. In combination, data from 
experiments with TMR-β2m, Pumilio-GFP and AF647-ovalbumin, strongly indicate an inhibition 
in the lysosomal degradation of endocytosed proteins by fragmented fibrils.   
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Figure 4.10: Analysis of the effect of fibrils on the degradation of AF647-ovalbumin in RAW 264.7 cells. 
Cells were incubated with either fragmented fibrils at a final monomer equivalent concentration of 1.2 
µM, 1.2 µM β2m monomer or fibril growth buffer for 24 h. Cells were then pulsed with AF647-ovalbumin 
for 4 h and analysed for cell-associated fluorescence immediately after pulse (0 h chase) or cultured for 
a further 24 h in the absence of AF647-ovalbumin and analysed (24 h chase). (A) Representative flow 
cytometry data comparing cell-associated fluorescence at 24 h chase with that at 0 h chase. (B) 
Quantification of flow cytometry data. Ovalbumin fluorescence (%) was calculated by normalising the 
fluorescence at 24 h chase to the fluorescence at 0 h chase for each treatment. Error bars represent one 
S.E.M. over three independent experiments containing three replicates each. Flow cytometry data was 
collected on a BD LSRFortessa analyser (Becton Dickinson). ** signifies a p value of <0.01.   
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Figure 4.11: Analysis of the effect of fibrils on the degradation of AF647-ovalbumin in SH-SY5Y cells. 
Cells were incubated with either fragmented fibrils at a final monomer equivalent concentration of 1.2 
µM, 1.2 µM β2m monomer or fibril growth buffer for 24 h. Cells were then pulsed with AF647-ovalbumin 
for 6 h and analysed for cell-associated fluorescence immediately after pulse (0 h chase) or cultured for 
a further 24 h in the absence of AF647-ovalbumin and analysed (24 h chase). (A) Representative flow 
cytometry data comparing cell-associated fluorescence at 24 h chase with that at 0 h chase. (B) 
Quantification of flow cytometry data. Ovalbumin fluorescence (%) was calculated by normalising the 
fluorescence at 24 h chase to the fluorescence at 0 h chase for each treatment. Error bars represent one 
S.E.M. over three independent experiments containing three replicates each. Flow cytometry data was 
collected on a BD LSRFortessa analyser (Becton Dickinson). *** signifies a p value of <0.001.   
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4.2.1.4 Magic Red™ as a lysosomal protease substrate 
All of the assays on lysosomal proteolysis described above rely on internalisation of the 
labelled protein substrate by endocytosis. Impairment in the lysosome-mediated degradation 
of these labelled proteins could be due to inhibition of lysosomal proteases or a disruption in 
delivery of cargo to lysosomes. In order to distinguish between these two possibilities, 
lysosomal proteolysis was assayed using a commercially available substrate, Magic Red™ 
cathepsin B substrate.  Like in the assays described above, this substrate provides a method to 
assay varying levels of lysosomal hydrolase (in this case cathepsin B) activity in intact and living 
cells. The substrate, which is conjugated to a cresyl violet fluorophore, is non-fluorescent when 
uncleaved. It contains a cathepsin B targeting sequence. Cathepsin B cleaves the substrate 
releasing the flurophores which are then free to fluoresce. Cresyl violet fluorescence can 
therefore be used as a measure of cathepsin B activity in cells. Crucially, because the Magic 
Red™ cathepsin B substrate is cell membrane permeable, it does not require endocytosis for 
targeted delivery to the lysosome. 
Disruption in delivery of cargo to lysosomes as discussed in section (Section 1.5.4.2.3) and 
endolysosomal trafficking has been heavily implicated in neurodegenerative diseases [255, 
256, 292, 323, 324, 394, 395]. For this reason, experiments were focused on analysis of the 
effect of fragmented fibrils on a model neuronal cell line, SH-SY5Y.  
In order to confirm that the Magic Red™ cathepsin B substrate is cleaved in the lysosome, SH-
SY5Y cells were incubated with Magic Red™ cathepsin B substrate and cresyl violet 
fluorescence was visualised by live cell confocal microscopy. SH-SY5Y cells were incubated with 
or without Magic Red™ cathepsin B substrate (Section 2.7.2.1). Cells were then stained with 
LysoTracker Green prior to imaging. Cresyl violet fluorescence co-localised with LysoTracker 
green positive compartments (Figure 4.12), indicating that the Magic Red™ cathepsin B 
substrate is cleaved in acidic compartments that presumably correspond to lysosomes.  
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Figure 4.12: Analysis of the internalisation and cleavage of Magic red™ cathepsin B substrate. SH-SY5Y 
cells were incubated with Magic Red™ cathepsin B substrate (top panel) or in the absence of Magic 
Red™ cathepsin B substrate (bottom panel) for 1 h. Magic red™ is fluorescent upon cleavage. Cells were 
washed and stained with LysoTracker Green prior to imaging. Cells were imaged using a Zeiss LSM700 
confocal microscope and a 63X objective. Representative confocal images for each condition are shown. 
Scale bar represents 10 µm.  
Having established that Magic Red™ cathepsin B substrate is cleaved in acidic compartments, 
SH-SY5Y cells were incubated with either fragmented β2m fibrils or controls (fibril growth 
buffer and β2m monomer controls) for 24 h. Cells were then incubated with the Magic Red™ 
cathepsin B substrate and cell-associated fluorescence was quantified by flow cytometry 
(Section 2.7.2.1). Cleavage of Magic Red™ cathepsin B substrate was not significantly affected 
by fragmented fibrils in SH-SY5Y cells (Figure 4.13), suggesting that fibrils do not inhibit 
cathepsin B activity. Since the Magic Red™ cathepsin B substrate is cell permeable and thus 
does not require targeted delivery to the lysosome, the decreased lysosome-mediated 
degradation observed with TMR-β2m, Pumilio-GFP and AF647-ovalbumin could therefore be 
due to: 1) inhibition of other lysosomal proteases and hydrolases, 2) disruption in 
endolysosomal trafficking or 3) disruption in targeted delivery of cargo to lysosomes.  
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Figure 4.13: Analysis of the effect of fibrils on lysosomal cathepsin B activity. SH-SY5Y cells were 
incubated with either fragmented β2m fibrils at a final monomer equivalent concentration of 1.2 µM, 1.2 
µM β2m monomer or fibril growth buffer for 24 h. Cells were then washed and incubated with Magic 
Red™ cathepsin B substrate for 1 h. Magic Red™ cathepsin B substrate is fluorescent upon cleavage and 
therefore cell-associated fluorescence gives a measure of cathepsin B activity in cells. Cells were washed 
and analysed for cell-associated fluorescence by flow cytometry. (A) Representative flow cytometry data 
comparing cathepsin B activity in buffer, monomer and fibril treated cells. (B) Quantification of flow 
cytometry data.  Cathepsin B activity (%) was calculated by normalising against signal from cells that 
were incubated with fibril growth buffer (100 %). Error bars represent one S.E.M. over three 
independent experiments each containing three replicates per condition. Flow cytometry data was 
collected on a BD LSRFortessa analyser (Becton Dickinson).  
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4.2.2 Analysis of the effect of fibrils on autophagy 
Disruption in autophagy has been heavily implicated in neurodegenerative amyloid diseases 
(discussed in Section 1.5.4.2.3)[255, 256, 292]. With this precedent in mind, the impairment of 
the lysosome mediated degradation of exogenously added protein substrates but not of the 
cell permeant Magic Red™ cathepsin B substrate could indicate disruption in cargo delivery to 
lysosomes or endolysosomal trafficking. The effect of fibrils on endolysosomal trafficking will 
be discussed in chapter 5. One of the proposed mechanisms of autophagy disruption in 
amyloid disease is a perturbation in the delivery of cargo (autophagosomes) to lysosomes 
which is essential for the formation of functional autolysosomes [255]. Another proposed 
mechanism is the inhibition of lysosomal mediated degradation in autolysosomes [255]. A 
preliminary investigation of the effect of fibrils on autophagy was conducted by 
immunoblotting with an antibody against the B form of LC3, a commonly used autophagy 
marker [396]. LC3-II is the lipidated form of LC3-I. Lipidation is required for recruitment to 
autophagosomes and is therefore used as an indicator of autophagy activation. The anti-LC3 B 
antibody recognises both, LC3-I and LC3-II.  
SH-SY5Y cells were incubated with fragmented β2m fibrils or β2m monomer as a control for the 
times indicated. Cells were then lysed and immunoblotted with LC3 B (Section 2.6). Cells 
incubated with fibrils had an increased amount of LC3-II present (Figure 4.14). Fibrils increase 
the amount of LC3-II present, as early as 2 h post-treatment. This could be symptomatic of 
enhanced autophagy, perhaps as a protective mechanism to cope with fibril load but could 
also be indicative of blocked autophagy due to disruption in the delivery of autophagosomes 
to lysosomes. A detailed investigation of autophagy is required to be able to distinguish 
between the two possibilities.  
 
Figure 4.14: Immunoblotting analysis of the effect of fibrils on autophagy with LC3B. SH-SY5Y cells 
were incubated with 1.2 µM monomer (M) or 1.2 µM (monomer equivalent) fragmented fibrils (F) for 
the times indicated. Cells were then lysed and immunoblotted with LC3B. LC3-I (filled arrow) and LC3-II 
(open arrow) are detected in the cell lysates.  
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4.2.3 Analysis of the effect of fibrils on the lysosomal hydrolase, β-
glucocerebrosidase 
In order to investigate whether fragmented β2m fibrils had an effect on other lysosomal 
hydrolases, β-glucocerebrosidase was selected for further analysis into lysosomal function. β-
glucocerebrosidase is a lysosomal hydrolase that cleaves glucocerebroside to yield glucose and 
ceramide. β-glucocerebrosidase is mutated in Gaucher’s disease, and it is of particular interest 
due to the association of Parkinson’s disease and Gaucher’s disease (discussed in Section 
1.5.4.2.4)[288, 311, 312, 316].  
The effect of fibrils on β-glucocerebrosidase activity was investigated (Section 2.7.3). This was 
achieved by using 5-(pentafluorobenzoylamino)fluorescein di-β-D-glucopyranoside (PFB-
FDGlu), a commercially available non-fluorescent substrate for β-glucocerebrosidase. PFB-
FDGlu is cleaved by glucocerebrosidase to yield the green fluorescent PFB-F product. As 
fluorescence is dependent on cleavage, cell-associated fluorescence can be used as a measure 
of β-glucocerebrosidase activity [397]. 
β-glucocerebrosidase activity  was measured in intact and living SH-SY5Y cells. 
Glucocerebroside is primarily cleaved in the cell by β-glucocerebrosidase. However, a non-
lysosomal glucocerebrosidase, termed β-glucosidase 2, also exists and may account for a small 
percentage of the cleavage of PFB-FDGlu [398]. The two enzymes differ in their sensitivity to 
conduritol B epoxide (CBE) which inhibits β-glucocerebrosidase but has no effect on β-
glucosidase 2 [398]. CBE therefore serves as a tool to distinguish between PFB-F fluorescence 
due to specific cleavage of PFB-FDGlu by β-glucocerebrosidase and cleavage due to β-
glucosidase 2.  CBE inhibits glucocerebrosidase activity by 70 % therefore indicating that 70 % 
of total PFB-FDGlu is cleaved by β-glucocerebrosidase, the lysosomal glucocerebrosidase 
(Figure 4.15). In contrast to the enzyme inhibitor, CBE, fragmented fibrils do not have a 
significant effect on β-glucocerebrosidase activity.   
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Figure 4.15: Analysis of the effect of fibrils on glucocerebrosidase activity. SH-SY5Y cells were 
incubated with either fragmented β2m fibrils at a final monomer equivalent concentration of 1.2 µM or 
1.2 µM β2m monomer for 24 h. Fibril growth buffer and CBE treated cells were included as controls. 
Cells were then washed and incubated with β-glucocerebrosidase substrate (PFB-FDGlu) for 1 h. PFB-
FDGlu is fluorescent upon cleavage, therefore cell-associated fluorescence gives a measure of 
glucocerebrosidase activity in cells. Cells were washed and analysed for cell-associated fluorescence by 
flow cytometry. (A) Representative flow cytometry data comparing glucocerebrosidase activity in fibril, 
monomer and buffer-treated cells. (B) Quantification of flow cytometry data. Glucocerebrosidase 
activity (%) was calculated by normalising against signal from cells incubated with fibril growth buffer 
(100 %). Error bars represent one S.E.M. over two independent experiments each containing three 
replicates per condition. Flow cytometry data was collected on a BD LSRFortessa analyser (Becton 
Dickinson).  *** indicates a p value of <0.001. 
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4.2.4 Analysis of the effect of fibrils on the lysosomal hydrolase, β-galactosidase 
Analysis of the effect of fibrils on lysosomal function was extended by assaying the activity of 
another lysosomal hydrolase, β-galactosidase. β-galactosidase is a glycosidase which cleaves 
the commercially available non-fluorescent substrate fluorescein di-β-D-galactopyranoside 
(FDG) to yield fluorescein. FDG has been used as a substrate to measure β-galactosidase 
activity in intact and living cells by flow cytometry [399].  
SH-SY5Y cells were incubated with either fragmented β2m fibrils or controls (fibril growth 
buffer and β2m monomer) as controls for 24 h. This was followed by incubation with FDG for 1 
h prior to analysis by flow cytometry (Section 2.7.3). Fragmented fibrils have a small but 
significant inhibitory effect on β-galactosidase activity when compared to cells treated with 
fibril growth buffer (Figure 4.16). 
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Figure 4.16: Analysis of the effect of fibrils on β-galactosidase activity. SH-SY5Y cells were incubated 
with either fragmented β2m fibrils at a final monomer equivalent concentration of 1.2 µM, 1.2 µM β2m 
monomer or fibril growth buffer for 24 h. Cells were then washed and incubated with β-galactosidase 
substrate (FDG) for 1 h. FDG is fluorescent upon cleavage, therefore cell-associated fluorescence gives a 
measure of β-galactosidase activity in cells. Cells were washed and analysed for cell-associated 
fluorescence by flow cytometry. (A) Representative flow cytometry data comparing β-galactosidase 
activity in fibril, monomer and buffer-treated cells. (B) Quantification of flow cytometry data. β-
galactosidase activity (%) was calculated by normalising against signal from cells incubated with fibril 
growth buffer (100 %). Error bars represent one S.E.M. over three independent experiments each 
containing three replicates per condition. Flow cytometry data was collected on a BD LSRFortessa 
analyser (Becton Dickinson). ** indicates a p value of <0.01.   
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4.3 Discussion 
Internalisation of exogenously applied amyloid material in vitro allowing access to endocytic 
compartments has been widely reported in the literature for a range of disease-associated 
amyloid aggregates [240-245, 247, 248, 400]. This could be relevant to extracellular amyloid 
aggregates that accumulate in vivo such as Aβ, IAPP and β2m amongst others. Internalisation 
of amyloid aggregates and access to endocytic compartments may also be relevant to disease-
associated amyloid proteins which form intracellular inclusions in vivo such as α-synuclein. α-
synuclein has been reported to be secreted into cerebrospinal fluid, thus allowing for the 
potential to aggregate extracellularly prior to internalisation [401]. Furthermore, intracellular 
α-synuclein amyloid aggregates have been reported to induce neuronal death, which then 
facilitates leakage of α-synuclein amyloid aggregates into the extracellular space, resulting in 
spread to neighbouring cells which internalise these aggregates allowing access to endocytic 
compartments (reviewed in [402]). Upon internalisation, amyloid aggregates accumulate in the 
lysosome and increasing evidence points towards disruption of the lysosomal compartment in 
amyloid disease. This has been discussed in detail in (Section 1.5.4.2). Based on this precedent, 
and the trafficking of fragmented β2m fibrils to the lysosome, the lysosome was selected for 
further investigation. Experiments were limited to fragmented fibrils due to their greater 
access to the lysosome. 
One of the reported mechanisms of lysosomal dysfunction in amyloid disease is perturbation 
of lysosomal degradation. For example, overexpression of human IAPP in rodent models leads 
to the formation of IAPP oligomers, which have been shown to inhibit lysosome dependent 
degradation, which in turn impairs autophagy [289]. Lysosomal degradation is a key function of 
the lysosome and its impairment has been shown to be detrimental to cell health. Inhibition of 
lysosomal proteolysis in primary neurons has been shown to retard axonal transport of 
autolysosomes, late endosomes and lysosomes resulting in their accumulation in axonal 
swellings causing an Alzheimer’s like axonal dystrophy [284]. On the other hand, enhancement 
of proteasomal and lysosomal mediated degradation results in the rescue of toxicity from Aβ 
and Huntingtin aggregates [285, 286]. Impairment of lysosomal proteolysis could therefore 
have significant consequences on cell health and disease progression.  
The effect of fragmented fibrils on lysosomal degradation was therefore assayed. Fragmented 
fibrils inhibit the degradation of endocytosed proteins, but do not inhibit cleavage of the 
membrane permeant Magic Red™ cathepsin B substrate (Figure 4.3, Figure 4.4, Figure 4.5, 
Figure 4.10, Figure 4.11 and Figure 4.13). This could be due to a saturation of the proteolytic 
machinery with fibrils overwhelming lysosomal proteases other than cathepsin B; or due to a 
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disruption in endolysosomal trafficking by fibrils without significantly inhibiting lysosomal 
proteases. Impaired endolysosomal trafficking would disrupt delivery of cargo containing 
lysosomal substrates to the lysosome. Future experiments on other lysosomal proteases such 
as cathepsins K and L using membrane permeant substrates, would help establish whether or 
not fibrils saturate the proteolytic machinery.  In addition, disruption to the lysosomal 
membrane has been frequently reported as a mechanism underlying both Alzheimer’s disease 
and Parkinson’s disease [242, 245, 251, 263] (Section 1.5.4.2.1). Lysosomal membrane damage 
would result in alteration of lysosomal pH and globally inhibit lysosomal hydrolases. 
Fragmented fibrils, however, do not have a significant effect on β-glucocerebrosidase activity 
and only have a modest effect on β-galactosidase activity. This provides evidence against gross 
damage to the lysosomal membrane as a mechanism for impairment in degradation of 
endocytosed proteins. Further evidence for this comes from ongoing work by other members 
of the laboratory which demonstrates that fragmented fibrils do not have a detectable effect 
on the integrity of the lysosomal membrane (Eric Hewitt, personal communications and Figure 
4.17).  
Autophagy dysfunction has been repeatedly connected to neurodegenerative diseases and has 
been proposed as an underlying mechanism for disease progression [255, 256]. The effect of 
fragmented fibrils on autophagy was therefore analysed by immunoblotting in preliminary 
experiments. One of the first clues to altered autophagy is the accumulation of 
autophagosomes [255]. Indeed, autophagosomal accumulation has been reported in 
neurodegenerative diseases [255, 261, 290, 291]. Active autophagosomes recruit LC3-II and 
the level of LC3-I and LC3-II relative to each other is used as a marker to report autophagy 
[396]. An increase in LC3-II levels could result from upregulated autophagy (due to increased 
production of autophagosomes) but paradoxically could also result from impaired autophagy 
(due to a block in delivery of autophagosomes to lysosomes or impaired autolysosomal 
clearance) [255, 293]. Interpretation of upregulated autophagy or blocked autophagy should 
therefore be approached with caution. Immunoblotting analysis with an anti-LC3-B antibody 
provides interesting preliminary evidence of altered autophagy in response to fibrils (Figure 
4.14). In combination with data from experiments showing a fibril-mediated disruption in 
degradation of endocytosed proteins but not of the membrane permeant Magic Red™ 
cathepsin B substrate; this fibril-mediated increase in autophagosomes could indicate a 
disruption of cargo delivery to the lysosome. However, further experiments need to be 
conducted before an assessment of the direction of effect on autophagy can be made. Future 
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experiments should aim to distinguish between defects in autophagy induction, cargo 
sequestration and autophagosome clearance. 
 
Figure 4.17: Analysis of the effect of fragmented fibrils on lysosomal membrane permeabilisation. SH-
SY5Y cells were incubated with fragmented fibrils at a final concentration of 1.2 µM (monomer 
equivalent) for 2 or 24 h. Cells were then incubated with LysoTracker Green and cell-associated 
fluorescence was quantified by flow cytometry. Sphingosine, which causes lysosomal rupture and thus 
disrupts lysosomal pH was included as a positive control. Cells were incubated with 15 µM sphingosine 
for 15 min prior to LysoTracker Green staining. As LysoTracker Green accumulates in acidic vesicles, 
LysoTracker green staining reflects the amount of intact lysosomes in a cell. LysoTracker green 
fluorescence (%) was calculated by normalising against signal from control cells incubated with fibril 
growth buffer (100 %). Error bars represent one S.E.M. over three independent experiments containing 
three replicates each. Flow cytometry data was collected on a BD LSRFortessa analyser. Experiment 
performed by Eric Hewitt, University of Leeds. 
A decrease in lysosome mediated degradation through the delivery of cargo to lysosomes, 
could impact upon autophagy. Autophagosome clearance relies on delivery of 
autophagosomes to lysosomes, and alterations in autophagosome clearance have been 
recurrently implicated in neurodegenerative disorders [255]. Accumulation of undigested 
substrates and the decreased content or activity of lysosomal hydrolases could result in 
degradative failure of lysosomes leading to defective autophagosome clearance [255]. The 
accumulation of autophagosomes is proposed to be detrimental to cellular function by 
interfering with intracellular trafficking [403]. In addition, autophagosomes have been shown 
to act as an endogenous source of Aβ1-42 in cellular and animal models due to the accumulation 
of APP and proteases in autophagosomes [403]. Aged autophagosomes that persist in the 
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cytosol can suffer from a loss of membrane integrity and can release enclosed aggregating 
proteins which could induce aggregation of cytosolic proteins [255].  
This chapter demonstrates that fragmented β2m fibrils disrupt lysosomal mediated 
degradation of endocytosed proteins, but do not have a general inhibitory effect on lysosomal 
hydrolases. Defects in endolysosomal trafficking would impair delivery of cargo to lysosomes 
and may rationalise the observed differences on the effect of fibrils on lysosomal proteolysis 
(Figure 4.3, Figure 4.4, Figure 4.5, Figure 4.10, Figure 4.11 and Figure 4.13). The effect of fibrils 
on endolysosomal trafficking is discussed in the following chapter.   
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5 Analysis of the effect of amyloid fibrils on membrane 
trafficking 
5.1 Introduction 
Membrane trafficking describes the journey that proteins make, beginning with entry into the 
early secretory pathway at the ER, followed by transition via the Golgi apparatus to their final 
destination such as the extracellular milieu, plasma membrane or other intracellular organelles 
[404]. It also includes the internalisation of proteins from the plasma membrane, their 
recycling back to the plasma membrane or targeted delivery to the lysosome after movement 
through the late endosome and multivesicular body (MVB) compartments [404]. Proteins are 
mainly transferred through the cell in many different vesicular bodies. These vesicles can 
undergo fission, docking and fusion events between donor and acceptor compartments [405]. 
These vesicles, whether derived from the ER, other intracellular organelles or the plasma 
membrane, are decorated with unique protein complexes, as well as tethering and regulatory 
factors which target the vesicle to its acceptor compartment [404]. For example, the SNARE 
(soluble N-ethylmaleimide-sensitive fusion attachment protein receptor) proteins are a highly 
conserved group of proteins which have been found to regulate membrane trafficking [406]. 
SNARE proteins are present on both the vesicle and the acceptor and contain coiled-coiled 
domains which come together to enable vesicle docking and fusion [407]. Ras-related Rab 
GTPases are another family of proteins which in conjunction with SNARE proteins have been 
shown to be involved in the regulation of membrane trafficking [408].  
Alterations in membrane trafficking are associated with the pathogenesis of amyloid diseases 
such as Parkinson’s disease and Alzheimer’s disease [394, 395]. Evidence of the association of 
Parkinson’s disease and trafficking defects first came from the observation of abnormal 
interactions of Rab3a, Rab5 and Rab8 with mutant (A30P) but not wild-type α-synuclein in 
transgenic mice models [409]. In studies using a yeast model of Parkinson’s disease, α-
synuclein was shown to block ER-to-Golgi vesicular trafficking. Interestingly, the 
overexpression of Rab1, which is involved in the forward ER-to-Golgi trafficking process, 
rescued α-synuclein induced-toxicity in yeast, Drosophila and C. elegans models as well as in 
primary rat neurons [410]. In a follow up study from the same group, α-synuclein was shown 
to impair multiple trafficking steps in vitro, and Rab3a and Rab8a were demonstrated to 
ameliorate toxicity in neuronal models of Parkinson’s disease [411]. Genome wide association 
studies have identified genes encoding LRRK2 and Rab7L1 as risk factors in Parkinson’s disease. 
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Importantly, disease-associated defects in Rab7L1 and LRRK2 were shown to cause 
endolysosomal and Golgi sorting defects [412].  
Genome wide association studies have also demonstrated links between defects in membrane 
trafficking and Alzheimer’s disease. For example, several genes involved in the recycling of 
endosomal vesicles have been implicated, such as bridging integrator 1 (BIN1), 
phosphatidylinositol-binding clathrin assembly protein (PICALM) and sortilin-related receptor 1 
(SORL1) (reviewed in [394]). Like with Parkinson’s disease, yeast models of Alzheimer’s disease 
have been useful in connecting disruptions in membrane trafficking to disease pathogenesis. 
Endocytic trafficking defects, in particular disruptions in clathrin-mediated endocytosis were 
highlighted as pathogenic factors in a genome-wide toxicity screen in a yeast model of 
Alzheimer’s disease [323]. The demonstration of small molecules which restore endocytosis to 
ameliorate toxicity in yeast models of Alzheimer’s disease provides further evidence for a 
pathogenic role of membrane trafficking defects [413]. Lastly, perturbations in membrane 
trafficking are implicated in other amyloid diseases. Aggregates from the amyloidogenic 
proteins huntingtin, ataxin-1 and superoxide dismutase-1 (SOD1) have been shown to inhibit 
clathrin-mediated endocytosis in mammalian cells [414].        
A closer investigation of the effect of fragmented β2m fibrils on membrane trafficking was 
prompted by two observations. The first was the observation of a greater amount of formazan 
needles in response to fibril treatment (Figure 3.17). This suggests an alteration in the 
trafficking of MTT and/or its reduced form, formazan, in fibril-treated cells. The second was 
the demonstration of fibril-mediated impairment in lysosomal degradation of endocytosed 
proteins, which could potentially be due to altered endolysosomal trafficking (Figure 4.10 and 
Figure 4.11). Investigation of membrane trafficking was achieved by analysing the localisation 
of the lysosomal membrane proteins LAMP-1 (lysosomal associated membrane protein 1) and 
CD63 (cluster of differentiation 63). LAMP-1 is an abundant lysosomal membrane protein 
which is involved in lysosomal trafficking by mediating attachment of lysosomes to transport 
machinery [280]. CD63, also known as LAMP-3, is a tetraspanin which interacts either directly 
or indirectly with many different proteins such as cell surface receptors, adaptor proteins, 
integrins and other tetraspanins [415]. LAMP-1 and CD63 are not static components of the 
lysosomal membrane; they have been shown to be in dynamic equilibrium between 
lysosomes, endosomes and the plasma membrane [416]. The trafficking of LAMP-1 and CD63 
has been studied in some detail (Figure 5.1). Newly synthesised LAMP-1 and CD63 are 
transported from the TGN to the endolysosomal compartment mainly via an intracellular route 
[416]. A small portion of newly synthesised LAMP-1 and CD63 is trafficked to the plasma 
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membrane [415, 417]. Although most LAMPs mainly reside in the lysosome, their cell surface 
expression has been reported; for example during the activation of platelets and cytotoxic T 
cells as well as in highly malignant tumour cells [280]. The elevated cell surface expression of 
CD63 impacts other local protein concentrations due to its ability to interact with an array of 
proteins [415]. The consequences of increased levels of LAMP-1 at the cell surface are not well 
understood but have been associated with lysosomal exocytosis [418]. Lysosomal exocytosis is 
required for plasma membrane repair and the correct functioning of cytotoxic lymphocytes 
[419, 420].  
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Figure 5.1: Overview of LAMP-1 and CD63 trafficking. After biosynthesis, newly synthesised LAMP-1 
and CD63 are transported from the TGN predominantly to endosomes via a direct intracellular pathway, 
or to the plasma membrane via an exocytic pathway. At the plasma membrane, LAMP-1 and CD63 are 
endocytosed and progress to mature lysosomes via late endosomes/multivesicular bodies (MVBs); 
however CD63 can also be recycled to the cell surface. In late endosomes/MVBs, CD63 is enriched in the 
intraluminal vesicles, which in certain conditions can be released into the extracellular space as 
exosomes. Adapted from [415-417].   
This chapter describes experiments that investigate the effect of fragmented fibrils on 
membrane trafficking. This was achieved by investigating the cell surface expression, 
subcellular localisation and total cellular levels of LAMP-1 and CD63. In order to examine 
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whether the impaired degradation of endocytosed proteins by fragmented β2m fibrils (Figure 
4.10 and Figure 4.11) was due to compromised delivery of cargo to the lysosome, a preliminary 
investigation on the effect of fibrils on fluid phase endocytosis was undertaken and will also be 
discussed.  
5.2 Results 
5.2.1 Analysis of the effect of fibrils on the cell surface expression of LAMP-1 and 
CD63 
Newly synthesised LAMP-1 and CD63 are trafficked to the lysosome predominantly via an 
intracellular route, however, a small amount of LAMP-1 and CD63 is trafficked to the plasma 
membrane [415, 417](Figure 5.1). LAMP-1 and CD63 may play a functional role at the plasma 
membrane or transit through the plasma membrane. These proteins are internalised from the 
plasma membrane and directed towards the lysosome or recycled back to the plasma 
membrane (Figure 5.1). A comparison of the levels of LAMP-1 and CD63 at the plasma 
membrane between controls and fibril treated cells may provide insights into the effect of 
fibrils on membrane trafficking. The cell-surface levels of LAMP-1 and CD63 were measured by 
incubation of non-permeabilised cells with fluorescently labelled antibodies followed by flow 
cytometric analysis (Section 682.8.1).  
SH-SY5Y cells were incubated with fragmented β2m fibrils or β2m monomer as a control. 
Blocking agents were used to minimise non-specific binding before incubation with LAMP-1 or 
CD63 specific antibodies. Additional controls incubated with matched isotype control 
antibodies (which are of the same isotype and have the same fluorescent label, but are not 
specific for any cellular proteins) were included for each experimental condition. Isotype 
controls were used to subtract any non-specific binding of antibodies. Cells incubated with 
fragmented fibrils have a significant increase in the cell surface expression of LAMP-1 (Figure 
5.2). This effect is observed after just 2 h of fibril incubation as well as 24 h after fibril 
incubation. Incubation with fragmented fibrils also significantly enhances the cell-surface 
expression of CD63 (Figure 5.3). This increase is more pronounced, and is also observed as 
early as 2 h after fibril incubation and still detected after 24 h of fibril incubation.  
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Figure 5.2: Analysis of the effect of fibrils on the cell surface expression of LAMP-1. SH-SY5Y cells were 
incubated with 1.2 µM β2m monomer or 1.2 µM (monomer equivalent) fragmented β2m fibrils for the 
times indicated. Cells were then stained with a fluorescently labelled antibody specific for LAMP-1 and 
cell-associated fluorescence was quantified by flow cytometry. (A) Representative flow cytometry data 
comparing cell surface LAMP-1 expression between monomer and fibril treated cells. (B) Quantification 
of flow cytometry data. Cell surface LAMP-1 (%) was calculated by normalising to signal from cells that 
were incubated with fibril growth buffer for 0 h (100 %). Error bars represent one S.E.M. over three 
independent experiments each containing three replicates each. * signifies a p value of <0.05. Flow 
cytometry data was collected on a BD LSRFortessa analyser (Becton Dickinson). 
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Figure 5.3: Analysis of the effect of fibrils on the cell surface expression of CD63. SH-SY5Y cells were 
incubated with 1.2 µM β2m monomer or 1.2 µM (monomer equivalent) fragmented β2m fibrils for the 
times indicated. Cells were then stained with a fluorescently labelled antibody specific for CD63 and cell-
associated fluorescence was quantified by flow cytometry. (A) Representative flow cytometry data 
comparing cell surface CD63 expression between monomer and fibril treated cells. (B) Quantification of 
flow cytometry data. Cell surface CD63 (%) was calculated by normalising to signal from cells that were 
incubated with fibril growth buffer for 0 h (100 %). Error bars represent one S.E.M. over three 
independent experiments each containing three replicates each. ** signifies a p value of <0.01. Flow 
cytometry data was collected on a BD LSRFortessa analyser (Becton Dickinson).   
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5.2.2 Immunoblotting analysis of the effect of fibrils on lysosomal protein 
expression 
The increased cell surface expression of LAMP-1 and CD63 could be due to an increase in the 
overall expression of LAMP-1 and CD63, or due to a re-distribution of LAMP-1 and CD63. In 
order to investigate whether fragmented fibrils increased the overall expression of LAMP-1 
and CD63, the total cellular levels of these proteins were assessed by immunoblotting. SH-SY5Y 
cells were incubated with fragmented β2m fibrils or β2m monomer as a control. Cell lysates 
were immunoblotted with antibodies specific for LAMP-1 and CD63 (Section 2.6) and for 
GAPDH as a loading control. Total levels of LAMP-1 and CD63 were comparable for monomer 
and fibril treated cells indicating that fragmented fibrils do not increase the expression of 
LAMP-1 and CD63 (Figure 5.4). In order to investigate whether fragmented fibrils induced a 
compensatory increase in proteins involved in lysosomal degradation, the total cellular levels 
of the lysosomal hydrolase, cathepsin D were also analysed by immunoblotting (Section 2.6). 
As with LAMP-1 and CD63, levels of cathepsin-D were not affected by fibril treatment (Figure 
5.4). 
 
 
Figure 5.4: Immunoblotting analysis of the effect of fibrils on total levels of LAMP-1, CD63 and 
Cathepsin-D. SH-SY5Y cells were incubated with 1.2 µM β2m monomer (M) or 1.2 µM (monomer 
equivalent) fragmented β2m fibrils (F) for the times indicated. Cells were then lysed and probed with 
antibodies specific for LAMP-1, CD63 or cathepsin D.  Representative blots from three independent 
experiments are shown.  
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5.2.3 Immunofluorescence microscopy analysis of the effect of fibrils on the 
intracellular distribution of LAMP-1 and CD63 
In order to investigate whether the increased expression of LAMP-1 and CD63 at the cell 
surface was due to a major re-distribution of existing pools of LAMP-1 and CD63 by 
fragmented fibrils, the intracellular distributions of LAMP-1 and CD63 were analysed by 
immunofluorescence microscopy. SH-SY5Y cells were cultured on coverslips and incubated 
with fragmented β2m fibrils or β2m monomer as a control. Cells were permeabilised and 
stained with anti-LAMP-1 or anti-CD63 antibodies. Despite subtle variations in antibody 
staining, a gross change in the intracellular distribution of LAMP-1 and CD63 was not observed 
(Figure 5.5 and Figure 5.6). The increase in the cell-surface levels of LAMP-1 and CD63 
measured by flow cytometry (Figure 5.2 and Figure 5.3) is therefore likely to represent a small 
percentage of total LAMP-1 and CD63.  
137 
 
 
Figure 5.5: Immunofluorescence microscopy analysis of the effect of fibrils on the distribution of 
LAMP-1. SH-SY5Y cells were incubated with 1.2 µM β2m monomer or 1.2 µM (monomer equivalent) 
fragmented β2m fibrils for the indicated times. Cells were then fixed, permeabilised and stained with an 
anti-LAMP-1 antibody followed by a fluorescently labelled anti-mouse secondary antibody. Coverslips 
were imaged using a Zeiss LSM700 confocal microscope and a 63X objective. Representative confocal 
images for each condition are shown. Scale bar represents 10 µm.  
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Figure 5.6: Immunofluorescence microscopy analysis of the effect of fibrils on the distribution of 
CD63. SH-SY5Y cells were incubated with 1.2 µM β2m monomer or 1.2 µM (monomer equivalent) 
fragmented β2m fibrils for the indicated times. Cells were then fixed, permeabilised and stained with an 
anti-CD63 antibody followed by a fluorescently labelled anti-mouse secondary antibody. Coverslips were 
imaged using a Zeiss LSM700 confocal microscope and a 63X objective. Representative confocal images 
for each condition are shown. Scale bar represents 10 µm.  
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5.2.4 Analysis of the effect of fibrils on the trafficking of newly synthesised LAMP-1 
and CD63 
In order to investigate whether the small percentage of total LAMP-1 and CD63 at the cell-
surface corresponded to newly synthesised protein, the effect of fibrils on the trafficking of 
newly synthesised LAMP-1 and CD63 was investigated. As described in Figure 5.1, majority of 
the newly synthesised LAMP-1 and CD63 is directly trafficked to the lysosome; however a 
minority is trafficked via the plasma membrane [415, 417]. The protein synthesis inhibitor, 
cycloheximde, was employed to distinguish between effects on newly synthesised being 
diverted to, or retained at, the plasma membrane; and existing protein being redistributed to 
the plasma membrane. Cycloheximide inhibits proteins synthesis by blocking the translation of 
mRNA on cytosolic 80S ribosomes.  
SH-SY5Y cells were pre- incubated for 1 h with cycloheximide to inhibit protein synthesis. Cells 
were then incubated with fragmented β2m fibrils or β2m monomer as a control. After 
incubation with fibrils or monomer, cells were stained with a fluorescently labelled antibody 
specific for LAMP-1 or CD63 (Section 2.8.2). Cycloheximide treatment has a significant 
decrease in the expression of LAMP-1 at the cell surface of fibril treated cells (Figure 5.7). A 
significant decrease in the cell surface expression of CD63 was also observed upon pre-
treatment with cycloheximide in fibril treated cells (Figure 5.8). These results demonstrate that 
at least a portion of the increase in LAMP-1 and CD63 at the cell surface in response to fibril 
treatment is from newly synthesised protein. This therefore suggests that fibrils alter the 
trafficking of newly synthesised LAMP-1 and CD63 by diverting them to the plasma membrane.   
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Figure 5.7: Analysis of the effect of cycloheximide on cell surface levels of LAMP-1. SH-SY5Y cells were 
pre-treated with cycloheximide for 1 h before incubation with 1.2 µM β2m monomer or 1.2 µM 
(monomer equivalent) fragmented β2m fibrils for 2 h. Cells were then stained with a fluorescently 
labelled antibody specific for LAMP-1 and cell-associated fluorescence was quantified by flow 
cytometry. (A) Representative flow cytometry data showing the effect of cycloheximide on cell surface 
LAMP-1 expression. (B) Quantification of flow cytometry data. Cell surface LAMP-1 (%) was calculated by 
normalising to signal from cells that were incubated with fibril growth buffer for 0 h (100 %). Error bars 
represent one S.E.M. over three independent experiments containing three replicates each. ** signifies 
a p value of <0.01. Flow cytometry data was collected on a BD LSRFortessa analyser (Becton Dickinson).  
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Figure 5.8: Analysis of the effect of cycloheximide on cell surface levels of CD63. SH-SY5Y cells were 
pre-treated with cycloheximide for 1 h before incubation with 1.2 µM β2m monomer or 1.2 µM 
(monomer equivalent) fragmented β2m fibrils for 2 h. Cells were then stained with a fluorescently 
labelled antibody specific for CD63 and cell-associated fluorescence was quantified by flow cytometry. 
(A) Representative flow cytometry data showing the effect of cycloheximide on cell surface CD63 
expression. (B) Quantification of flow cytometry data. Cell surface CD63 (%) was calculated by 
normalising to signal from cells that were incubated with fibril growth buffer for 0 h (100 %). Error bars 
represent one S.E.M. over 3 independent experiments containing three replicates each. * signifies a p 
value of <0.05. Flow cytometry data was collected on a BD LSRFortessa analyser (Becton Dickinson).  
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5.2.5 Analysis of the effect of fibrils on endocytosis 
Fragmented β2m fibrils impair the trafficking of LAMP-1 and CD63 (Figure 5.2 and Figure 5.3). 
Perturbations in trafficking would rationalise the inhibition in degradation of endocytosed 
proteins in fibril-treated cells (Figure 4.10 and Figure 4.11). In order to investigate the effect of 
fragmented β2m fibrils on fluid-phase endocytosis, the endocytosis of fluorescently labelled 
dextrans was assayed by measuring cell-associated fluorescence by flow cytometry. SH-SY5Y 
cells were incubated with either fragmented β2m fibrils or controls (fibril growth buffer and 
β2m monomer) for 24 h. Cells were then washed and incubated with a fluorescently labelled 
dextran, Alexa Fluor® 680 dextran (AF680-dextran) of molecular weight (MW) 10, 000 Da for 
24 h. Dextrans are relatively inert polysaccharides which are resistant to cleavage in eukaryotic 
cells due to their uncommon α-1,6-polyglucose linkages [421]. Due to their resistance to 
cleavage and therefore their accumulation in cells, cell-associated fluorescence of dextrans can 
be used as a measure of uptake. Following thorough washing, cells were analysed for cell-
associated fluorescence by flow cytometry (Section 2.8.3.1).  
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Figure 5.9: Analysis of the effect of fibrils on the uptake of fluorescently labelled dextran. SH-SY5Y 
cells were incubated with 1.2 µM β2m monomer or 1.2 µM (monomer equivalent) fragmented β2m 
fibrils for 24 h. Cells were then washed and incubated with AF680-dextran for 24 h. Cell-associated 
fluorescence was quantified by flow cytometry. (A) Representative flow cytometry data comparing 
AF680-dextran uptake. (B) Quantification of flow cytometry data. Cell-associated ovalbumin (%) was 
calculated by normalising against signal from cells that were incubated with fibril growth buffer (100 %). 
Error bars represent one S.D. over three replicates. Flow cytometry data was collected on a BD 
LSRFortessa analyser (Becton Dickinson).  
Fragmented fibrils did not have a significant effect on the endocytosis of labelled dextran 
when compared to buffer and monomer treated cells (Figure 5.9). However, these data do not 
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provide any information on the trafficking of dextrans after internalisation by cells. For 
instance, if the trafficking of dextran is disrupted after internalisation, i.e. the delivery of cargo 
to the lysosomes is impaired, cell-associated fluorescence by flow cytometry would not 
distinguish between dextran accumulation in early endosomes, late endosomes, MVBs and 
lysosomes. For this reason, a preliminary investigation into the trafficking of labelled dextran 
to lysosomes was performed (Section 2.8.3.2). This was achieved by pre-incubation of SH-SY5Y 
cells with Alexa Fluor® 568 10,000 MW dextran, (AF586-dextran). As dextrans are resistance to 
cleavage by lysosomal hydrolases and accumulate in lysosomes, AF586-dextran fed before the 
addition of fibrils, can act as a marker for lysosomes. Cells were then washed thoroughly and 
incubated with fragmented β2m fibrils or fibril growth buffer as a control. Following thorough 
washing, cells were incubated with a second fluorescently labelled dextran of a different 
colour, Alexa Fluor® 680 10,000 MW dextran (AF680-dextran). The degree of overlap between 
the two dextrans could therefore be indicative of delivery of cargo to the lysosome and can 
thus be used to determine if fibrils disrupt the sorting of endocytosed material to the 
lysosome. When such a degree of overlap was analysed by live cell confocal microscopy, and 
Manders’ colocalisation coefficients (MCC) quantified using Image J, a significant reduction in 
the overlap of AF586-dextran and AF680-dextran was observed when cells were treated with 
fibrils compared to cells incubated with fibril growth buffer (Figure 5.10, Figure 5.11 and 
Section 2.8.3.2). MCC is independent of signal proportionality i.e. the absolute levels of AF568-
dextran and AF680-dextran and is therefore unaffected by differences (if any) in levels of 
uptake of the two dextrans [330].This suggests that fibrils impair delivery of endocytosed 
material to lysosomes. 
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Figure 5.10: Live cell confocal microscopy analysis of the effect of fibrils on endocytosis. SH-SY5Y cells 
were incubated with AF568-dextran for 24 h. Cells were then thoroughly washed and incubated with 
either fibril growth buffer or 1.2 µM (monomer equivalent) fragmented β2m fibrils for 24 h. This was 
followed by washing and incubation with a second fluorescently labelled dextran, AF680-dextran for 24 
h. Cells were washed thoroughly prior to imaging using a Zeiss LSM700 confocal microscope with a 63X 
objective. Representative confocal images for each condition are shown. Scale bar represents 10 µm.  
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Figure 5.11: Colocalisation analysis of the effect of fibrils on endocytosis. Colocalisation analysis was 
performed on the experiment shown in (Figure 5.10) with Image J using the JACoP plugin. Costes’ 
threshold was subtracted from the images before MCC analysis was performed. M1 and M2, Manders' 
coefficients were calculated from 20 images per condition. M1 represents the fraction of AF680-dextran 
that colocalises with AF568-dextran. M2 represents the fraction of AF568-dextran that colocalises with 
AF680-dextran. Error bars indicate one S.E.M. over twenty images. Both M1 (p < 0.01) and M2 (p < 0.05) 
are significantly different in fibril treated cells compared to buffer treated cells.  
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5.3 Discussion 
The membrane trafficking system including endocytosis, exocytosis and intracellular trafficking 
is a finely controlled system which regulates many cellular processes. Cellular health and 
function relies on the system and there are several examples of disease associated with 
defects in membrane trafficking [404]. For example, the importance of proper trafficking of 
lysosomal proteins is demonstrated by the lysosomal storage disorder (LSD), mucolipidosis 
type II (I-cell disease) [404]. The enzyme N-acetylglucosamine phosphotransferase, which 
catalyses the incorporation of a mannose-6-phosphate (M6P) moiety on newly synthesised 
lysosomal enzymes is mutated in patients suffering from mucolipidosis type II [422, 423]. 
Lysosomal enzymes are targeted to lysosomes via this M6P moiety and mutations in N-
acetylglucosamine phosphotransferase result in the improper trafficking of lysosomal enzymes 
to the extracellular space [424]. Accumulating evidence also suggests that trafficking may be 
altered in amyloid diseases such as Alzheimer’s, Parkinson’s and Huntington’s disease 
(reviewed in [394, 395, 404]). Disruptions to membrane trafficking could therefore have 
significant pathogenic consequences.  
The fibril-induced increase in extracellular formazan needles in the MTT assay suggests an 
alteration in the trafficking of MTT and/or formazan (Figure 3.17). This prompted a closer 
investigation of membrane trafficking. Indeed, β2m fibrils enhance the expression of LAMP-1 
and CD63 at the cell surface without increasing their production or inducing a gross re-
distribution of existing protein pools (Figure 5.2, Figure 5.3, Figure 5.4, Figure 5.5 and Figure 
5.6). Fibrils exert their effect, in part, on the trafficking of newly synthesised LAMP-1 and CD63 
(Figure 5.7 and Figure 5.8). A portion of existing CD63 is also trafficked to the plasma 
membrane in fibril-treated cells. This could involve a block in the trafficking of newly 
synthesised protein from the TGN to late endosomes resulting in more newly synthesised 
LAMP-1 and CD63 being trafficked to the lysosome via the plasma membrane. Indeed, 
depletion of the adaptor protein complex, AP-3, which is involved in the transport of lysosomal 
membrane proteins to late endosomes/lysosomes, has been shown to enhance the cell-
surface expression of LAMP-1 and CD63 [415, 425].  Alternatively, this could be due to an 
increase in newly synthesised protein being trafficked to the plasma membrane or the 
retention of protein at the plasma membrane due to reduced endocytosis of LAMP-1 and CD63 
(Figure 5.12).  
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Figure 5.12: Model of fibril-mediated perturbation in trafficking of LAMP-1, CD63 and endocytosed 
cargo. Upon internalisation, fragmented fibrils perturbed membrane trafficking. This perturbation could 
be due to a block in trafficking of LAMP-1 and CD63 from the TGN to late endosomes (1). Alternatively, it 
could be due to increased trafficking of LAMP-1 and CD63 to the plasma membrane (2), or reduced 
endocytosis (3). Fragmented fibrils also impaired delivery of endocytosed cargo to lysosomes (4).  
Trafficking defects have been reported in association with Parkinson’s disease. α-synuclein was 
shown to not only block trafficking from the ER to the Golgi, but also block multiple trafficking 
steps [410, 411]. Although these studies were performed by overexpressing α-synuclein in 
yeast models and investigating membrane trafficking interactions in vitro from purified cell 
components, important parallels are apparent. The trafficking steps implicated in α-synuclein 
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mediated disruption, include, but are not limited to, trafficking between secretory vesicles and 
the plasma membrane, early endosomes and late endosomes, and between late endosomes 
and lysosomes [411]. The direction of the effect of α-synuclein on these trafficking steps is not 
known. 
It is possible that fragmented fibrils are capable of interacting with accessory and regulatory 
proteins which mediate trafficking. For example, a disease-associated mutant (A30P) α-
synuclein, has been shown to interact abnormally with the regulatory proteins Rab3a, Rab5 
and Rab8 [409]. The rescue of amyloid-induced toxicity by overexpression of Rab1, Rab3a and 
Rab8 in yeast models provides further evidence for abnormal interactions between amyloid 
aggregates and regulatory proteins [410, 411]. However, these interactions would require the 
presence of amyloid aggregates in the cytosol. As evidence of lysosomal rupture has not been 
detected in our laboratory (Eric Hewitt, personal communications and Figure 4.17), it is 
unlikely that fibrils escape into the cytosol from the lysosome. However, these interactions 
may be mediated by fibrils inside trafficking vesicles, by interacting with adaptor proteins 
directly or indirectly via other cargo proteins.  
Although preliminary, the investigation into the effect of fibrils on endocytosis was 
informative. Fibrils did not affect the fluid phase internalisation of cargo as demonstrated by 
the flow cytometry analysis of dextran uptake (Figure 5.9). However, it is possible that other 
forms of endocytosis are affected or trafficking of endocytosed cargo is disrupted after 
internalisation by cells. A fibril-mediated reduction in endocytosis could explain why LAMP-1 
and CD63 accumulate at the cell surface. Fibrils appear to inhibit the delivery of cargo to 
lysosomes (Figure 5.10 and Figure 5.11). A reduction in delivery of endocytosed cargo to 
lysosomes could explain why the degradation of endocytosed proteins is impaired in fibril-
treated cells but the degradation of cell membrane permeable Magic Red™ cathepsin B is 
unaffected (Figure 4.7, Figure 4.8 and Figure 4.13). Ovalbumin was shown to co-stain with 
LysoTracker Green when its internalisation and intracellular localisation was analysed by live 
cell confocal microscopy (Figure 4.7 and Figure 4.8). As LysoTracker Green accumulates in 
acidic compartments, and cannot distinguish between lysosomes and late endosomes, it is not 
possible to determine whether trafficking of endocytosed ovalbumin was impaired. 
Other studies have demonstrated an inhibition of clathrin-mediated endocytosis by amyloid 
aggregates [413, 414]. It is possible that fibrils may indeed inhibit clathrin-mediated 
endocytosis but have no effect on fluid phase uptake. Future work should investigate the 
effects of fibrils on different forms of endocytosis. For example, clathrin-mediated endocytosis 
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and caveolae-mediated endocytosis are implicated in the internalisation of CD63 from the 
plasma membrane [415]. Investigation into the effect of fibrils on the endocytosis of known 
cargo for clathrin-mediated and caveolae-mediated endocytosis such as the transferrin 
receptor, and the SV40 virion respectively could be informative [426]. A more thorough 
investigation into the block in intracellular trafficking could be guided by the combination of 
dextrans with markers to early endosomes, late endosomes and MVBs. Fibrils may have a 
temporal dependent effect on endocytosis, and therefore analysis of endocytosis at shorter 
time points than 24 h may be instructive. The data described in this chapter demonstrate that 
fragmented β2m fibrils impair the trafficking of lysosomal membrane proteins and of 
endocytosed cargo to lysosomes.  
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6 Investigation of the role of the molecular chaperone, Hsp70 in 
fibril-mediated cell disruption 
6.1 Introduction 
6.1.1 Hsp70 and its role in amyloid disease 
The activation of the heat shock response and in particular, the elevation of Hsp70 levels, has 
been shown to have a neuroprotective effect in several models of neurodegeneration. This 
protective effect is thought to be principally due to its role as a chaperone (reviewed in [427]). 
Hsp70 is a 70 kDa protein which performs its role as a chaperone by interacting with exposed 
hydrophobic amino acids in various proteins. It directs its substrates into a variety of distinct 
fates by hydrolysing ATP. Hsp70 acts at multiple steps in a protein’s life cycle; from folding, 
trafficking, remodelling and degradation (reviewed in [428]). Hsp70 is composed of three 
major domains: the N-terminal nucleotide binding domain (NBD); the substrate binding 
domain (SBD) and a C-terminal α-helical lid. All three domains are required for Hsp70 to 
function as a molecular chaperone [428]. In humans, there are 11 genes recognised as 
encoding Hsp70 family members. These include amongst others, the constitutive cytosolic 
member Hsc70, the stress-induced cytosolic Hsp70, ER-localised Grp78 and mitochondria-
localised Grp 75 [429]. In addition to its role in cellular protein quality control and proteostasis, 
Hsp70 has been shown to promote cell survival by inhibiting lysosomal membrane 
permeabilisation (LMP), enhancing lysosomal catabolism and preventing apoptosis (reviewed 
in [430]).  
Members of the Hsp40 and Hsp70 families have been found to colocalise with nuclear 
aggregates in poly-glutamine diseases, as observed in human and mouse brains (reviewed in 
[427]). This suggests that cellular protein quality control mechanisms are activated in poly-
glutamine diseases. Indeed, overexpression of Hsp70 has been shown to be protective in a 
drosophila model of the poly-glutamine disease, spinocerebellar ataxia 3, as well as mouse 
models of the poly-glutamine diseases, spinocerebellar ataxia 1 and spinobulbar muscular 
atrophy (SBMA) [431-433]. A neuroprotective role for Hsp70 has also been described for 
Parkinson’s disease, where Hsp70 overexpression reduced α-synuclein accumulation and 
toxicity in mouse and drosophila models [217, 434]. In all these examples, the protective role 
of Hsp70 has been described for intracellular Hsp70. However, heat shock proteins are also 
found extracellularly and numerous studies have demonstrated a protective role for 
extracellular Hsc70 and Hsp70 against nutrient deprivation in neurons, smooth muscle cells 
and monocytes (reviewed in [427]). Hsp70 has been shown to be released from some cells, 
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and taken up by others in a biologically active form [435, 436]. Although the extracellular 
mechanism of action of Hsp70 protection is unknown, there is evidence to suggest that Hsp70 
can be internalised and imported into the cytoplasm and nucleus of various cell types thus 
increasing their survival (reviewed in [427]). Indeed, exogenous administration of Hsp70 to rat 
microglial cultures has been demonstrated to enhance the clearance of Aβ [437]. Extracellular 
Hsp70 has also been shown to protect against neurodegeneration in a mouse model of 
amyotrophic lateral sclerosis (ALS) [438].  
6.1.2  Hsp70 and its role in lysosomal storage diseases 
Lysosomal storage disorders (LSDs) are a group of diverse inherited diseases caused by 
mutations in lysosomal proteins [430]. In spite of their varied monogenetic origin, LSDs have a 
number of cellular and clinical manifestations in common [439]. These include perturbed 
lysosomal trafficking, autophagy dysfunction, increased oxidative stress, disrupted calcium 
homeostasis, lysosomal destabilisation, enhanced ER-stress responses and cell death [439]. 
The heat shock response, and in particular the members of the Hsp70 family, influence many 
of the primary and secondary cellular processes of LSDs, and thus it is unsurprising that 
emerging evidence implicates a protective role for Hsp70 in LSDs [430]. Disrupted homeostasis 
due to the presence of dysfunctional, often misfolded, lysosomal proteins as well as the 
accumulation of potentially toxic substrates with a variety of downstream effects are recurring 
themes in LSDs [430, 439].  
Key functions of the Hsp70 family of molecular chaperones include assisting the folding of 
newly synthesised or damaged proteins, preventing protein aggregation, and targeting 
severely damaged proteins for degradation [199]. Hsp70 can therefore play a protective role in 
disease pathogenesis in LSDs. For example, celastrol, which activates the heat shock response, 
has been shown to enhance both the quantity and the catalytic activity of the mutated 
enzyme, glucocerebrosidase in Gaucher’s disease models [440]. Hsp70 has also been shown to 
be protective in models of Niemann Pick disease A and B [441]. In this instance, exogenously 
applied recombinant Hsp70 was shown to be trafficked to the lysosome and protection was 
mediated by enhancing the activity of mutated acid sphingomyelinase [441]. 
Striking similarities between LSDs and amyloid diseases such as Alzheimer’s, Parkinson’s and 
Huntington’s disease with respect to the involvement of the lysosome are apparent [306]. 
Hsp70 has been shown to have a protective effect in both amyloidoses and LSDs as discussed 
above. Taking advantage of the endocytic machinery to traffic recombinant Hsp70 to the 
lysosome [441], the role of Hsp70 in fibril-mediated lysosomal disruption was investigated. 
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This was based on the observations of impaired lysosomal function and trafficking of lysosomal 
membrane proteins by fragmented β2m fibrils. The Hsp70 used in the experiments described 
here is the cytosolic stress-inducible Hsp70 (Hsp70(1A), herein referred to as Hsp70) which has 
been shown to translocate to the lysosomal compartment under conditions of cellular stress 
[442]. It is the same isoform which has been shown to be trafficked to the lysosome and play a 
protective role in models of Niemann Pick disease A and B [441]. This chapter describes 
experiments designed to investigate whether or not Hsp70 is protective against fragmented 
β2m fibrils.  
6.2 Results 
6.2.1 Expression and purification of Hsp70 
In order to generate Hsp70 to determine if Hsp70 protected cells against the deleterious 
effects of amyloid fibrils, recombinant Hsp70 was expressed in BL21 (DE3) pLysS cells carrying 
the pET28b-Hsp70(1A) plasmid according to an established protocol [333] (Section 2.9 and 
Figure 6.1). Cells were lysed after induction with IPTG and the soluble fraction of the cell lysate 
was purified by Ni-NTA chromatography. The protein was eluted via a step gradient and Hsp70 
elutes as a single peak at an imidazole concentration of 200 mM (Figure 6.2 and Figure 6.3). 
Fractions spanning this single peak were pooled and dialysed prior to further purification by 
size exclusion chromatography.  
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Figure 6.1: Schematic of Hsp70 expression and purification strategy.  
This, however, did not successfully separate the protein into well resolved peaks as judged by 
the size exclusion chromatography profile (Figure 6.4). SDS-PAGE analysis of the size exclusion 
chromatography eluate shows the presence of a less abundant, lower band which could be a 
contaminant or a proteolytic fragment of Hsp70 (predicted molecular mass of Hsp70 is 72 KDa) 
(Figure 6.5). The protein was therefore pooled and dialysed against 20 mM Tris.HCl pH 8.0 
prior to further purification by anion exchange chromatography. Purification by anion 
exchange chromatography separated the protein into sharper, well resolved peaks (Figure 
6.6).  
Analysis of purity by SDS-PAGE revealed that the second peak corresponds to relatively pure 
Hsp70 (Figure 6.7). Electrospray ionisation mass spectrometry was used to determine the 
molecular weight of the purified protein (Figure 6.8). A molecular mass of 72085 Da is 
consistent with the purified protein being hexa his-tagged monomeric Hsp70 with the N 
terminal methionine excised (expected mass 72084.36 Da). Excision of the N terminal 
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methionine has been shown to be a common modification of proteins in the cytosol of 
Escherichia coli [443]. The purified Hsp70 was stored at -80 °C.    
 
Figure 6.2: Ni-NTA affinity chromatography purification of Hsp70. Recombinant N-hexa-His tagged 
Hsp70 was overexpressed in BL21 (DE3) pLysS cells transformed with the pET28b-Hsp70(1A) plasmid 
[333]. Cells were harvested from induced cultures and lysed. Cell lysates were filtered and loaded onto 
an XK26 column containing 25 ml Ni Sepharose High Performance. 1 indicates a disruption in the 
absorbance at 280 nm due to accidental loading of air on to the column. 2 indicates a wash step with 40 
mM imidazole and 3 indicates an elution step with 200 mM imidazole. Samples from 2 and 3 were 
collected for SDS-PAGE analysis.   
156 
 
 
Figure 6.3: SDS-PAGE analysis of Hsp70 purification by Ni-NTA chromatography. Samples were 
resolved by 10% Tris-glycine SDS-PAGE and visualised by Coomassie Blue. Lane 1 – marker; 2 – whole 
cell lysate of induced cells; 3 – soluble fraction of whole cell lysate; 4 – flow-through (1 in Figure 6.2) ; 5 
– wash with 40 mM imidazole (2 in Figure 6.2); 6 to 14 – samples spanning peak that elutes at 200 mM 
Imidazole (3 in Figure 6.2).  
 
 
Figure 6.4: Size exclusion chromatography purification of Hsp70. Fractions corresponding to the Ni-NTA 
affinity chromatography elution peak (3 in Figure 6.2) were pooled and dialysed against 50 mM Tris.HCl 
pH 7.4 containing 150 mM KCl and 2 mM MgCl2. Dialysed protein was concentrated to 12 mg/ml prior to 
loading on to a Superdex 75 HiLoad 26/60 size exclusion column for further purification. Samples 
spanning both peaks (indicated by ¥) were collected for SDS-PAGE analysis. 
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Figure 6.5: SDS-PAGE analysis of size exclusion chromatography purification of Hsp70. Samples were 
resolved by 10% Tris-glycine SDS-PAGE and visualised by Coomassie Blue. Lane 1 – marker; 2 to 15 
samples spanning both peaks from the size exclusion chromatography elution profile (¥ in Figure 6.4). * 
Indicates a band corresponding to either a contaminant or degradation product of Hsp70.  
 
Figure 6.6: Further purification of Hsp70 by anion exchange chromatography. Fractions spanning both 
peaks from size exclusion chromatography purification (¥ in Figure 6.4) were pooled and dialysed 
against 20 mM Tris.HCl pH 8.0 and loaded onto a Resource Q anion-exchange column. A linear gradient 
of 0 – 700 mM NaCl in 20 mM Tris.HCl pH 8.0 over 80 ml was applied to elute the protein. Fractions from 
peaks 1 and 2 were collected for SDS-PAGE analysis.   
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Figure 6.7: SDS-PAGE analysis of anion exchange chromatography purification of Hsp70. Samples were 
resolved by 10% Tris-glycine SDS-PAGE and visualised by Coomassie Blue. Lane 1 – marker; 2 to 9 – 
samples spanning the second peak (2 on Figure 6.6); 10-11 – samples spanning the first peak (1 on 
Figure 6.6). * indicates a band corresponding to a contaminant or degradation product of Hsp70.  
 
Figure 6.8: Electrospray ionisation mass spectrometry (ESI-MS) analysis of purified Hsp70. Mass 
profiles generated by Maximum Entropy processing of the ESI-MS m/z spectra. The peak corresponding 
to 72085.00 ± 0 Da represents hexa-his-tagged monomeric Hsp70. The peaks to the right correspond to 
Hsp70 bound to sodium and potassium ions. ESI-MS analysis was performed by Dr James Ault 
(University of Leeds, Astbury mass spectrometry facility manager). 
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6.2.2 Analysis of the intracellular localisation of recombinant Hsp70 
To confirm that exogenously added, purified, recombinant Hsp70 was indeed trafficked to the 
lysosome as shown previously, its intracellular localisation was analysed by live cell confocal 
microscopy [441]. Purified Hsp70 was fluorescently labelled with Alexa Fluor® 405 prior to 
incubation with RAW 264.7 cells for 4 h (Section 2.10.1). Cells were stained with LysoTracker 
Green and imaged. Labelled Hsp70 was found in intracellular punctate structures which 
colocalised with LysoTracker Green (Figure 6.9).  
 
Figure 6.9: Analysis of the internalisation and localisation of labelled Hsp70 in RAW 264.7 cells. RAW 
264.7 cells were incubated with 3 µM Alexa Fluor® 405 Hsp70 for 4 h. Cells were washed and stained 
with 50 nM LysoTracker Green 30 min prior to imaging. Images were acquired using a Zeiss LSM510 
confocal microscope with a 40X objective. Representative confocal images are shown. Scale bar 
represents 10 µm.  
6.2.3 Investigation of the role of Hsp70 in amyloid-mediated disruption of MTT 
reduction 
To investigate whether Hsp70 could protect against inhibition of MTT reduction by fragmented 
β2m fibrils, RAW 264.7 and SH-SY5Y cells were pre-incubated with Hsp70 4 h (RAW 264.7) or 6 
h (SH-SY5Y) prior to incubation with fragmented fibrils (Section 2.10.2). The MTT assay was 
then employed to measure the effect of Hsp70 on MTT reduction by fibril-treated cells. Pre-
incubation of cells with Hsp70 reduced the inhibition of MTT reduction by fragmented β2m 
fibrils in both RAW 264.7 and SH-SY5Y cells (Figure 6.10).  
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Figure 6.10: Analysis of the effect of Hsp70 on MTT reduction in fibril treated cells. RAW 264.7 (A) and 
SH-SY5Y (B) were pre-incubated with Hsp70 at the concentrations indicated for 4 h (RAW 264.7) or 6 h 
(SH-SY5Y). Cells were then incubated with 1.2 µM (monomer equivalent) fragmented β2m fibrils or fibril 
growth buffer as a control for 24 h prior to analysis of MTT reduction. MTT reduction (%) was calculated 
by normalising against cells treated with the respective concentrations of Hsp70 and fibril growth buffer 
(100 %). Error bars represent one S.E.M. over three independent experiments containing five replicates 
each. *** signifies a p value of <0.001. 
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6.2.4 Investigation of the role of W90F Hsp70 in amyloid-mediated disruption of 
MTT reduction 
In addition to its role as a molecular chaperone, Hsp70 is also involved in the regulation of LMP 
[444]. LMP causes the release of cathepsins and other hydrolases from the lysosomal lumen to 
the cytosol. It is therefore a potentially lethal event due to digestion of vital proteins as well as 
activation of additional hydrolases such as caspases [283]. LMP is induced by a range of 
different stimuli including activation by cell death effectors such as Bax [283]. Exogenously 
added Hsp70 has been shown to be trafficked to the lysosome and to inhibit LMP by stabilising 
lysosomes. This stabilising effect is due to the binding of Hsp70 to the endolysosomal lipid 
bis(monoacylglycero)phosphate (BMP). This interaction enhances sphingomyelin catabolism 
thus increasing cellular levels of ceramide and resulting in lysosomal stability [441]. By 
changing the lipid composition of inner lysosomal membranes, sphingolipid catabolism is 
thought to enhance the stability of the lysosomal membrane [445]. A single point mutation in 
the ATPase domain of Hsp70 at residue 90, which changes a tryptophan residue to a 
phenylalanine residue (W90F), has been shown to specifically abolish the interaction between 
Hsp70 and BMP whilst retaining the structural and functional aspects of the Hsp70 chaperone 
[441]. W90F Hsp70 is therefore unable to protect against LMP in contrast to wild-type Hsp70 in 
models of Niemann Pick disease A and B [441]. Recent work in our laboratory has shown that 
fragmented β2m fibrils disrupt artificial lipid bilayers which contain BMP [446]. W90F Hsp70 
was used as a tool to investigate whether the interaction of Hsp70 and BMP was necessary for 
protection from fragmented β2m fibrils. 
W90F Hsp70, was expressed in BL21 (DE3) pLysS cells carrying the pET28b-W90F Hsp70(1A) 
plasmid and then purified using the same protocol as used for wild-type Hsp70 [333] (Figure 
6.1 and Section 2.9). The purity of W90F Hsp70 was confirmed by analytical size exclusion 
chromatography and SDS-PAGE analysis (Figure 6.11 and Figure 6.12). 
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Figure 6.11: Analytical size exclusion chromatography of purified W90F Hsp70. Purified W90F Hsp70 
was separated by size exclusion chromatography using an analytical size exclusion column (Superdex 
200 10/300 GL).  Samples from both peaks (1 and 2) were collected for SDS-PAGE analysis. 
 
Figure 6.12: SDS-PAGE analysis of analytical size exclusion chromatography of purified W90F Hsp70. 
Samples were resolved by 10% Tris-glycine SDS-PAGE and visualised by Coomassie Blue. 1 – Marker; 2 to 
4 samples spanning the first peak from the size exclusion chromatography elution profile (1 in Figure 
6.11); 5 to 11 – samples spanning the second peak (2 in Figure 6.11).  
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The effect of W90F Hsp70 on the inhibition of MTT reduction by fragmented β2m fibrils was 
investigated. Cells were pre-incubated with Hsp70 or W90F Hsp70 prior to incubation with 
fragmented fibrils (Section 2.10.2). W90F Hsp70 also protects against fibril-mediated inhibition 
in MTT reduction (Figure 6.13). This protection, observed in both RAW 264.7 and SH-SY5Y cells, 
is comparable to that conferred by wild-type Hsp70. This suggests that Hsp70 rescue is unlikely 
to require the interaction of Hsp70 with the endolysosomal lipid, BMP.  
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Figure 6.13: Analysis of the effect of W90F Hsp70 on the fibril-mediated disruption of MTT reduction. 
RAW 264.7 (A) and SH-SY5Y (B) were pre-incubated with Hsp70 or W90F Hsp70 at the concentrations 
indicated for 4 h (RAW 264.7) or 6 h (SH-SY5Y). Cells were then incubated with 1.2 µM (monomer 
equivalent) fragmented fibrils or fibril growth buffer as a control for 24 h prior to analysis of MTT 
reduction. MTT reduction (%) was calculated by normalising against cells treated with the respective 
concentrations of W90F Hsp70 or Hsp70, and fibril growth buffer. Error bars represent one S.E.M. over 
three independent experiments containing five replicates each. *, ** and *** signify p values of <0.05, 
<0.01 and <0.001 respectively. 
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6.2.5 Investigation of the effect of Hsp70 on fibril-mediated alteration in formazan 
trafficking 
To investigate whether Hsp70 protected against the fibril-mediated alteration in formazan 
trafficking in the MTT assay, SH-SY5Y cells were pre-incubated with Hsp70 prior to incubation 
with fragmented fibrils (Section 2.10.3). In the absence of Hsp70, phase contrast microscopy 
analysis showed accumulation of formazan as extracellular needles in fibril-treated cells and 
intracellular granules in buffer-treated controls (Figure 6.14). Pre-incubation with Hsp70 had a 
subtle effect on the production of extracellular needles by fibril-treated cells. Although 
formazan still accumulated in extracellular needles, intracellular granules were also observed 
(bottom panel in Figure 6.14). Such intracellular granules are not observed in the absence of 
Hsp70.  
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Figure 6.14: Phase contrast microscopy analysis of the effect of Hsp70 on formazan trafficking. SH-
SY5Y cells were pre-incubated with either 3 µM Hsp70 or PBS as a control for 6 hours prior to 24 h 
incubation with 1.2 µM (monomer equivalent) fragmented β2m fibrils or fibril growth buffer. Cells were 
incubated with MTT 90 min before imaging by phase contrast microscopy. Reduced formazan was 
visualised as dark intracellular granules (open triangle) or extracellular needles (filled triangle). Images 
were acquired on a Leica DM IL inverted contrasting microscope connected to a Leica DC 300F camera 
(Leica microsystems). Representative images are shown. The scale bar represents 20 µm. 
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6.2.6 Further investigation into the effect of Hsp70 on fibril-mediated cell 
disruption 
Due to the observation of fibril-mediated perturbation in LAMP-1 trafficking (Figure 5.2), the 
effect of Hsp70 on the cell-surface expression of LAMP-1 in fibril-treated cells was analysed by 
flow cytometry (Section 2.10.4). SH-SY5Y cells were pre-incubated with Hsp70 prior to 
incubation with fragmented β2m fibrils or controls. Hsp70 did not have a significant effect on 
the cell surface LAMP-1 expression in cells incubated with fragmented fibrils or controls (Figure 
6.15). 
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Figure 6.15: Analysis of the effect of Hsp70 on the cell surface expression of LAMP-1. SH-SY5Y cells 
were pre-incubated with either 3 µM Hsp70 or PBS as a control prior to incubation with 1.2 µM 
(monomer equivalent) fragmented β2m fibrils or controls (1.2 µM β2m monomer or fibril growth buffer). 
Cells were then stained with fluorescently labelled anti-LAMP-1. Cell-associated fluorescence was 
quantified by flow cytometry. (A) Representative flow cytometry data showing the effect of Hsp70 on 
cell-surface LAMP-1 expression. (B) Quantification of flow cytometry data. Cell surface LAMP-1 (%) was 
calculated by normalising to signal from cells that were incubated with fibril growth buffer (100 %). Error 
bars represent one S.E.M. over three independent experiments each containing three replicates each. 
Flow cytometry data was collected on a BD LSRFortessa analyser (Becton Dickinson).  
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In order to further examine the effects of Hsp70 on the fibril-associated disruption of cellular 
function, its role in ovalbumin degradation in fibril-treated cells was analysed by flow 
cytometry (Section 2.10.5). This was based on the observation of impairment in degradation of 
endocytosed proteins in cells incubated with fragmented β2m fibrils (Figure 4.10 and Figure 
4.11). SH-SY5Y cells were pre-incubated with Hsp70 for 6 h before incubation with fragmented 
fibrils or controls for 24 h. Cells were then pulsed with a fluorescent protein substrate, Alexa 
Fluor® 647 ovalbumin (AF647-ovalbumin) for 6 h. Following pulse, cells were analysed for cell-
associated fluorescence immediately (0 h chase) or cultured for a further 24 h in the absence 
of AF647-ovalbumin and then analysed (24 h chase). Pre-incubation of cells with Hsp70 
restored ovalbumin degradation in fibril-treated cells to levels comparable to controls (Figure 
6.16). Hsp70 therefore restores the ability of fibril-treated cells to degrade endocytosed 
proteins. 
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Figure 6.16: Analysis of the effect of Hsp70 on the degradation of fluorescently labelled ovalbumin in 
fibril treated cells. SH-SY5Y cells were pre-incubated with Hsp70 at the concentrations indicated for 6 h 
prior to incubation with fragmented fibrils or controls. Cells were then pulsed with A647-ovalbumin and 
its degradation over time was followed by measuring cell-associated fluorescence immediately after 
pulsing with labelled ovalbumin (0 h chase) or 24 h later (24 h chase). (A) Representative flow cytometry 
data showing the effect of Hsp70 on ovalbumin degradation. (B) Quantification of flow cytometry data. 
Ovalbumin fluorescence (%) was calculated by normalising the fluorescence at 24 h chase to the 
fluorescence at 0 h chase (100 %). Error bars represent one S.E.M. over three independent experiments 
containing three replicates each. *** signifies a p value of <0.001. Flow cytometry data was collected on 
a BD LSRFortessa analyser (Becton Dickinson).  
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6.3 Discussion 
The experiments described here demonstrate protection by Hsp70 from cellular disruption 
mediated by fragmented fibrils. Pre-incubation of cells with Hsp70 prior to incubation with 
fragmented fibrils, confers protection against amyloid-mediated impairment in MTT reduction 
and ovalbumin degradation. As the single point mutant, W90F Hsp70, is also able to protect 
against amyloid-mediated impairment in MTT reduction, this protection is unlikely to be due to 
enhancement of acid sphingomyelinase activity through interactions with BMP. Pre-incubation 
of cells with Hsp70, does not however, protect against fibril-mediated perturbation in LAMP-1 
trafficking. 
In vitro studies on the effect of Hsp70 on α-synuclein fibril formation have demonstrated that 
Hsp70 inhibits fibril formation by binding to prefibrillar species [447, 448]. The constitutively 
expressed member of the Hsp70 family, Hsc70, has also been shown to inhibit α-synuclein 
fibril formation [449]. Furthermore, Hsc70 was shown to ‘coat’ α-synuclein fibrils. α-synuclein 
fibrils coated with Hsp70 were shown to be less toxic than uncoated fibrils [449]. In light of this 
precedent, it is possible that Hsp70 has a direct effect on β2m fibrils. β2m fibrils, like all amyloid 
fibrils, have the potential to disaggregate and release soluble species. Fibril disaggregation has 
been demonstrated to be associated with toxicity [166, 191, 192]. Indeed, in vitro studies on 
the effect of Hsp70 on fragmented β2m fibrils demonstrate a reduction in the rate of fibril 
disaggregation (Kevin Tipping, personal communications and Figure 6.17). Hsp70 protection 
could be mediated by its stabilising effect on fibrils thus reducing the release of potentially 
deleterious, soluble oligomeric species. Alternatively, by interacting with fragmented β2m 
fibrils, Hsp70 could mask fibril surfaces, thus preventing abnormal interactions with cellular 
proteins or lipids.  
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Figure 6.17: Analysis of the effect of Hsp70 on disaggregation of β2m fibrils. Fibril disaggregation was 
followed over time by measuring ThT fluorescence. Hsp70 and fragmented β2m fibrils were diluted in 50 
mM sodium phosphate buffer at pH 7.4 containing 10 µM ThT, 30 mM NaCl and 3 mM KCl, to the 
concentrations indicated. ThT fluorescence was monitored and results were normalised to ThT 
fluorescence at 0 min for each sample (1.0). Representative data averaged from three independent 
replicates are shown. ThT was excited at 440 nm and fluorescence measured at 480 nm. Experiment 
performed by Kevin Tipping, University of Leeds.  
However, the experiments described in this chapter differ fundamentally from the studies 
mentioned above [447, 449]. Both these studies involve pre-incubation of Hsp70/Hsc70 with 
α-synuclein monomer/fibrils prior to incubation with cells, whereas experiments here involve 
pre-incubation of cells with Hsp70 prior to incubation with fibrils. Hsp70 presumably only 
comes into contact with β2m fibrils in the lysosome. Therefore, although a direct interaction of 
Hsp70 with β2m fibrils and a reduction in disaggregation is theoretically plausible, it is likely 
that other factors are also involved.  
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It is possible that pre-incubation of cells with Hsp70 could ‘coat’ inner membranes of 
endosomes, late endosomes and lysosomes prior to fibril insult. For example, Hsp70 has been 
shown to bind to membrane lipids and this binding is enhanced at lysosomal pH [441]. Hsp70, 
by binding to membrane lipids, could therefore obstruct abnormal interactions of fibrils with 
these lipids. Indeed, fragmented β2m fibrils have been shown to interact with synthetic 
liposomes, with fibril-lipid interactions resulting in membrane distortion and blebbing [231]. In 
addition, recent work in our laboratory has shown that fragmented β2m fibrils interact with 
and damage synthetic lipid bilayers [446]. This interaction is dependent on pH, with lipid 
bilayers being particularly susceptible to damage at low pH [446]. Lipid composition has also 
been shown to be important and damage by fragmented β2m fibrils is enhanced in lipid 
bilayers containing BMP [446]. Although the protection by Hsp70 is unlikely to be via 
interaction with BMP, it is possible that Hsp70 binds to other membrane lipids. Lysosomal 
membrane damage is not apparent in cells incubated with fragmented β2m fibrils (Eric Hewitt, 
personal communications and Figure 4.17); however, it is possible that β2m fibrils interact with 
endosomal, late endosomal and lysosomal membrane lipids in a cellular context. Abnormal 
interactions with these lipids could result in disruptions in the endolysosomal system. 
Hsp70 could also protect cells from the deleterious effects of fragmented β2m fibrils by 
enhancing the activities of lysosomal enzymes such as the proteases involved in lysosomal 
degradation. Indeed, celastrol, which induces Hsp70, has been shown to enhance the 
enzymatic activity of glucocerebrosidase in models of Gaucher’s disease [440]. Hsp70 has also 
been shown to enhance the activity of acid sphingomyelinase, the enzyme mutated in 
Niemann Pick disease A and B, and this enhancement leads to protection in models of 
Niemann Pick disease A and B models [441]. Hsp70 activation has also been demonstrated to 
boost the activities of enzymes with metabolic disease-causing mutations, such as cystathione 
β-synthase and methylene tetrahydrofolate reductase [450]. By boosting the activity of 
lysosomal proteases, Hsp70 could protect against fibril-mediated impairment in degradation of 
endocytosed proteins. This could also explain why Hsp70 has no effect on LAMP-1 trafficking 
but restores the degradation of ovalbumin.  
The pharmacological enhancement of Hsp70 is an attractive therapeutic strategy and has been 
explored as treatment for several amyloid diseases [451]. In addition to its efficacy in 
Gaucher’s disease models, celastrol has also been shown to have a protective effect in animal 
models of Parkinson’s disease, Huntington’s disease and ALS models with superoxide 
dismutase-1 (SOD1) mutations [452-454]. 17-N-allylamino-17-demethoxygeldanamycin (17-
AAG), an analogue of the Hsp90 inhibitor, geldanamycin, inhibits Hsp90 by blocking the 
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interaction between Hsp90 and heat shock transcription factor 1 (HSF1) [430]. By doing so, 
geldanamycin and its derivatives, increase the levels of activated HSF1, thus resulting in the 
activation of the heat shock response, including activation of Hsp70 [430, 451]. Treatment with 
17-AAG has been shown to attenuate the toxicity of α-synuclein in cell models of Parkinson’s 
disease, as well as polyglutamine in mouse models of the polyglutamine disease, SBMA [455, 
456]. Finally, arimoclomol has been shown to activate the heat shock response in stressed cells 
by stabilising activated HSF1 thus resulting in the upregulation of molecular chaperones, 
including Hsp70 [451]. Arimoclomol has been demonstrated to be protective in mouse models 
of ALS with SOD1 mutations, as well as mouse models of SBMA [457-459]. Arimoclomol is 
currently being investigated in phase II clinical trials of ALS [451].  
This chapter demonstrates that Hsp70 confers protection against some of the observed 
deleterious effects of fragmented β2m fibrils. This adds to the growing body of evidence 
indicating a protective role for Hsp70 in amyloid disease. A detailed investigation into the 
mechanism of Hsp70 protection from fragmented β2m fibrils could inform future therapeutic 
strategies against amyloid disease.  
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7 Discussion and future work 
Although the close association between appearance of amyloid deposits and onset of 
pathological events has been clear for many years, the mechanisms of disease pathogenesis 
remain unclear [79]. Due to the lack of correlation between fibril load and disease severity, 
research efforts have focused on the investigation of pre-fibrillar aggregates [79, 135, 143-
145]. However, accumulating evidence also implicates fibrils as amyloid species with toxic 
potential [173, 177-186]. The role of amyloid fibrils in disease pathogenesis is being 
reappraised in light of this accumulating evidence [176]. The experiments described in this 
thesis investigated the effect of amyloid fibrils on cellular function.  
β2m was used a model to study amyloid disease based on the extensive characterisation of 
fibril formation pathways, various intermediate species and amyloid fibrils [125, 189, 337, 340, 
341, 368]. In addition, β2m amyloid fibrils formed in vitro have been shown to share structural 
characteristics with ex vivo β2m amyloid fibrils [366]. The β2m fibrils generated and 
incorporated in the experiments described here, display characteristic amyloid properties such 
as binding to ThT and the conformation-specific anti-fibril antibody WO1 [86, 327]. The 
fragmentation of β2m fibrils has been shown to yield nanoscale β2m fibrils which display the 
same structural characteristics but are of a reduced average length [190]. Fragmented β2m 
fibrils have a greater biological activity as evidenced by their ability to inhibit MTT reduction to 
a greater extent than their unfragmented counterparts [190]. The fragmented β2m fibrils 
generated here also display this enhanced biological activity and were therefore selected for 
further investigation. Previous work in the laboratory using macrophages and primary human 
monocytes demonstrated that β2m fibrils are trafficked to the lysosome where they persist 
[247, 248]. Building on this, the effect of β2m fibrils on lysosome function was investigated. 
7.1 Lysosome dysfunction and its role in amyloid disease 
Previous work showed that internalisation of β2m fibrils was length-dependent with 
fragmented fibrils being internalised to a greater extent than unfragmented fibrils (Andrew 
Hellewell, personal communications). This difference in internalisation, and hence access to 
intracellular organelles such as the lysosome, rationalises the differences in biological activity 
observed. Lysosomal dysfunction is a recurrent theme in reported mechanisms underlying 
amyloid diseases [278]. The data presented in this thesis support the notion that lysosomes 
are a key target in amyloid disease. As protein degradation is a crucial function of the 
lysosome, the effect of fragmented β2m fibrils on the ability of lysosomes to perform this 
function was investigated. Fragmented fibrils were shown to impair the degradation of 
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endocytosed proteins. However, the proteolysis of the cell permeant Magic Red™ cathepsin B 
substrate was unaffected by fragmented fibrils. This could be due to a saturating effect on 
lysosomal proteolytic machinery by fibrils acting on proteases other than cathepsin B or 
disruption in trafficking of endocytosed cargo to lysosomes. Experiments investigating the 
effect of fragmented β2m fibrils on other lysosomal hydrolases show no effect on β-
glucocerebrosidase activity and only a modest effect on β-galactosidase activity. This suggests 
that fragmented fibrils only inhibit the capacity of cells to degrade proteins.  
Future work investigating whether fragmented fibrils saturate proteolytic machinery could 
involve investigation of activities of other lysosomal cysteine proteases such as cathepsin L and 
K using commercially available cell permeant substrates similar to that used for cathepsin B. 
Further investigation could also include aspartic and serine proteases. In order to analyse 
whether fragmented fibrils disrupt the trafficking of endocytosed cargo to lysosomes, the 
trafficking of endocytosed fluorescently labelled protein substrate could be further 
characterised. As LysoTracker Green accumulates in acidic vesicles, it does not necessarily 
distinguish between late endosomes and lysosomes. A more detailed characterisation could 
involve antibody markers to organelles in the endolysosomal pathway such as the early 
endosome marker (anti-EEA1), the late endosome marker (anti-Rab7) and the lysosomal 
marker (anti-LAMP-1). For example, live cell confocal microscopy could be used to analyse and 
quantify the colocalisation of AF647-ovalbumin with anti-EEA1, anti-Rab7 and anti-LAMP-1 in 
order to identify the block in trafficking of endocytosed cargo.  This could also extend to 
investigation of the effect of fragmented fibrils on other lysosomal hydrolases using substrates 
that require targeted delivery to the lysosome.  
The inhibition of degradation of endocytosed proteins by fragmented fibrils, and thus their 
accumulation in cells, has a number of derived consequences. Impairment in degradation 
could also affect resident cellular proteins whose accumulation could have further reaching 
consequences. If the function of these resident cellular proteins requires their recycling, their 
entrapment in dysfunctional lysosomes would influence cellular signalling pathways. 
Lysosomal dysfunction would also impact upon autophagy and autophagy dysfunction is 
recurrently reported as a mechanism underlying neurodegenerative diseases such as 
Alzheimer’s, Parkinson’s and Huntington’s diseases [278].  
Indications of altered autophagy are often deduced by observations of autophagosome 
accumulation [242, 255, 261, 290, 291]. Indeed a preliminary investigation into the effects of 
fragmented β2m fibrils indicates altered autophagy; however it is unclear whether this 
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alteration corresponds to a compensatory upregulation of autophagy or a block in 
autophagosome clearance. Further investigation into the effect of fibrils on autophagy could 
involve experiments that distinguish between effects on fusion of autophagosomes to 
lysosomes to form functional autolysosomes, and the degradation in and clearance of 
autolysosomes. For example, immunofluorescence microscopy analysis of fixed cells stained 
with anti-LC3B and anti-cathepsin D should provide information on autophagosome and 
lysosome fusion. Cathepsin D is a lysosomal hydrolase and therefore antibodies specific for 
cathepsin D could be used to stain lysosomes. LC3-II, the lipidated form of LC3-I is recruited to 
active autophagosomes and therefore the anti-LC3B antibody (which recognises both LC3-I and 
LC3-II) could be used to stain autophagosomes. Activated autophagosomes could be 
distinguished from non-activated autophagosomes by incorporating a commercially available 
selective permeabilisation solution which extracts cytosolic LC3-I without affecting LC3-II 
(Merck Millipore). Co-localisation analysis of cathepsin D and LC3-II could therefore be 
informative on fusion of autophagosomes and lysosomes. Elucidation of degradation in the 
autolysosome is more challenging. One approach could involve monitoring the time-
dependent decrease of an autophagy-degradable marker in the presence or absence of fibrils. 
The caveat with this approach, however, is that the marker may be degraded by autophagy-
independent mechanisms and of course fibrils may impair the degradation of the marker 
without impairing autophagy.  
Inhibition of lysosomal function has been implicated in the pathogenesis of amyloid disease 
[278]. This is particularly highlighted by a study using primary mouse cortical neurons which 
demonstrated that inhibition of lysosomal proteolysis by protease inhibitors or by suppression 
of lysosomal acidification, retarded transport of autolysosomes, late endosomes and 
lysosomes and resulted in their accumulation in dystrophic axonal swellings. Interestingly 
these dystrophic swellings resembled those observed in Alzheimer’s disease mouse models 
and were reversed when lysosomal proteolysis was restored [284].  
Lysosomal dysfunction could also contribute to the pathology of DRA. β2m amyloid fibrils 
deposit in osteoarticular tissues and result in bone and joint destruction [52, 53]. 
Macrophages, which infiltrate β2m amyloid deposits in vivo, have been shown to internalise 
β2m fibrils and traffic them to the lysosome where they persist [247, 248, 390]. β2m fibrils in 
the lysosome could reduce the degradative capacity of these cells whose function relies 
heavily on degradation. Furthermore, β2m fibrils have the potential to disrupt bone 
remodelling due to their demonstrated ability to perturb primary human cells implicated in the 
pathology of DRA (osteoblasts and osteoclasts) [248]. Bone remodelling requires the concerted 
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action of osteoclasts (which resorb bone) and osteoblasts (which produce bone) [460]. β2m 
fibrils were shown to inhibit the ability of osteoclasts to resorb bone [248]. Bone resorption by 
osteoclasts involves lysosome-like organelles and fibril-mediated lysosomal dysfunction could 
rationalise this inhibition [460]. 
7.2 Membrane trafficking perturbations and their role in amyloid 
disease 
Accumulating evidence implicates trafficking defects in Alzheimer’s, Parkinson’s and 
Huntington’s diseases [323, 394, 395, 409-413]. Fragmented fibrils were shown to enhance the 
expression of the lysosomal membrane proteins, LAMP-1 and CD63 at the cell surface without 
increasing their expression or inducing a gross re-distribution of existing protein pools. 
Inhibition of protein synthesis using cycloheximide, inhibited, in part, this increase in LAMP-1 
and CD63 at the cell surface suggesting that fragmented fibrils alter the trafficking of newly 
synthesised LAMP-1 and CD63. This could be due to impairment in trafficking of newly 
synthesised protein from the TGN to late endosomes. On the other hand, an increase in 
trafficking of newly synthesised protein to the plasma membrane or the retention of protein at 
the plasma membrane could rationalise this observation.  
A preliminary investigation of the effect of fibrils on fluid phase endocytosis using dextrans 
indicates that fibrils do not affect the overall uptake of dextrans but may disrupt trafficking of 
endocytosed cargo to the lysosome. This would rationalise the impairment in ovalbumin 
degradation and the lack of effect of fibrils on the cleavage of the membrane permeant Magic 
Red™ cathepsin B substrate. It could also explain the increased levels of LC3-II in fibril treated 
cells as a perturbation in delivery of cargo (such as autophagosomes) to lysosomes, would 
result in defective autophagosome clearance. 
Amyloid-mediated trafficking defects have been proposed to occur via abnormal interactions 
with regulatory proteins which mediate trafficking such as α-synuclein interactions with Rab1, 
Rab3a, Rab5 and Rab8 [409-411]. Reported trafficking defects also include amyloid-mediated 
inhibition of clathrin-mediated endocytosis by Aβ, huntingtin, ataxain-1 and superoxide 
dismutase-1 amyloid aggregates [323, 413, 414]. It is possible that fragmented fibrils 
participate in abnormal interactions with other proteins inside trafficking 
vesicles/endosomes/lysosomes and by doing so, alter the trafficking of LAMP-1 and CD63. 
Identification of such interacting proteins would be informative on the mechanism of 
trafficking disruption. 
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As inhibition of clathrin-mediated endocytosis has been linked to amyloid disease, it would be 
interesting to see whether fragmented fibrils disrupt clathrin-mediated endocytosis [323, 414]. 
This could be achieved by measuring the uptake of fluorescently labelled transferrin, which has 
been shown to occur via binding to the transferrin receptor followed by clathrin-mediated 
endocytosis of the transferrin-transferrin receptor complex [414, 461]. Future work could also 
involve the investigation of trafficking of other lysosomal proteins such as lysosomal 
hydrolases to the lysosome. If fragmented fibrils do indeed block the delivery of cargo to 
lysosomes, it would be informative to identify the precise step at which this block occurs. This 
could be inferred from the experiments with labelled ovalbumin and organelle markers 
suggested above. Alternatively, dextrans could be incorporated into these experiments. Due to 
their resistance to hydrolysis, dextrans would have the added bonus of being able to 
distinguish effects on trafficking from effects on lysosome-mediated degradation. 
7.3 Future therapeutic strategies for amyloid disease 
A large body of evidence indicates that elevation of Hsp70 levels is protective in several 
models of neurodegeneration [217, 427, 431-434, 437, 438].  The role of Hsp70 in fibril 
mediated cell-disruption was therefore investigated. Consistent with previous reports, 
recombinant Hsp70 was internalised by cells and trafficked to intracellular compartments 
which co-stained with LysoTracker Green [441]. Hsp70 protected cell from fibril-mediated 
inhibition of MTT reduction and impairment in degradation of endocytosed protein, but did 
not confer protection against membrane trafficking defects. Protection may be mediated by 
stabilising fibrils and preventing release of potentially deleterious soluble species, or by 
masking the fibril surface and preventing abnormal interactions with cellular proteins. 
Alternatively, Hsp70 has been shown to bind membrane lipids, and may bind to lipids found on 
the inner membranes of endosomes, late endosomes or lysosomes [441]. By doing so, Hsp70 
may prevent fibril-mediated disruption in cargo delivery to the lysosome. Hsp70 could also 
recue the degradation of endocytosed protein by enhancing the activity of lysosomal enzymes. 
Investigation into the interaction partners of Hsp70 in lysosomes isolated from cells pre-
incubated with Hsp70 in the presence and absence of fibrils may shed further light on the 
protection mechanism. The pharmacological and genetic enhancement of molecular 
chaperones including Hsp70 is being explored as a therapeutic strategy against protein 
conformational diseases, lysosomal storage diseases (LSDs) and amyloidosis [197, 214, 215, 
430, 451]. In addition, the targeted delivery of recombinant Hsp70 is currently in preclinical 
development for multiple LSDs [462]. This therapeutic strategy could also apply to amyloid 
diseases. Further characterisation of the mechanism of protection by Hsp70 demonstrated 
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here would therefore be beneficial, not only in understanding the mechanism by which fibrils 
mediate cell-disruption but may also inform future therapeutic strategies. 
In combination with previous studies, the work described in this thesis implicates the lysosome 
as a key target in the pathogenesis of amyloid disease, and can be used to inform therapeutic 
strategies. For example, enhancement of lysosomal function would clear amyloid, counteract 
the deleterious effects of fibrils and could restore cellular health.  The recent discovery of a 
gene network which globally controls and co-ordinates lysosomal biogenesis, autophagy, 
exocytosis and endocytosis has shed light on how lysosomes adapt to environmental cues 
[304]. This lysosomal gene network is referred to as the co-ordinated lysosomal expression and 
regulation (CLEAR) network and it is controlled by a master regulator, transcription factor EB 
(TFEB) [304]. TFEB has been shown to positively regulate genes in the CLEAR network, control 
the number of lysosomes and enhance the clearance of lysosomal substrates [278]. 
Interestingly, TFEB activation has been investigated as a therapeutic strategy for lysosomal 
storage diseases as well as neurodegenerative diseases. For example, TFEB gene delivery 
restored lysosomal levels in a mouse model of Parkinson’s disease and diminished 
dopaminergic neurodegeneration [261]. TFEB was also shown to enhance degradation and 
decrease neurotoxicity in a mouse model of Huntington’s disease [463]. It is predicted that 
overexpression of TFEB would in turn enhance the expression of lysosomal genes resulting in 
enhanced lysosomal degradation. It would be interesting to see whether overexpression of 
TFEB would be protective in the context of impaired degradation of endocytosed proteins in 
fibril-treated cells. Future work could incorporate cells transfected with TFEB in assays 
analysing the effect of fragmented fibrils on ovalbumin degradation.  
7.4 Summary 
In summary, this thesis demonstrates that fragmented β2m fibrils target the lysosome and 
disrupt lysosomal function. Fragmented β2m fibrils also perturb the trafficking of lysosomal 
membrane proteins. Preliminary work suggests that fragmented β2m fibrils disrupt delivery of 
endocytosed cargo to lysosomes and may therefore impact on autophagy. Lysosomal 
dysfunction and disruptions in trafficking have significant consequences on cellular function. 
Molecular mechanisms by which nanoscale amyloid fibrils may target the lysosome and 
endolysosomal pathway thus impacting on disease pathogenesis are depicted in Figure 7.1.   
  
181 
 
 
Figure 7.1: Model of cellular disruption by fragmented β2m amyloid fibrils. β2m fibrils have been 
shown be internalised and trafficked to the lysosome [247, 248](Andrew Hellewell, personal 
communications). β2m fibrils may disrupt cellular function by the following mechanisms. 1) Fragmented 
fibrils may inhibit the transport of lysosomal membrane proteins such as LAMP-1 and CD63 from the 
TGN to late endosomes. 2) The trafficking of lysosomal membrane proteins such as LAMP-1 and CD63 to 
the plasma membrane may be enhanced by fragmented fibrils. 3) Endocytosis of lysosomal membrane 
proteins at the cell surface may be inhibited by fragmented fibrils. 4) The delivery of contents of early 
endosomes such as ovalbumin, dextrans and fragmented fibrils may be blocked by fragmented fibrils. 5) 
Lysosome mediated degradation may be impaired by saturation of the proteolytic machinery by 
fragmented fibrils.  Protection by Hsp70 from fibril-mediated cell disruption could be mediated by the 
following mechanisms. 6) Hsp70 may stabilise fibrils thus preventing disaggregation or mask fibril 
surfaces and prevent abnormal interactions with cellular proteins. 7) Hsp70 may enhance lysosomal 
proteases and thus overcome fibril-mediated inhibition of degradation of endocytosed proteins. 8) 
Hsp70 may interact with lipids in the inner membranes of endosomes, late endosomes and lysosomes 
and thus rescue cells from fibril-mediated disruption of endocytosed cargo to lysosomes.    
182 
 
8 References 
1 Chiti, F. and Dobson, C.M. (2006) Protein misfolding, functional amyloid, and human 
disease. Annu Rev Biochem 75, 333-366 
2 Hebert, L.E., Weuve, J., Scherr, P.A., and Evans, D.A. (2013) Alzheimer disease in the 
United States (2010-2050) estimated using the 2010 census. Neurology 80, 1778-1783 
3 Stefani, M. and Dobson, C.M. (2003) Protein aggregation and aggregate toxicity: new 
insights into protein folding, misfolding diseases and biological evolution. J Mol Med 
(Berl) 81, 678-699 
4 Sipe, J.D., Benson, M.D., Buxbaum, J.N., Ikeda, S., Merlini, G., Saraiva, M.J., and 
Westermark, P. (2012) Amyloid fibril protein nomenclature: 2012 recommendations 
from the Nomenclature Committee of the International Society of Amyloidosis. Amyloid 
19, 167-170 
5 Hardy, J. (2006) A hundred years of Alzheimer's disease research. Neuron 52, 3-13 
6 Anand, R., Gill, K.D., and Mahdi, A.A. (2014) Therapeutics of Alzheimer's disease: Past, 
present and future. Neuropharmacology 76 Pt A, 27-50 
7 Passmore, M.J., Ho, A., and Gallagher, R. (2012) Behavioral and psychological symptoms 
in moderate to severe Alzheimer's disease: a palliative care approach emphasizing 
recognition of personhood and preservation of dignity. J Alzheimers Dis 29, 1-13 
8 Ghidoni, R., Paterlini, A., and Benussi, L. (2013) Translational proteomics in Alzheimer's 
disease and related disorders. Clin Biochem 46, 480-486 
9 Blessed, G., Tomlinson, B.E., and Roth, M. (1968) The association between quantitative 
measures of dementia and of senile change in the cerebral grey matter of elderly 
subjects. Br J Psychiatry 114, 797-811 
10 Glenner, G.G. and Wong, C.W. (1984) Alzheimer's disease: initial report of the 
purification and characterization of a novel cerebrovascular amyloid protein. Biochem 
Biophys Res Commun 120, 885-890 
11 Lee, V.M., Balin, B.J., Otvos, L., Jr., and Trojanowski, J.Q. (1991) A68: a major subunit of 
paired helical filaments and derivatized forms of normal Tau. Science 251, 675-678 
12 Hardy, J.A. and Higgins, G.A. (1992) Alzheimer's disease: the amyloid cascade hypothesis. 
Science 256, 184-185 
13 Coulson, E.J., Paliga, K., Beyreuther, K., and Masters, C.L. (2000) What the evolution of 
the amyloid protein precursor supergene family tells us about its function. Neurochem 
Int 36, 175-184 
183 
 
14 Nalivaeva, N.N. and Turner, A.J. (2013) The amyloid precursor protein: a biochemical 
enigma in brain development, function and disease. FEBS Lett 587, 2046-2054 
15 Young-Pearse, T.L., Bai, J., Chang, R., Zheng, J.B., LoTurco, J.J., and Selkoe, D.J. (2007) A 
critical function for beta-amyloid precursor protein in neuronal migration revealed by in 
utero RNA interference. J Neurosci 27, 14459-14469 
16 Ross, C.A. and Poirier, M.A. (2004) Protein aggregation and neurodegenerative disease. 
Nat Med 10 Suppl, S10-17 
17 Esler, W.P. and Wolfe, M.S. (2001) A portrait of Alzheimer secretases--new features and 
familiar faces. Science 293, 1449-1454 
18 Kayed, R., Head, E., Thompson, J.L., McIntire, T.M., Milton, S.C., Cotman, C.W., and 
Glabe, C.G. (2003) Common structure of soluble amyloid oligomers implies common 
mechanism of pathogenesis. Science 300, 486-489 
19 Welander, H., Franberg, J., Graff, C., Sundstrom, E., Winblad, B., and Tjernberg, L.O. 
(2009) Abeta43 is more frequent than Abeta40 in amyloid plaque cores from Alzheimer 
disease brains. J Neurochem 110, 697-706 
20 Medeiros, R., Baglietto-Vargas, D., and LaFerla, F.M. (2011) The role of tau in Alzheimer's 
disease and related disorders. CNS Neurosci Ther 17, 514-524 
21 Dixit, R., Ross, J.L., Goldman, Y.E., and Holzbaur, E.L. (2008) Differential regulation of 
dynein and kinesin motor proteins by tau. Science 319, 1086-1089 
22 Li, H.L., Wang, H.H., Liu, S.J., Deng, Y.Q., Zhang, Y.J., Tian, Q., Wang, X.C., Chen, X.Q., 
Yang, Y., Zhang, J.Y., Wang, Q., Xu, H., Liao, F.F., and Wang, J.Z. (2007) Phosphorylation 
of tau antagonizes apoptosis by stabilizing beta-catenin, a mechanism involved in 
Alzheimer's neurodegeneration. Proc Natl Acad Sci U S A 104, 3591-3596 
23 Van Den Eeden, S.K., Tanner, C.M., Bernstein, A.L., Fross, R.D., Leimpeter, A., Bloch, D.A., 
and Nelson, L.M. (2003) Incidence of Parkinson's disease: variation by age, gender, and 
race/ethnicity. Am J Epidemiol 157, 1015-1022 
24 de Lau, L.M. and Breteler, M.M. (2006) Epidemiology of Parkinson's disease. Lancet 
Neurol 5, 525-535 
25 Shulman, J.M., De Jager, P.L., and Feany, M.B. (2011) Parkinson's disease: genetics and 
pathogenesis. Annu Rev Pathol 6, 193-222 
26 Fahn, S. (2003) Description of Parkinson's disease as a clinical syndrome. Ann N Y Acad 
Sci 991, 1-14 
27 Waxman, E.A. and Giasson, B.I. (2009) Molecular mechanisms of alpha-synuclein 
neurodegeneration. Biochim Biophys Acta 1792, 616-624 
184 
 
28 Vargas, K.J., Makani, S., Davis, T., Westphal, C.H., Castillo, P.E., and Chandra, S.S. (2014) 
Synucleins regulate the kinetics of synaptic vesicle endocytosis. J Neurosci 34, 9364-9376 
29 Rodriguez-Oroz, M.C., Jahanshahi, M., Krack, P., Litvan, I., Macias, R., Bezard, E., and 
Obeso, J.A. (2009) Initial clinical manifestations of Parkinson's disease: features and 
pathophysiological mechanisms. Lancet Neurol 8, 1128-1139 
30 Dickson, D.W., Braak, H., Duda, J.E., Duyckaerts, C., Gasser, T., Halliday, G.M., Hardy, J., 
Leverenz, J.B., Del Tredici, K., Wszolek, Z.K., and Litvan, I. (2009) Neuropathological 
assessment of Parkinson's disease: refining the diagnostic criteria. Lancet Neurol 8, 
1150-1157 
31 Hawkes, C.H. (2008) The prodromal phase of sporadic Parkinson's disease: does it exist 
and if so how long is it? Mov Disord 23, 1799-1807 
32 Brichta, L., Greengard, P., and Flajolet, M. (2013) Advances in the pharmacological 
treatment of Parkinson's disease: targeting neurotransmitter systems. Trends Neurosci 
36, 543-554 
33 Soto, C. (2003) Unfolding the role of protein misfolding in neurodegenerative diseases. 
Nat Rev Neurosci 4, 49-60 
34 Pillay, K. and Govender, P. (2013) Amylin uncovered: a review on the polypeptide 
responsible for type II diabetes. Biomed Res Int 2013, 826706 
35 UKPDS (1998) Intensive blood-glucose control with sulphonylureas or insulin compared 
with conventional treatment and risk of complications in patients with type 2 diabetes 
(UKPDS 33). UK Prospective Diabetes Study (UKPDS) Group. Lancet 352, 837-853 
36 Westermark, P., Wernstedt, C., Wilander, E., Hayden, D.W., O'Brien, T.D., and Johnson, 
K.H. (1987) Amyloid fibrils in human insulinoma and islets of Langerhans of the diabetic 
cat are derived from a neuropeptide-like protein also present in normal islet cells. Proc 
Natl Acad Sci U S A 84, 3881-3885 
37 Cooper, G.J., Willis, A.C., Clark, A., Turner, R.C., Sim, R.B., and Reid, K.B. (1987) 
Purification and characterization of a peptide from amyloid-rich pancreases of type 2 
diabetic patients. Proc Natl Acad Sci U S A 84, 8628-8632 
38 Rotondo, F., Vidal, S., Bell, D., Horvath, E., Kovacs, K., Scheithauer, B.W., and Lloyd, R.V. 
(2003) Immunohistochemical localization of amylin in human pancreas, thyroid, pituitary 
and their tumors. Acta Histochem 105, 303-307 
39 Martin, C. (2006) The physiology of amylin and insulin: maintaining the balance between 
glucose secretion and glucose uptake. Diabetes Educ 32 Suppl 3, 101S-104S 
40 Cluck, M.W., Chan, C.Y., and Adrian, T.E. (2005) The regulation of amylin and insulin 
gene expression and secretion. Pancreas 30, 1-14 
185 
 
41 Hoppener, J.W. and Lips, C.J. (2006) Role of islet amyloid in type 2 diabetes mellitus. Int J 
Biochem Cell Biol 38, 726-736 
42 Hoppener, J.W., Verbeek, J.S., de Koning, E.J., Oosterwijk, C., van Hulst, K.L., Visser-
Vernooy, H.J., Hofhuis, F.M., van Gaalen, S., Berends, M.J., Hackeng, W.H., and et al. 
(1993) Chronic overproduction of islet amyloid polypeptide/amylin in transgenic mice: 
lysosomal localization of human islet amyloid polypeptide and lack of marked 
hyperglycaemia or hyperinsulinaemia. Diabetologia 36, 1258-1265 
43 Rochester, C.D. and Akiyode, O. (2014) Novel and emerging diabetes mellitus drug 
therapies for the type 2 diabetes patient. World J Diabetes 5, 305-315 
44 Lopes, D.H., Colin, C., Degaki, T.L., de Sousa, A.C., Vieira, M.N., Sebollela, A., Martinez, 
A.M., Bloch, C., Jr., Ferreira, S.T., and Sogayar, M.C. (2004) Amyloidogenicity and 
cytotoxicity of recombinant mature human islet amyloid polypeptide (rhIAPP). J Biol 
Chem 279, 42803-42810 
45 Gejyo, F., Odani, S., Yamada, T., Honma, N., Saito, H., Suzuki, Y., Nakagawa, Y., 
Kobayashi, H., Maruyama, Y., Hirasawa, Y., and et al. (1986) Beta 2-microglobulin: a new 
form of amyloid protein associated with chronic hemodialysis. Kidney Int 30, 385-390 
46 Pamer, E. and Cresswell, P. (1998) Mechanisms of MHC class I--restricted antigen 
processing. Annu Rev Immunol 16, 323-358 
47 Rock, K.L. and Goldberg, A.L. (1999) Degradation of cell proteins and the generation of 
MHC class I-presented peptides. Annu Rev Immunol 17, 739-779 
48 Floege, J., Bartsch, A., Schulze, M., Shaldon, S., Koch, K.M., and Smeby, L.C. (1991) 
Clearance and synthesis rates of beta 2-microglobulin in patients undergoing 
hemodialysis and in normal subjects. J Lab Clin Med 118, 153-165 
49 Floege, J. and Ketteler, M. (2001) beta2-microglobulin-derived amyloidosis: an update. 
Kidney Int Suppl 78, S164-171 
50 Gejyo, F., Homma, N., Suzuki, Y., and Arakawa, M. (1986) Serum levels of beta 2-
microglobulin as a new form of amyloid protein in patients undergoing long-term 
hemodialysis. N Engl J Med 314, 585-586 
51 Rabindranath, K.S., Strippoli, G.F., Daly, C., Roderick, P.J., Wallace, S., and MacLeod, A.M. 
(2006) Haemodiafiltration, haemofiltration and haemodialysis for end-stage kidney 
disease. Cochrane Database Syst Rev, CD006258 
52 Otsubo, S., Kimata, N., Okutsu, I., Oshikawa, K., Ueda, S., Sugimoto, H., Mitobe, M., 
Uchida, K., Otsubo, K., Nitta, K., and Akiba, T. (2009) Characteristics of dialysis-related 
amyloidosis in patients on haemodialysis therapy for more than 30 years. Nephrol Dial 
Transplant 24, 1593-1598 
186 
 
53 Linke, R.P., Schaeffer, J., Gielow, P., Lindner, P., Lottspeich, F., Pluckthun, A., and Weiss, 
E.H. (2000) Production of recombinant human beta2-microglobulin for scintigraphic 
diagnosis of amyloidosis in uremia and hemodialysis. Eur J Biochem 267, 627-633 
54 Hodkinson, J.P., Ashcroft, A.E., and Radford, S.E. (2012) Protein misfolding and toxicity in 
dialysis-related amyloidosis. In Non-fibrillar amyloidogenic protein assemblies : common 
cytotoxins underlying degenerative diseases (Rahimi, F. and Bitan, G., eds), pp. 377-405, 
Springer 
55 Saito, A. and Gejyo, F. (2006) Current clinical aspects of dialysis-related amyloidosis in 
chronic dialysis patients. Ther Apher Dial 10, 316-320 
56 Campistol, J.M. (2001) Dialysis-related amyloidosis after renal transplantation. Semin 
Dial 14, 99-102 
57 Yamamoto, S., Kazama, J.J., Narita, I., Naiki, H., and Gejyo, F. (2009) Recent progress in 
understanding dialysis-related amyloidosis. Bone 45 Suppl 1, S39-42 
58 Maury, C.P. (2009) The emerging concept of functional amyloid. J Intern Med 265, 329-
334 
59 Chernoff, Y.O. (2004) Amyloidogenic domains, prions and structural inheritance: 
rudiments of early life or recent acquisition? Curr Opin Chem Biol 8, 665-671 
60 Fowler, D.M., Koulov, A.V., Balch, W.E., and Kelly, J.W. (2007) Functional amyloid--from 
bacteria to humans. Trends Biochem Sci 32, 217-224 
61 Smith, J.F., Knowles, T.P., Dobson, C.M., Macphee, C.E., and Welland, M.E. (2006) 
Characterization of the nanoscale properties of individual amyloid fibrils. Proc Natl Acad 
Sci U S A 103, 15806-15811 
62 Chapman, M.R., Robinson, L.S., Pinkner, J.S., Roth, R., Heuser, J., Hammar, M., Normark, 
S., and Hultgren, S.J. (2002) Role of Escherichia coli curli operons in directing amyloid 
fiber formation. Science 295, 851-855 
63 Barnhart, M.M. and Chapman, M.R. (2006) Curli biogenesis and function. Annu Rev 
Microbiol 60, 131-147 
64 Hammar, M., Arnqvist, A., Bian, Z., Olsen, A., and Normark, S. (1995) Expression of two 
csg operons is required for production of fibronectin- and congo red-binding curli 
polymers in Escherichia coli K-12. Mol Microbiol 18, 661-670 
65 Evans, M.L. and Chapman, M.R. (2014) Curli biogenesis: order out of disorder. Biochim 
Biophys Acta 1843, 1551-1558 
66 Nenninger, A.A., Robinson, L.S., Hammer, N.D., Epstein, E.A., Badtke, M.P., Hultgren, S.J., 
and Chapman, M.R. (2011) CsgE is a curli secretion specificity factor that prevents 
amyloid fibre aggregation. Mol Microbiol 81, 486-499 
187 
 
67 Nenninger, A.A., Robinson, L.S., and Hultgren, S.J. (2009) Localized and efficient curli 
nucleation requires the chaperone-like amyloid assembly protein CsgF. Proc Natl Acad 
Sci U S A 106, 900-905 
68 Robinson, L.S., Ashman, E.M., Hultgren, S.J., and Chapman, M.R. (2006) Secretion of curli 
fibre subunits is mediated by the outer membrane-localized CsgG protein. Mol Microbiol 
59, 870-881 
69 Prusiner, S.B. (1982) Novel proteinaceous infectious particles cause scrapie. Science 216, 
136-144 
70 Prusiner, S.B. (1998) Prions. Proc Natl Acad Sci U S A 95, 13363-13383 
71 Hofmann, J. and Vorberg, I. (2013) Life cycle of cytosolic prions. Prion 7, 369-377 
72 Uptain, S.M. and Lindquist, S. (2002) Prions as protein-based genetic elements. Annu Rev 
Microbiol 56, 703-741 
73 True, H.L., Berlin, I., and Lindquist, S.L. (2004) Epigenetic regulation of translation reveals 
hidden genetic variation to produce complex traits. Nature 431, 184-187 
74 Shorter, J. and Lindquist, S. (2005) Prions as adaptive conduits of memory and 
inheritance. Nat Rev Genet 6, 435-450 
75 Lian, H.Y., Jiang, Y., Zhang, H., Jones, G.W., and Perrett, S. (2006) The yeast prion protein 
Ure2: structure, function and folding. Biochim Biophys Acta 1764, 535-545 
76 Wickner, R.B., Edskes, H.K., Roberts, B.T., Baxa, U., Pierce, M.M., Ross, E.D., and 
Brachmann, A. (2004) Prions: proteins as genes and infectious entities. Genes Dev 18, 
470-485 
77 Jensen, M.A., True, H.L., Chernoff, Y.O., and Lindquist, S. (2001) Molecular population 
genetics and evolution of a prion-like protein in Saccharomyces cerevisiae. Genetics 159, 
527-535 
78 Chien, P., Weissman, J.S., and DePace, A.H. (2004) Emerging principles of conformation-
based prion inheritance. Annu Rev Biochem 73, 617-656 
79 Knowles, T.P., Vendruscolo, M., and Dobson, C.M. (2014) The amyloid state and its 
association with protein misfolding diseases. Nat Rev Mol Cell Biol 15, 384-396 
80 Hearing, V.J. (2000) The melanosome: the perfect model for cellular responses to the 
environment. Pigment Cell Res 13 Suppl 8, 23-34 
81 Fowler, D.M., Koulov, A.V., Alory-Jost, C., Marks, M.S., Balch, W.E., and Kelly, J.W. (2006) 
Functional amyloid formation within mammalian tissue. PLoS Biol 4, e6 
82 Berson, J.F., Theos, A.C., Harper, D.C., Tenza, D., Raposo, G., and Marks, M.S. (2003) 
Proprotein convertase cleavage liberates a fibrillogenic fragment of a resident 
glycoprotein to initiate melanosome biogenesis. J Cell Biol 161, 521-533 
188 
 
83 Maji, S.K., Perrin, M.H., Sawaya, M.R., Jessberger, S., Vadodaria, K., Rissman, R.A., 
Singru, P.S., Nilsson, K.P., Simon, R., Schubert, D., Eisenberg, D., Rivier, J., Sawchenko, P., 
Vale, W., and Riek, R. (2009) Functional amyloids as natural storage of peptide 
hormones in pituitary secretory granules. Science 325, 328-332 
84 Sipe, J.D. and Cohen, A.S. (2000) Review: history of the amyloid fibril. J Struct Biol 130, 
88-98 
85 Shewmaker, F., McGlinchey, R.P., and Wickner, R.B. (2011) Structural insights into 
functional and pathological amyloid. J Biol Chem 286, 16533-16540 
86 Nilsson, M.R. (2004) Techniques to study amyloid fibril formation in vitro. Methods 34, 
151-160 
87 Westermark, G.T., Johnson, K.H., and Westermark, P. (1999) Staining methods for 
identification of amyloid in tissue. Methods Enzymol 309, 3-25 
88 Sunde, M., Serpell, L.C., Bartlam, M., Fraser, P.E., Pepys, M.B., and Blake, C.C. (1997) 
Common core structure of amyloid fibrils by synchrotron X-ray diffraction. J Mol Biol 
273, 729-739 
89 Dobson, C.M. (2003) Protein folding and misfolding. Nature 426, 884-890 
90 Eisenberg, D. and Jucker, M. (2012) The amyloid state of proteins in human diseases. Cell 
148, 1188-1203 
91 Serpell, L.C., Sunde, M., Benson, M.D., Tennent, G.A., Pepys, M.B., and Fraser, P.E. 
(2000) The protofilament substructure of amyloid fibrils. J Mol Biol 300, 1033-1039 
92 Sunde, M. and Blake, C. (1997) The structure of amyloid fibrils by electron microscopy 
and X-ray diffraction. Adv Protein Chem 50, 123-159 
93 Bauer, H.H., Aebi, U., Haner, M., Hermann, R., Muller, M., and Merkle, H.P. (1995) 
Architecture and polymorphism of fibrillar supramolecular assemblies produced by in 
vitro aggregation of human calcitonin. J Struct Biol 115, 1-15 
94 Saiki, M., Honda, S., Kawasaki, K., Zhou, D., Kaito, A., Konakahara, T., and Morii, H. 
(2005) Higher-order molecular packing in amyloid-like fibrils constructed with linear 
arrangements of hydrophobic and hydrogen-bonding side-chains. J Mol Biol 348, 983-
998 
95 Sawaya, M.R., Sambashivan, S., Nelson, R., Ivanova, M.I., Sievers, S.A., Apostol, M.I., 
Thompson, M.J., Balbirnie, M., Wiltzius, J.J., McFarlane, H.T., Madsen, A.O., Riekel, C., 
and Eisenberg, D. (2007) Atomic structures of amyloid cross-beta spines reveal varied 
steric zippers. Nature 447, 453-457 
96 Pedersen, J.S., Andersen, C.B., and Otzen, D.E. (2010) Amyloid structure--one but not the 
same: the many levels of fibrillar polymorphism. FEBS J 277, 4591-4601 
189 
 
97 Eanes, E.D. and Glenner, G.G. (1968) X-ray diffraction studies on amyloid filaments. J 
Histochem Cytochem 16, 673-677 
98 Serpell, L. (2014) Amyloid structure. Essays Biochem 56, 1-10 
99 Makin, O.S. and Serpell, L.C. (2005) Structures for amyloid fibrils. FEBS J 272, 5950-5961 
100 Fitzpatrick, A.W., Debelouchina, G.T., Bayro, M.J., Clare, D.K., Caporini, M.A., Bajaj, V.S., 
Jaroniec, C.P., Wang, L., Ladizhansky, V., Muller, S.A., MacPhee, C.E., Waudby, C.A., 
Mott, H.R., De Simone, A., Knowles, T.P., Saibil, H.R., Vendruscolo, M., Orlova, E.V., 
Griffin, R.G., and Dobson, C.M. (2013) Atomic structure and hierarchical assembly of a 
cross-beta amyloid fibril. Proc Natl Acad Sci U S A 110, 5468-5473 
101 Marshall, K.E., Marchante, R., Xue, W.F., and Serpell, L.C. (2014) The relationship 
between amyloid structure and cytotoxicity. Prion 8, 5-9 
102 Petkova, A.T., Ishii, Y., Balbach, J.J., Antzutkin, O.N., Leapman, R.D., Delaglio, F., and 
Tycko, R. (2002) A structural model for Alzheimer's beta -amyloid fibrils based on 
experimental constraints from solid state NMR. Proc Natl Acad Sci U S A 99, 16742-
16747 
103 Luhrs, T., Ritter, C., Adrian, M., Riek-Loher, D., Bohrmann, B., Dobeli, H., Schubert, D., 
and Riek, R. (2005) 3D structure of Alzheimer's amyloid-beta(1-42) fibrils. Proc Natl Acad 
Sci U S A 102, 17342-17347 
104 Lu, J.X., Qiang, W., Yau, W.M., Schwieters, C.D., Meredith, S.C., and Tycko, R. (2013) 
Molecular structure of beta-amyloid fibrils in Alzheimer's disease brain tissue. Cell 154, 
1257-1268 
105 Van Melckebeke, H., Wasmer, C., Lange, A., Ab, E., Loquet, A., Bockmann, A., and Meier, 
B.H. (2010) Atomic-resolution three-dimensional structure of HET-s(218-289) amyloid 
fibrils by solid-state NMR spectroscopy. J Am Chem Soc 132, 13765-13775 
106 Makin, O.S., Atkins, E., Sikorski, P., Johansson, J., and Serpell, L.C. (2005) Molecular basis 
for amyloid fibril formation and stability. Proc Natl Acad Sci U S A 102, 315-320 
107 Morris, K.L., Rodger, A., Hicks, M.R., Debulpaep, M., Schymkowitz, J., Rousseau, F., and 
Serpell, L.C. (2013) Exploring the sequence-structure relationship for amyloid peptides. 
Biochem J 450, 275-283 
108 Luheshi, L.M. and Dobson, C.M. (2009) Bridging the gap: from protein misfolding to 
protein misfolding diseases. FEBS Lett 583, 2581-2586 
109 Xue, W.F., Homans, S.W., and Radford, S.E. (2008) Systematic analysis of nucleation-
dependent polymerization reveals new insights into the mechanism of amyloid self-
assembly. Proc Natl Acad Sci U S A 105, 8926-8931 
190 
 
110 Kashchiev, D., Cabriolu, R., and Auer, S. (2013) Confounding the paradigm: peculiarities 
of amyloid fibril nucleation. J Am Chem Soc 135, 1531-1539 
111 Nesterov, E.E., Skoch, J., Hyman, B.T., Klunk, W.E., Bacskai, B.J., and Swager, T.M. (2005) 
In vivo optical imaging of amyloid aggregates in brain: design of fluorescent markers. 
Angew Chem Int Ed Engl 44, 5452-5456 
112 Kaminski Schierle, G.S., van de Linde, S., Erdelyi, M., Esbjorner, E.K., Klein, T., Rees, E., 
Bertoncini, C.W., Dobson, C.M., Sauer, M., and Kaminski, C.F. (2011) In situ 
measurements of the formation and morphology of intracellular beta-amyloid fibrils by 
super-resolution fluorescence imaging. J Am Chem Soc 133, 12902-12905 
113 McGuire, E.K., Motskin, M., Bolognesi, B., Bergin, S.D., Knowles, T.P., Skepper, J., 
Luheshi, L.M., McComb, D.W., Dobson, C.M., and Porter, A.E. (2012) Selenium-enhanced 
electron microscopic imaging of different aggregate forms of a segment of the amyloid 
beta peptide in cells. ACS Nano 6, 4740-4747 
114 Serio, T.R., Cashikar, A.G., Kowal, A.S., Sawicki, G.J., Moslehi, J.J., Serpell, L., Arnsdorf, 
M.F., and Lindquist, S.L. (2000) Nucleated conformational conversion and the replication 
of conformational information by a prion determinant. Science 289, 1317-1321 
115 Cheon, M., Chang, I., Mohanty, S., Luheshi, L.M., Dobson, C.M., Vendruscolo, M., and 
Favrin, G. (2007) Structural reorganisation and potential toxicity of oligomeric species 
formed during the assembly of amyloid fibrils. PLoS Comput Biol 3, 1727-1738 
116 Dusa, A., Kaylor, J., Edridge, S., Bodner, N., Hong, D.P., and Fink, A.L. (2006) 
Characterization of oligomers during alpha-synuclein aggregation using intrinsic 
tryptophan fluorescence. Biochemistry 45, 2752-2760 
117 Stefani, M. (2010) Biochemical and biophysical features of both oligomer/fibril and cell 
membrane in amyloid cytotoxicity. FEBS J 277, 4602-4613 
118 Woods, L.A., Radford, S.E., and Ashcroft, A.E. (2013) Advances in ion mobility 
spectrometry-mass spectrometry reveal key insights into amyloid assembly. Biochim 
Biophys Acta 1834, 1257-1268 
119 Carulla, N., Zhou, M., Arimon, M., Gairi, M., Giralt, E., Robinson, C.V., and Dobson, C.M. 
(2009) Experimental characterization of disordered and ordered aggregates populated 
during the process of amyloid fibril formation. Proc Natl Acad Sci U S A 106, 7828-7833 
120 Caughey, B. and Lansbury, P.T. (2003) Protofibrils, pores, fibrils, and neurodegeneration: 
separating the responsible protein aggregates from the innocent bystanders. Annu Rev 
Neurosci 26, 267-298 
191 
 
121 Lashuel, H.A., Hartley, D.M., Petre, B.M., Wall, J.S., Simon, M.N., Walz, T., and Lansbury, 
P.T., Jr. (2003) Mixtures of wild-type and a pathogenic (E22G) form of Abeta40 in vitro 
accumulate protofibrils, including amyloid pores. J Mol Biol 332, 795-808 
122 Mastrangelo, I.A., Ahmed, M., Sato, T., Liu, W., Wang, C., Hough, P., and Smith, S.O. 
(2006) High-resolution atomic force microscopy of soluble Abeta42 oligomers. J Mol Biol 
358, 106-119 
123 Ferrone, F. (1999) Analysis of protein aggregation kinetics. Methods Enzymol 309, 256-
274 
124 Jarrett, J.T. and Lansbury, P.T., Jr. (1992) Amyloid fibril formation requires a chemically 
discriminating nucleation event: studies of an amyloidogenic sequence from the 
bacterial protein OsmB. Biochemistry 31, 12345-12352 
125 Jahn, T.R. and Radford, S.E. (2008) Folding versus aggregation: polypeptide 
conformations on competing pathways. Arch Biochem Biophys 469, 100-117 
126 Kayed, R., Head, E., Sarsoza, F., Saing, T., Cotman, C.W., Necula, M., Margol, L., Wu, J., 
Breydo, L., Thompson, J.L., Rasool, S., Gurlo, T., Butler, P., and Glabe, C.G. (2007) Fibril 
specific, conformation dependent antibodies recognize a generic epitope common to 
amyloid fibrils and fibrillar oligomers that is absent in prefibrillar oligomers. Mol 
Neurodegener 2, 18 
127 Glabe, C.G. (2008) Structural classification of toxic amyloid oligomers. J Biol Chem 283, 
29639-29643 
128 Hardy, J. and Selkoe, D.J. (2002) The amyloid hypothesis of Alzheimer's disease: progress 
and problems on the road to therapeutics. Science 297, 353-356 
129 Lansbury, P.T. and Lashuel, H.A. (2006) A century-old debate on protein aggregation and 
neurodegeneration enters the clinic. Nature 443, 774-779 
130 Pike, C.J., Walencewicz, A.J., Glabe, C.G., and Cotman, C.W. (1991) In vitro aging of beta-
amyloid protein causes peptide aggregation and neurotoxicity. Brain Res 563, 311-314 
131 Geula, C., Wu, C.K., Saroff, D., Lorenzo, A., Yuan, M., and Yankner, B.A. (1998) Aging 
renders the brain vulnerable to amyloid beta-protein neurotoxicity. Nat Med 4, 827-831 
132 Lorenzo, A., Razzaboni, B., Weir, G.C., and Yankner, B.A. (1994) Pancreatic islet cell 
toxicity of amylin associated with type-2 diabetes mellitus. Nature 368, 756-760 
133 Lorenzo, A. and Yankner, B.A. (1994) Beta-amyloid neurotoxicity requires fibril formation 
and is inhibited by congo red. Proc Natl Acad Sci U S A 91, 12243-12247 
134 Naslund, J., Haroutunian, V., Mohs, R., Davis, K.L., Davies, P., Greengard, P., and 
Buxbaum, J.D. (2000) Correlation between elevated levels of amyloid beta-peptide in the 
brain and cognitive decline. JAMA 283, 1571-1577 
192 
 
135 Lue, L.F., Kuo, Y.M., Roher, A.E., Brachova, L., Shen, Y., Sue, L., Beach, T., Kurth, J.H., 
Rydel, R.E., and Rogers, J. (1999) Soluble amyloid beta peptide concentration as a 
predictor of synaptic change in Alzheimer's disease. Am J Pathol 155, 853-862 
136 McLean, C.A., Cherny, R.A., Fraser, F.W., Fuller, S.J., Smith, M.J., Beyreuther, K., Bush, 
A.I., and Masters, C.L. (1999) Soluble pool of Abeta amyloid as a determinant of severity 
of neurodegeneration in Alzheimer's disease. Ann Neurol 46, 860-866 
137 Wang, J., Dickson, D.W., Trojanowski, J.Q., and Lee, V.M. (1999) The levels of soluble 
versus insoluble brain Abeta distinguish Alzheimer's disease from normal and pathologic 
aging. Exp Neurol 158, 328-337 
138 Moechars, D., Dewachter, I., Lorent, K., Reverse, D., Baekelandt, V., Naidu, A., Tesseur, I., 
Spittaels, K., Haute, C.V., Checler, F., Godaux, E., Cordell, B., and Van Leuven, F. (1999) 
Early phenotypic changes in transgenic mice that overexpress different mutants of 
amyloid precursor protein in brain. J Biol Chem 274, 6483-6492 
139 Dickson, D.W., Crystal, H.A., Mattiace, L.A., Masur, D.M., Blau, A.D., Davies, P., Yen, S.H., 
and Aronson, M.K. (1992) Identification of normal and pathological aging in 
prospectively studied nondemented elderly humans. Neurobiol Aging 13, 179-189 
140 Haass, C. and Selkoe, D.J. (2007) Soluble protein oligomers in neurodegeneration: 
lessons from the Alzheimer's amyloid beta-peptide. Nat Rev Mol Cell Biol 8, 101-112 
141 Campioni, S., Mannini, B., Zampagni, M., Pensalfini, A., Parrini, C., Evangelisti, E., Relini, 
A., Stefani, M., Dobson, C.M., Cecchi, C., and Chiti, F. (2010) A causative link between the 
structure of aberrant protein oligomers and their toxicity. Nat Chem Biol 6, 140-147 
142 Bucciantini, M., Giannoni, E., Chiti, F., Baroni, F., Formigli, L., Zurdo, J., Taddei, N., 
Ramponi, G., Dobson, C.M., and Stefani, M. (2002) Inherent toxicity of aggregates 
implies a common mechanism for protein misfolding diseases. Nature 416, 507-511 
143 Slow, E.J., Graham, R.K., Osmand, A.P., Devon, R.S., Lu, G., Deng, Y., Pearson, J., Vaid, K., 
Bissada, N., Wetzel, R., Leavitt, B.R., and Hayden, M.R. (2005) Absence of behavioral 
abnormalities and neurodegeneration in vivo despite widespread neuronal huntingtin 
inclusions. Proc Natl Acad Sci U S A 102, 11402-11407 
144 Arrasate, M., Mitra, S., Schweitzer, E.S., Segal, M.R., and Finkbeiner, S. (2004) Inclusion 
body formation reduces levels of mutant huntingtin and the risk of neuronal death. 
Nature 431, 805-810 
145 Bowman, A.B., Yoo, S.Y., Dantuma, N.P., and Zoghbi, H.Y. (2005) Neuronal dysfunction in 
a polyglutamine disease model occurs in the absence of ubiquitin-proteasome system 
impairment and inversely correlates with the degree of nuclear inclusion formation. 
Hum Mol Genet 14, 679-691 
193 
 
146 Roher, A.E. and Kuo, Y.M. (1999) Isolation of amyloid deposits from brain. Methods 
Enzymol 309, 58-67 
147 Harper, J.D., Wong, S.S., Lieber, C.M., and Lansbury, P.T. (1997) Observation of 
metastable Abeta amyloid protofibrils by atomic force microscopy. Chem Biol 4, 119-125 
148 Walsh, D.M., Lomakin, A., Benedek, G.B., Condron, M.M., and Teplow, D.B. (1997) 
Amyloid beta-protein fibrillogenesis. Detection of a protofibrillar intermediate. J Biol 
Chem 272, 22364-22372 
149 Rochet, J.C., Conway, K.A., and Lansbury, P.T., Jr. (2000) Inhibition of fibrillization and 
accumulation of prefibrillar oligomers in mixtures of human and mouse alpha-synuclein. 
Biochemistry 39, 10619-10626 
150 Poirier, M.A., Li, H., Macosko, J., Cai, S., Amzel, M., and Ross, C.A. (2002) Huntingtin 
spheroids and protofibrils as precursors in polyglutamine fibrilization. J Biol Chem 277, 
41032-41037 
151 Green, J.D., Goldsbury, C., Kistler, J., Cooper, G.J., and Aebi, U. (2004) Human amylin 
oligomer growth and fibril elongation define two distinct phases in amyloid formation. J 
Biol Chem 279, 12206-12212 
152 Woods, L.A., Platt, G.W., Hellewell, A.L., Hewitt, E.W., Homans, S.W., Ashcroft, A.E., and 
Radford, S.E. (2011) Ligand binding to distinct states diverts aggregation of an amyloid-
forming protein. Nat Chem Biol 7, 730-739 
153 Mukai, H., Isagawa, T., Goyama, E., Tanaka, S., Bence, N.F., Tamura, A., Ono, Y., and 
Kopito, R.R. (2005) Formation of morphologically similar globular aggregates from 
diverse aggregation-prone proteins in mammalian cells. Proc Natl Acad Sci U S A 102, 
10887-10892 
154 Lee, H.J. and Lee, S.J. (2002) Characterization of cytoplasmic alpha-synuclein aggregates. 
Fibril formation is tightly linked to the inclusion-forming process in cells. J Biol Chem 277, 
48976-48983 
155 Townsend, M., Shankar, G.M., Mehta, T., Walsh, D.M., and Selkoe, D.J. (2006) Effects of 
secreted oligomers of amyloid beta-protein on hippocampal synaptic plasticity: a potent 
role for trimers. J Physiol 572, 477-492 
156 Cleary, J.P., Walsh, D.M., Hofmeister, J.J., Shankar, G.M., Kuskowski, M.A., Selkoe, D.J., 
and Ashe, K.H. (2005) Natural oligomers of the amyloid-beta protein specifically disrupt 
cognitive function. Nat Neurosci 8, 79-84 
157 Walsh, D.M., Klyubin, I., Fadeeva, J.V., Cullen, W.K., Anwyl, R., Wolfe, M.S., Rowan, M.J., 
and Selkoe, D.J. (2002) Naturally secreted oligomers of amyloid beta protein potently 
inhibit hippocampal long-term potentiation in vivo. Nature 416, 535-539 
194 
 
158 Lesne, S., Koh, M.T., Kotilinek, L., Kayed, R., Glabe, C.G., Yang, A., Gallagher, M., and 
Ashe, K.H. (2006) A specific amyloid-beta protein assembly in the brain impairs memory. 
Nature 440, 352-357 
159 Pountney, D.L., Lowe, R., Quilty, M., Vickers, J.C., Voelcker, N.H., and Gai, W.P. (2004) 
Annular alpha-synuclein species from purified multiple system atrophy inclusions. J 
Neurochem 90, 502-512 
160 Klyubin, I., Betts, V., Welzel, A.T., Blennow, K., Zetterberg, H., Wallin, A., Lemere, C.A., 
Cullen, W.K., Peng, Y., Wisniewski, T., Selkoe, D.J., Anwyl, R., Walsh, D.M., and Rowan, 
M.J. (2008) Amyloid beta protein dimer-containing human CSF disrupts synaptic 
plasticity: prevention by systemic passive immunization. J Neurosci 28, 4231-4237 
161 Broersen, K., Rousseau, F., and Schymkowitz, J. (2010) The culprit behind amyloid beta 
peptide related neurotoxicity in Alzheimer's disease: oligomer size or conformation? 
Alzheimers Res Ther 2, 12 
162 Hoshi, M., Sato, M., Matsumoto, S., Noguchi, A., Yasutake, K., Yoshida, N., and Sato, K. 
(2003) Spherical aggregates of beta-amyloid (amylospheroid) show high neurotoxicity 
and activate tau protein kinase I/glycogen synthase kinase-3beta. Proc Natl Acad Sci U S 
A 100, 6370-6375 
163 White, J.A., Manelli, A.M., Holmberg, K.H., Van Eldik, L.J., and Ladu, M.J. (2005) 
Differential effects of oligomeric and fibrillar amyloid-beta 1-42 on astrocyte-mediated 
inflammation. Neurobiol Dis 18, 459-465 
164 Billings, L.M., Oddo, S., Green, K.N., McGaugh, J.L., and LaFerla, F.M. (2005) 
Intraneuronal Abeta causes the onset of early Alzheimer's disease-related cognitive 
deficits in transgenic mice. Neuron 45, 675-688 
165 Koffie, R.M., Meyer-Luehmann, M., Hashimoto, T., Adams, K.W., Mielke, M.L., Garcia-
Alloza, M., Micheva, K.D., Smith, S.J., Kim, M.L., Lee, V.M., Hyman, B.T., and Spires-Jones, 
T.L. (2009) Oligomeric amyloid beta associates with postsynaptic densities and 
correlates with excitatory synapse loss near senile plaques. Proc Natl Acad Sci U S A 106, 
4012-4017 
166 Cremades, N., Cohen, S.I., Deas, E., Abramov, A.Y., Chen, A.Y., Orte, A., Sandal, M., 
Clarke, R.W., Dunne, P., Aprile, F.A., Bertoncini, C.W., Wood, N.W., Knowles, T.P., 
Dobson, C.M., and Klenerman, D. (2012) Direct observation of the interconversion of 
normal and toxic forms of alpha-synuclein. Cell 149, 1048-1059 
167 Gosavi, N., Lee, H.J., Lee, J.S., Patel, S., and Lee, S.J. (2002) Golgi fragmentation occurs in 
the cells with prefibrillar alpha-synuclein aggregates and precedes the formation of 
fibrillar inclusion. J Biol Chem 277, 48984-48992 
195 
 
168 Winner, B., Jappelli, R., Maji, S.K., Desplats, P.A., Boyer, L., Aigner, S., Hetzer, C., Loher, 
T., Vilar, M., Campioni, S., Tzitzilonis, C., Soragni, A., Jessberger, S., Mira, H., Consiglio, A., 
Pham, E., Masliah, E., Gage, F.H., and Riek, R. (2011) In vivo demonstration that alpha-
synuclein oligomers are toxic. Proc Natl Acad Sci U S A 108, 4194-4199 
169 Lindersson, E., Beedholm, R., Hojrup, P., Moos, T., Gai, W., Hendil, K.B., and Jensen, P.H. 
(2004) Proteasomal inhibition by alpha-synuclein filaments and oligomers. J Biol Chem 
279, 12924-12934 
170 Nucifora, L.G., Burke, K.A., Feng, X., Arbez, N., Zhu, S., Miller, J., Yang, G., Ratovitski, T., 
Delannoy, M., Muchowski, P.J., Finkbeiner, S., Legleiter, J., Ross, C.A., and Poirier, M.A. 
(2012) Identification of novel potentially toxic oligomers formed in vitro from 
mammalian-derived expanded huntingtin exon-1 protein. J Biol Chem 287, 16017-16028 
171 Demuro, A., Mina, E., Kayed, R., Milton, S.C., Parker, I., and Glabe, C.G. (2005) Calcium 
dysregulation and membrane disruption as a ubiquitous neurotoxic mechanism of 
soluble amyloid oligomers. J Biol Chem 280, 17294-17300 
172 Reixach, N., Deechongkit, S., Jiang, X., Kelly, J.W., and Buxbaum, J.N. (2004) Tissue 
damage in the amyloidoses: Transthyretin monomers and nonnative oligomers are the 
major cytotoxic species in tissue culture. Proc Natl Acad Sci U S A 101, 2817-2822 
173 Gharibyan, A.L., Zamotin, V., Yanamandra, K., Moskaleva, O.S., Margulis, B.A., 
Kostanyan, I.A., and Morozova-Roche, L.A. (2007) Lysozyme amyloid oligomers and 
fibrils induce cellular death via different apoptotic/necrotic pathways. J Mol Biol 365, 
1337-1349 
174 Anderluh, G., Gutierrez-Aguirre, I., Rabzelj, S., Ceru, S., Kopitar-Jerala, N., Macek, P., 
Turk, V., and Zerovnik, E. (2005) Interaction of human stefin B in the prefibrillar 
oligomeric form with membranes. Correlation with cellular toxicity. FEBS J 272, 3042-
3051 
175 Rigacci, S., Bucciantini, M., Relini, A., Pesce, A., Gliozzi, A., Berti, A., and Stefani, M. 
(2008) The (1-63) region of the p53 transactivation domain aggregates in vitro into 
cytotoxic amyloid assemblies. Biophys J 94, 3635-3646 
176 Gilbert, B.J. (2013) The role of amyloid beta in the pathogenesis of Alzheimer's disease. J 
Clin Pathol 66, 362-366 
177 Petkova, A.T., Leapman, R.D., Guo, Z., Yau, W.M., Mattson, M.P., and Tycko, R. (2005) 
Self-propagating, molecular-level polymorphism in Alzheimer's beta-amyloid fibrils. 
Science 307, 262-265 
196 
 
178 Qiang, W., Yau, W.M., Luo, Y., Mattson, M.P., and Tycko, R. (2012) Antiparallel beta-
sheet architecture in Iowa-mutant beta-amyloid fibrils. Proc Natl Acad Sci U S A 109, 
4443-4448 
179 Picone, P., Carrotta, R., Montana, G., Nobile, M.R., San Biagio, P.L., and Di Carlo, M. 
(2009) Abeta oligomers and fibrillar aggregates induce different apoptotic pathways in 
LAN5 neuroblastoma cell cultures. Biophys J 96, 4200-4211 
180 Mossuto, M.F., Dhulesia, A., Devlin, G., Frare, E., Kumita, J.R., de Laureto, P.P., Dumoulin, 
M., Fontana, A., Dobson, C.M., and Salvatella, X. (2010) The non-core regions of human 
lysozyme amyloid fibrils influence cytotoxicity. J Mol Biol 402, 783-796 
181 Mossuto, M.F., Bolognesi, B., Guixer, B., Dhulesia, A., Agostini, F., Kumita, J.R., Tartaglia, 
G.G., Dumoulin, M., Dobson, C.M., and Salvatella, X. (2011) Disulfide bonds reduce the 
toxicity of the amyloid fibrils formed by an extracellular protein. Angew Chem Int Ed Engl 
50, 7048-7051 
182 Novitskaya, V., Bocharova, O.V., Bronstein, I., and Baskakov, I.V. (2006) Amyloid fibrils of 
mammalian prion protein are highly toxic to cultured cells and primary neurons. J Biol 
Chem 281, 13828-13836 
183 Lee, Y.J., Savtchenko, R., Ostapchenko, V.G., Makarava, N., and Baskakov, I.V. (2011) 
Molecular structure of amyloid fibrils controls the relationship between fibrillar size and 
toxicity. PLoS One 6, e20244 
184 Engel, M.F., Khemtemourian, L., Kleijer, C.C., Meeldijk, H.J., Jacobs, J., Verkleij, A.J., de 
Kruijff, B., Killian, J.A., and Hoppener, J.W. (2008) Membrane damage by human islet 
amyloid polypeptide through fibril growth at the membrane. Proc Natl Acad Sci U S A 
105, 6033-6038 
185 Bucciantini, M., Nosi, D., Forzan, M., Russo, E., Calamai, M., Pieri, L., Formigli, L., 
Quercioli, F., Soria, S., Pavone, F., Savistchenko, J., Melki, R., and Stefani, M. (2012) Toxic 
effects of amyloid fibrils on cell membranes: the importance of ganglioside GM1. FASEB 
J 26, 818-831 
186 Pieri, L., Bucciantini, M., Nosi, D., Formigli, L., Savistchenko, J., Melki, R., and Stefani, M. 
(2006) The yeast prion Ure2p native-like assemblies are toxic to mammalian cells 
regardless of their aggregation state. J Biol Chem 281, 15337-15344 
187 Stokin, G.B., Lillo, C., Falzone, T.L., Brusch, R.G., Rockenstein, E., Mount, S.L., Raman, R., 
Davies, P., Masliah, E., Williams, D.S., and Goldstein, L.S. (2005) Axonopathy and 
transport deficits early in the pathogenesis of Alzheimer's disease. Science 307, 1282-
1288 
197 
 
188 Meyer-Luehmann, M., Spires-Jones, T.L., Prada, C., Garcia-Alloza, M., de Calignon, A., 
Rozkalne, A., Koenigsknecht-Talboo, J., Holtzman, D.M., Bacskai, B.J., and Hyman, B.T. 
(2008) Rapid appearance and local toxicity of amyloid-beta plaques in a mouse model of 
Alzheimer's disease. Nature 451, 720-724 
189 Gosal, W.S., Morten, I.J., Hewitt, E.W., Smith, D.A., Thomson, N.H., and Radford, S.E. 
(2005) Competing pathways determine fibril morphology in the self-assembly of beta2-
microglobulin into amyloid. J Mol Biol 351, 850-864 
190 Xue, W.F., Hellewell, A.L., Gosal, W.S., Homans, S.W., Hewitt, E.W., and Radford, S.E. 
(2009) Fibril fragmentation enhances amyloid cytotoxicity. J Biol Chem 284, 34272-
34282 
191 Martins, I.C., Kuperstein, I., Wilkinson, H., Maes, E., Vanbrabant, M., Jonckheere, W., 
Van Gelder, P., Hartmann, D., D'Hooge, R., De Strooper, B., Schymkowitz, J., and 
Rousseau, F. (2008) Lipids revert inert Abeta amyloid fibrils to neurotoxic protofibrils 
that affect learning in mice. EMBO J 27, 224-233 
192 Picotti, P., De Franceschi, G., Frare, E., Spolaore, B., Zambonin, M., Chiti, F., de Laureto, 
P.P., and Fontana, A. (2007) Amyloid fibril formation and disaggregation of fragment 1-
29 of apomyoglobin: insights into the effect of pH on protein fibrillogenesis. J Mol Biol 
367, 1237-1245 
193 Olzscha, H., Schermann, S.M., Woerner, A.C., Pinkert, S., Hecht, M.H., Tartaglia, G.G., 
Vendruscolo, M., Hayer-Hartl, M., Hartl, F.U., and Vabulas, R.M. (2011) Amyloid-like 
aggregates sequester numerous metastable proteins with essential cellular functions. 
Cell 144, 67-78 
194 Bolognesi, B., Kumita, J.R., Barros, T.P., Esbjorner, E.K., Luheshi, L.M., Crowther, D.C., 
Wilson, M.R., Dobson, C.M., Favrin, G., and Yerbury, J.J. (2010) ANS binding reveals 
common features of cytotoxic amyloid species. ACS Chem Biol 5, 735-740 
195 Zampagni, M., Cascella, R., Casamenti, F., Grossi, C., Evangelisti, E., Wright, D., Becatti, 
M., Liguri, G., Mannini, B., Campioni, S., Chiti, F., and Cecchi, C. (2011) A comparison of 
the biochemical modifications caused by toxic and non-toxic protein oligomers in cells. J 
Cell Mol Med 15, 2106-2116 
196 Virok, D.P., Simon, D., Bozso, Z., Rajko, R., Datki, Z., Balint, E., Szegedi, V., Janaky, T., 
Penke, B., and Fulop, L. (2011) Protein array based interactome analysis of amyloid-beta 
indicates an inhibition of protein translation. J Proteome Res 10, 1538-1547 
197 Balch, W.E., Morimoto, R.I., Dillin, A., and Kelly, J.W. (2008) Adapting proteostasis for 
disease intervention. Science 319, 916-919 
198 
 
198 Koga, H., Kaushik, S., and Cuervo, A.M. (2011) Protein homeostasis and aging: The 
importance of exquisite quality control. Ageing Res Rev 10, 205-215 
199 Kim, Y.E., Hipp, M.S., Bracher, A., Hayer-Hartl, M., and Hartl, F.U. (2013) Molecular 
chaperone functions in protein folding and proteostasis. Annu Rev Biochem 82, 323-355 
200 Ciechanover, A., Orian, A., and Schwartz, A.L. (2000) Ubiquitin-mediated proteolysis: 
biological regulation via destruction. Bioessays 22, 442-451 
201 Bence, N.F., Sampat, R.M., and Kopito, R.R. (2001) Impairment of the ubiquitin-
proteasome system by protein aggregation. Science 292, 1552-1555 
202 Shimura, H., Hattori, N., Kubo, S., Mizuno, Y., Asakawa, S., Minoshima, S., Shimizu, N., 
Iwai, K., Chiba, T., Tanaka, K., and Suzuki, T. (2000) Familial Parkinson disease gene 
product, parkin, is a ubiquitin-protein ligase. Nat Genet 25, 302-305 
203 McNaught, K.S., Perl, D.P., Brownell, A.L., and Olanow, C.W. (2004) Systemic exposure to 
proteasome inhibitors causes a progressive model of Parkinson's disease. Ann Neurol 56, 
149-162 
204 Anfinsen, C.B. (1973) Principles that govern the folding of protein chains. Science 181, 
223-230 
205 Ellis, R.J. and Minton, A.P. (2006) Protein aggregation in crowded environments. Biol 
Chem 387, 485-497 
206 Ellis, R.J. (2001) Macromolecular crowding: an important but neglected aspect of the 
intracellular environment. Curr Opin Struct Biol 11, 114-119 
207 Hartl, F.U. and Hayer-Hartl, M. (2002) Molecular chaperones in the cytosol: from nascent 
chain to folded protein. Science 295, 1852-1858 
208 Bukau, B., Weissman, J., and Horwich, A. (2006) Molecular chaperones and protein 
quality control. Cell 125, 443-451 
209 Wilhelmus, M.M., Otte-Holler, I., Wesseling, P., de Waal, R.M., Boelens, W.C., and 
Verbeek, M.M. (2006) Specific association of small heat shock proteins with the 
pathological hallmarks of Alzheimer's disease brains. Neuropathol Appl Neurobiol 32, 
119-130 
210 Fargnoli, J., Kunisada, T., Fornace, A.J., Jr., Schneider, E.L., and Holbrook, N.J. (1990) 
Decreased expression of heat shock protein 70 mRNA and protein after heat treatment 
in cells of aged rats. Proc Natl Acad Sci U S A 87, 846-850 
211 Hall, D.M., Xu, L., Drake, V.J., Oberley, L.W., Oberley, T.D., Moseley, P.L., and Kregel, K.C. 
(2000) Aging reduces adaptive capacity and stress protein expression in the liver after 
heat stress. J Appl Physiol (1985) 89, 749-759 
199 
 
212 Pahlavani, M.A., Harris, M.D., Moore, S.A., Weindruch, R., and Richardson, A. (1995) The 
expression of heat shock protein 70 decreases with age in lymphocytes from rats and 
rhesus monkeys. Exp Cell Res 218, 310-318 
213 Gidalevitz, T., Ben-Zvi, A., Ho, K.H., Brignull, H.R., and Morimoto, R.I. (2006) Progressive 
disruption of cellular protein folding in models of polyglutamine diseases. Science 311, 
1471-1474 
214 Westerheide, S.D. and Morimoto, R.I. (2005) Heat shock response modulators as 
therapeutic tools for diseases of protein conformation. J Biol Chem 280, 33097-33100 
215 Mu, T.W., Ong, D.S., Wang, Y.J., Balch, W.E., Yates, J.R., 3rd, Segatori, L., and Kelly, J.W. 
(2008) Chemical and biological approaches synergize to ameliorate protein-folding 
diseases. Cell 134, 769-781 
216 Lotz, G.P., Legleiter, J., Aron, R., Mitchell, E.J., Huang, S.Y., Ng, C., Glabe, C., Thompson, 
L.M., and Muchowski, P.J. (2010) Hsp70 and Hsp40 functionally interact with soluble 
mutant huntingtin oligomers in a classic ATP-dependent reaction cycle. J Biol Chem 285, 
38183-38193 
217 Auluck, P.K., Chan, H.Y., Trojanowski, J.Q., Lee, V.M., and Bonini, N.M. (2002) Chaperone 
suppression of alpha-synuclein toxicity in a Drosophila model for Parkinson's disease. 
Science 295, 865-868 
218 Hageman, J., Rujano, M.A., van Waarde, M.A., Kakkar, V., Dirks, R.P., Govorukhina, N., 
Oosterveld-Hut, H.M., Lubsen, N.H., and Kampinga, H.H. (2010) A DNAJB chaperone 
subfamily with HDAC-dependent activities suppresses toxic protein aggregation. Mol Cell 
37, 355-369 
219 Berthelot, K., Cullin, C., and Lecomte, S. (2013) What does make an amyloid toxic: 
morphology, structure or interaction with membrane? Biochimie 95, 12-19 
220 Williams, T.L. and Serpell, L.C. (2011) Membrane and surface interactions of Alzheimer's 
Abeta peptide--insights into the mechanism of cytotoxicity. FEBS J 278, 3905-3917 
221 Necula, M., Chirita, C.N., and Kuret, J. (2003) Rapid anionic micelle-mediated alpha-
synuclein fibrillization in vitro. J Biol Chem 278, 46674-46680 
222 Knight, J.D. and Miranker, A.D. (2004) Phospholipid catalysis of diabetic amyloid 
assembly. J Mol Biol 341, 1175-1187 
223 Choo-Smith, L.P., Garzon-Rodriguez, W., Glabe, C.G., and Surewicz, W.K. (1997) 
Acceleration of amyloid fibril formation by specific binding of Abeta-(1-40) peptide to 
ganglioside-containing membrane vesicles. J Biol Chem 272, 22987-22990 
224 Lashuel, H.A. and Lansbury, P.T., Jr. (2006) Are amyloid diseases caused by protein 
aggregates that mimic bacterial pore-forming toxins? Q Rev Biophys 39, 167-201 
200 
 
225 Hebda, J.A. and Miranker, A.D. (2009) The interplay of catalysis and toxicity by amyloid 
intermediates on lipid bilayers: insights from type II diabetes. Annu Rev Biophys 38, 125-
152 
226 Green, J.D., Kreplak, L., Goldsbury, C., Li Blatter, X., Stolz, M., Cooper, G.S., Seelig, A., 
Kistler, J., and Aebi, U. (2004) Atomic force microscopy reveals defects within mica 
supported lipid bilayers induced by the amyloidogenic human amylin peptide. J Mol Biol 
342, 877-887 
227 Ta, H.P., Berthelot, K., Coulary-Salin, B., Castano, S., Desbat, B., Bonnafous, P., Lambert, 
O., Alves, I., Cullin, C., and Lecomte, S. (2012) A yeast toxic mutant of HET-s amyloid 
disrupts membrane integrity. Biochim Biophys Acta 1818, 2325-2334 
228 Zhang, Y.J., Shi, J.M., Bai, C.J., Wang, H., Li, H.Y., Wu, Y., and Ji, S.R. (2012) Intra-
membrane oligomerization and extra-membrane oligomerization of amyloid-beta 
peptide are competing processes as a result of distinct patterns of motif interplay. J Biol 
Chem 287, 748-756 
229 Shai, Y. (1999) Mechanism of the binding, insertion and destabilization of phospholipid 
bilayer membranes by alpha-helical antimicrobial and cell non-selective membrane-lytic 
peptides. Biochim Biophys Acta 1462, 55-70 
230 Sparr, E., Engel, M.F., Sakharov, D.V., Sprong, M., Jacobs, J., de Kruijff, B., Hoppener, 
J.W., and Killian, J.A. (2004) Islet amyloid polypeptide-induced membrane leakage 
involves uptake of lipids by forming amyloid fibers. FEBS Lett 577, 117-120 
231 Milanesi, L., Sheynis, T., Xue, W.F., Orlova, E.V., Hellewell, A.L., Jelinek, R., Hewitt, E.W., 
Radford, S.E., and Saibil, H.R. (2012) Direct three-dimensional visualization of membrane 
disruption by amyloid fibrils. Proc Natl Acad Sci U S A 109, 20455-20460 
232 Petersen, O.H., Michalak, M., and Verkhratsky, A. (2005) Calcium signalling: past, 
present and future. Cell Calcium 38, 161-169 
233 Glabe, C.G. (2006) Common mechanisms of amyloid oligomer pathogenesis in 
degenerative disease. Neurobiol Aging 27, 570-575 
234 Ding, T.T., Lee, S.J., Rochet, J.C., and Lansbury, P.T., Jr. (2002) Annular alpha-synuclein 
protofibrils are produced when spherical protofibrils are incubated in solution or bound 
to brain-derived membranes. Biochemistry 41, 10209-10217 
235 Lashuel, H.A., Petre, B.M., Wall, J., Simon, M., Nowak, R.J., Walz, T., and Lansbury, P.T., 
Jr. (2002) Alpha-synuclein, especially the Parkinson's disease-associated mutants, forms 
pore-like annular and tubular protofibrils. J Mol Biol 322, 1089-1102 
201 
 
236 Wacker, J.L., Zareie, M.H., Fong, H., Sarikaya, M., and Muchowski, P.J. (2004) Hsp70 and 
Hsp40 attenuate formation of spherical and annular polyglutamine oligomers by 
partitioning monomer. Nat Struct Mol Biol 11, 1215-1222 
237 Lal, R., Lin, H., and Quist, A.P. (2007) Amyloid beta ion channel: 3D structure and 
relevance to amyloid channel paradigm. Biochim Biophys Acta 1768, 1966-1975 
238 Volles, M.J. and Lansbury, P.T., Jr. (2002) Vesicle permeabilization by protofibrillar alpha-
synuclein is sensitive to Parkinson's disease-linked mutations and occurs by a pore-like 
mechanism. Biochemistry 41, 4595-4602 
239 Kagan, B.L., Hirakura, Y., Azimov, R., and Azimova, R. (2001) The channel hypothesis of 
Huntington's disease. Brain Res Bull 56, 281-284 
240 Chafekar, S.M., Baas, F., and Scheper, W. (2008) Oligomer-specific Abeta toxicity in cell 
models is mediated by selective uptake. Biochim Biophys Acta 1782, 523-531 
241 Zhao, W.Q., Santini, F., Breese, R., Ross, D., Zhang, X.D., Stone, D.J., Ferrer, M., 
Townsend, M., Wolfe, A.L., Seager, M.A., Kinney, G.G., Shughrue, P.J., and Ray, W.J. 
(2010) Inhibition of calcineurin-mediated endocytosis and alpha-amino-3-hydroxy-5-
methyl-4-isoxazolepropionic acid (AMPA) receptors prevents amyloid beta oligomer-
induced synaptic disruption. J Biol Chem 285, 7619-7632 
242 Soura, V., Stewart-Parker, M., Williams, T.L., Ratnayaka, A., Atherton, J., Gorringe, K., 
Tuffin, J., Darwent, E., Rambaran, R., Klein, W., Lacor, P., Staras, K., Thorpe, J., and 
Serpell, L.C. (2012) Visualization of co-localization in Abeta42-administered 
neuroblastoma cells reveals lysosome damage and autophagosome accumulation 
related to cell death. Biochem J 441, 579-590 
243 Lee, H.J., Patel, S., and Lee, S.J. (2005) Intravesicular localization and exocytosis of alpha-
synuclein and its aggregates. J Neurosci 25, 6016-6024 
244 Sung, J.Y., Kim, J., Paik, S.R., Park, J.H., Ahn, Y.S., and Chung, K.C. (2001) Induction of 
neuronal cell death by Rab5A-dependent endocytosis of alpha-synuclein. J Biol Chem 
276, 27441-27448 
245 Freeman, D., Cedillos, R., Choyke, S., Lukic, Z., McGuire, K., Marvin, S., Burrage, A.M., 
Sudholt, S., Rana, A., O'Connor, C., Wiethoff, C.M., and Campbell, E.M. (2013) Alpha-
synuclein induces lysosomal rupture and cathepsin dependent reactive oxygen species 
following endocytosis. PLoS One 8, e62143 
246 Ren, P.H., Lauckner, J.E., Kachirskaia, I., Heuser, J.E., Melki, R., and Kopito, R.R. (2009) 
Cytoplasmic penetration and persistent infection of mammalian cells by polyglutamine 
aggregates. Nat Cell Biol 11, 219-225 
202 
 
247 Morten, I.J., Gosal, W.S., Radford, S.E., and Hewitt, E.W. (2007) Investigation into the 
role of macrophages in the formation and degradation of beta2-microglobulin amyloid 
fibrils. J Biol Chem 282, 29691-29700 
248 Porter, M.Y., Routledge, K.E., Radford, S.E., and Hewitt, E.W. (2011) Characterization of 
the response of primary cells relevant to dialysis-related amyloidosis to beta2-
microglobulin monomer and fibrils. PLoS One 6, e27353 
249 Barbero-Camps, E., Fernandez, A., Baulies, A., Martinez, L., Fernandez-Checa, J.C., and 
Colell, A. (2014) Endoplasmic Reticulum Stress Mediates Amyloid beta Neurotoxicity via 
Mitochondrial Cholesterol Trafficking. Am J Pathol 184, 2066-2081 
250 Li, J.Q., Yu, J.T., Jiang, T., and Tan, L. (2014) Endoplasmic Reticulum Dysfunction in 
Alzheimer's Disease. Mol Neurobiol  
251 Umeda, T., Tomiyama, T., Sakama, N., Tanaka, S., Lambert, M.P., Klein, W.L., and Mori, 
H. (2011) Intraneuronal amyloid beta oligomers cause cell death via endoplasmic 
reticulum stress, endosomal/lysosomal leakage, and mitochondrial dysfunction in vivo. J 
Neurosci Res 89, 1031-1042 
252 Bennett, E.J., Shaler, T.A., Woodman, B., Ryu, K.Y., Zaitseva, T.S., Becker, C.H., Bates, 
G.P., Schulman, H., and Kopito, R.R. (2007) Global changes to the ubiquitin system in 
Huntington's disease. Nature 448, 704-708 
253 Schmidt, M. and Finley, D. (2014) Regulation of proteasome activity in health and 
disease. Biochim Biophys Acta 1843, 13-25 
254 Huang, Q. and Figueiredo-Pereira, M.E. (2010) Ubiquitin/proteasome pathway 
impairment in neurodegeneration: therapeutic implications. Apoptosis 15, 1292-1311 
255 Wong, E. and Cuervo, A.M. (2010) Autophagy gone awry in neurodegenerative diseases. 
Nat Neurosci 13, 805-811 
256 Nixon, R.A. (2013) The role of autophagy in neurodegenerative disease. Nat Med 19, 
983-997 
257 Schon, E.A. and Przedborski, S. (2011) Mitochondria: the next (neurode)generation. 
Neuron 70, 1033-1053 
258 Sarafian, T.A., Ryan, C.M., Souda, P., Masliah, E., Kar, U.K., Vinters, H.V., Mathern, G.W., 
Faull, K.F., Whitelegge, J.P., and Watson, J.B. (2013) Impairment of mitochondria in adult 
mouse brain overexpressing predominantly full-length, N-terminally acetylated human 
alpha-synuclein. PLoS One 8, e63557 
259 Maruszak, A. and Zekanowski, C. (2011) Mitochondrial dysfunction and Alzheimer's 
disease. Prog Neuropsychopharmacol Biol Psychiatry 35, 320-330 
203 
 
260 Boland, B. and Campbell, V. (2004) Abeta-mediated activation of the apoptotic cascade 
in cultured cortical neurones: a role for cathepsin-L. Neurobiol Aging 25, 83-91 
261 Dehay, B., Bove, J., Rodriguez-Muela, N., Perier, C., Recasens, A., Boya, P., and Vila, M. 
(2010) Pathogenic lysosomal depletion in Parkinson's disease. J Neurosci 30, 12535-
12544 
262 Ji, Z.S., Miranda, R.D., Newhouse, Y.M., Weisgraber, K.H., Huang, Y., and Mahley, R.W. 
(2002) Apolipoprotein E4 potentiates amyloid beta peptide-induced lysosomal leakage 
and apoptosis in neuronal cells. J Biol Chem 277, 21821-21828 
263 Ditaranto, K., Tekirian, T.L., and Yang, A.J. (2001) Lysosomal membrane damage in 
soluble Abeta-mediated cell death in Alzheimer's disease. Neurobiol Dis 8, 19-31 
264 Liu, R.Q., Zhou, Q.H., Ji, S.R., Zhou, Q., Feng, D., Wu, Y., and Sui, S.F. (2010) Membrane 
localization of beta-amyloid 1-42 in lysosomes: a possible mechanism for lysosome 
labilization. J Biol Chem 285, 19986-19996 
265 De Kimpe, L., van Haastert, E.S., Kaminari, A., Zwart, R., Rutjes, H., Hoozemans, J.J., and 
Scheper, W. (2013) Intracellular accumulation of aggregated pyroglutamate amyloid 
beta: convergence of aging and Abeta pathology at the lysosome. Age (Dordr) 35, 673-
687 
266 Rugarli, E.I. and Langer, T. (2012) Mitochondrial quality control: a matter of life and 
death for neurons. EMBO J 31, 1336-1349 
267 Li, Z., Okamoto, K., Hayashi, Y., and Sheng, M. (2004) The importance of dendritic 
mitochondria in the morphogenesis and plasticity of spines and synapses. Cell 119, 873-
887 
268 MacAskill, A.F. and Kittler, J.T. (2010) Control of mitochondrial transport and localization 
in neurons. Trends Cell Biol 20, 102-112 
269 Menzies, R.A. and Gold, P.H. (1971) The turnover of mitochondria in a variety of tissues 
of young adult and aged rats. J Biol Chem 246, 2425-2429 
270 Miwa, S., Lawless, C., and von Zglinicki, T. (2008) Mitochondrial turnover in liver is fast in 
vivo and is accelerated by dietary restriction: application of a simple dynamic model. 
Aging Cell 7, 920-923 
271 Kaplan, B.B., Gioio, A.E., Hillefors, M., and Aschrafi, A. (2009) Axonal protein synthesis 
and the regulation of local mitochondrial function. Results Probl Cell Differ 48, 225-242 
272 Brown, M.R., Sullivan, P.G., and Geddes, J.W. (2006) Synaptic mitochondria are more 
susceptible to Ca2+overload than nonsynaptic mitochondria. J Biol Chem 281, 11658-
11668 
204 
 
273 Wang, Q.J., Ding, Y., Kohtz, D.S., Mizushima, N., Cristea, I.M., Rout, M.P., Chait, B.T., 
Zhong, Y., Heintz, N., and Yue, Z. (2006) Induction of autophagy in axonal dystrophy and 
degeneration. J Neurosci 26, 8057-8068 
274 Alikhani, N., Guo, L., Yan, S., Du, H., Pinho, C.M., Chen, J.X., Glaser, E., and Yan, S.S. 
(2011) Decreased proteolytic activity of the mitochondrial amyloid-beta degrading 
enzyme, PreP peptidasome, in Alzheimer's disease brain mitochondria. J Alzheimers Dis 
27, 75-87 
275 Kitada, T., Pisani, A., Porter, D.R., Yamaguchi, H., Tscherter, A., Martella, G., Bonsi, P., 
Zhang, C., Pothos, E.N., and Shen, J. (2007) Impaired dopamine release and synaptic 
plasticity in the striatum of PINK1-deficient mice. Proc Natl Acad Sci U S A 104, 11441-
11446 
276 Valente, E.M., Abou-Sleiman, P.M., Caputo, V., Muqit, M.M., Harvey, K., Gispert, S., Ali, 
Z., Del Turco, D., Bentivoglio, A.R., Healy, D.G., Albanese, A., Nussbaum, R., Gonzalez-
Maldonado, R., Deller, T., Salvi, S., Cortelli, P., Gilks, W.P., Latchman, D.S., Harvey, R.J., 
Dallapiccola, B., Auburger, G., and Wood, N.W. (2004) Hereditary early-onset Parkinson's 
disease caused by mutations in PINK1. Science 304, 1158-1160 
277 Vives-Bauza, C. and Przedborski, S. (2011) Mitophagy: the latest problem for Parkinson's 
disease. Trends Mol Med 17, 158-165 
278 Settembre, C., Fraldi, A., Medina, D.L., and Ballabio, A. (2013) Signals from the lysosome: 
a control centre for cellular clearance and energy metabolism. Nat Rev Mol Cell Biol 14, 
283-296 
279 de Duve, C. (2005) The lysosome turns fifty. Nat Cell Biol 7, 847-849 
280 Saftig, P. and Klumperman, J. (2009) Lysosome biogenesis and lysosomal membrane 
proteins: trafficking meets function. Nat Rev Mol Cell Biol 10, 623-635 
281 Kaushik, S. and Cuervo, A.M. (2012) Chaperone-mediated autophagy: a unique way to 
enter the lysosome world. Trends Cell Biol 22, 407-417 
282 Luzio, J.P., Pryor, P.R., and Bright, N.A. (2007) Lysosomes: fusion and function. Nat Rev 
Mol Cell Biol 8, 622-632 
283 Boya, P. and Kroemer, G. (2008) Lysosomal membrane permeabilization in cell death. 
Oncogene 27, 6434-6451 
284 Lee, S., Sato, Y., and Nixon, R.A. (2011) Lysosomal proteolysis inhibition selectively 
disrupts axonal transport of degradative organelles and causes an Alzheimer's-like 
axonal dystrophy. J Neurosci 31, 7817-7830 
285 Lai, A.Y., Lan, C.P., Hasan, S., Brown, M.E., and McLaurin, J. (2014) scyllo-Inositol 
promotes robust mutant Huntingtin protein degradation. J Biol Chem 289, 3666-3676 
205 
 
286 McLaurin, J., Golomb, R., Jurewicz, A., Antel, J.P., and Fraser, P.E. (2000) Inositol 
stereoisomers stabilize an oligomeric aggregate of Alzheimer amyloid beta peptide and 
inhibit abeta -induced toxicity. J Biol Chem 275, 18495-18502 
287 Tsunemi, T. and Krainc, D. (2014) Zn(2)(+) dyshomeostasis caused by loss of 
ATP13A2/PARK9 leads to lysosomal dysfunction and alpha-synuclein accumulation. Hum 
Mol Genet 23, 2791-2801 
288 Mazzulli, J.R., Xu, Y.H., Sun, Y., Knight, A.L., McLean, P.J., Caldwell, G.A., Sidransky, E., 
Grabowski, G.A., and Krainc, D. (2011) Gaucher disease glucocerebrosidase and alpha-
synuclein form a bidirectional pathogenic loop in synucleinopathies. Cell 146, 37-52 
289 Rivera, J.F., Gurlo, T., Daval, M., Huang, C.J., Matveyenko, A.V., Butler, P.C., and Costes, 
S. (2011) Human-IAPP disrupts the autophagy/lysosomal pathway in pancreatic beta-
cells: protective role of p62-positive cytoplasmic inclusions. Cell Death Differ 18, 415-426 
290 Nixon, R.A., Wegiel, J., Kumar, A., Yu, W.H., Peterhoff, C., Cataldo, A., and Cuervo, A.M. 
(2005) Extensive involvement of autophagy in Alzheimer disease: an immuno-electron 
microscopy study. J Neuropathol Exp Neurol 64, 113-122 
291 Kegel, K.B., Kim, M., Sapp, E., McIntyre, C., Castano, J.G., Aronin, N., and DiFiglia, M. 
(2000) Huntingtin expression stimulates endosomal-lysosomal activity, endosome 
tubulation, and autophagy. J Neurosci 20, 7268-7278 
292 Boland, B., Kumar, A., Lee, S., Platt, F.M., Wegiel, J., Yu, W.H., and Nixon, R.A. (2008) 
Autophagy induction and autophagosome clearance in neurons: relationship to 
autophagic pathology in Alzheimer's disease. J Neurosci 28, 6926-6937 
293 Rubinsztein, D.C., Cuervo, A.M., Ravikumar, B., Sarkar, S., Korolchuk, V., Kaushik, S., and 
Klionsky, D.J. (2009) In search of an "autophagomometer". Autophagy 5, 585-589 
294 Settembre, C., Fraldi, A., Jahreiss, L., Spampanato, C., Venturi, C., Medina, D., de Pablo, 
R., Tacchetti, C., Rubinsztein, D.C., and Ballabio, A. (2008) A block of autophagy in 
lysosomal storage disorders. Hum Mol Genet 17, 119-129 
295 Mizushima, N., Levine, B., Cuervo, A.M., and Klionsky, D.J. (2008) Autophagy fights 
disease through cellular self-digestion. Nature 451, 1069-1075 
296 He, C. and Klionsky, D.J. (2009) Regulation mechanisms and signaling pathways of 
autophagy. Annu Rev Genet 43, 67-93 
297 Cuervo, A.M. (2010) Chaperone-mediated autophagy: selectivity pays off. Trends 
Endocrinol Metab 21, 142-150 
298 Massey, A.C., Kaushik, S., Sovak, G., Kiffin, R., and Cuervo, A.M. (2006) Consequences of 
the selective blockage of chaperone-mediated autophagy. Proc Natl Acad Sci U S A 103, 
5805-5810 
206 
 
299 Nedelsky, N.B., Todd, P.K., and Taylor, J.P. (2008) Autophagy and the ubiquitin-
proteasome system: collaborators in neuroprotection. Biochim Biophys Acta 1782, 691-
699 
300 Cuervo, A.M., Stefanis, L., Fredenburg, R., Lansbury, P.T., and Sulzer, D. (2004) Impaired 
degradation of mutant alpha-synuclein by chaperone-mediated autophagy. Science 305, 
1292-1295 
301 Wang, Y., Martinez-Vicente, M., Kruger, U., Kaushik, S., Wong, E., Mandelkow, E.M., 
Cuervo, A.M., and Mandelkow, E. (2009) Tau fragmentation, aggregation and clearance: 
the dual role of lysosomal processing. Hum Mol Genet 18, 4153-4170 
302 Lee, J.A. and Gao, F.B. (2009) Inhibition of autophagy induction delays neuronal cell loss 
caused by dysfunctional ESCRT-III in frontotemporal dementia. J Neurosci 29, 8506-8511 
303 Filimonenko, M., Stuffers, S., Raiborg, C., Yamamoto, A., Malerod, L., Fisher, E.M., Isaacs, 
A., Brech, A., Stenmark, H., and Simonsen, A. (2007) Functional multivesicular bodies are 
required for autophagic clearance of protein aggregates associated with 
neurodegenerative disease. J Cell Biol 179, 485-500 
304 Sardiello, M., Palmieri, M., di Ronza, A., Medina, D.L., Valenza, M., Gennarino, V.A., Di 
Malta, C., Donaudy, F., Embrione, V., Polishchuk, R.S., Banfi, S., Parenti, G., Cattaneo, E., 
and Ballabio, A. (2009) A gene network regulating lysosomal biogenesis and function. 
Science 325, 473-477 
305 Schultz, M.L., Tecedor, L., Chang, M., and Davidson, B.L. (2011) Clarifying lysosomal 
storage diseases. Trends Neurosci 34, 401-410 
306 Settembre, C., Fraldi, A., Rubinsztein, D.C., and Ballabio, A. (2008) Lysosomal storage 
diseases as disorders of autophagy. Autophagy 4, 113-114 
307 Futerman, A.H. and van Meer, G. (2004) The cell biology of lysosomal storage disorders. 
Nat Rev Mol Cell Biol 5, 554-565 
308 Ravikumar, B., Duden, R., and Rubinsztein, D.C. (2002) Aggregate-prone proteins with 
polyglutamine and polyalanine expansions are degraded by autophagy. Hum Mol Genet 
11, 1107-1117 
309 Settembre, C., Annunziata, I., Spampanato, C., Zarcone, D., Cobellis, G., Nusco, E., Zito, 
E., Tacchetti, C., Cosma, M.P., and Ballabio, A. (2007) Systemic inflammation and 
neurodegeneration in a mouse model of multiple sulfatase deficiency. Proc Natl Acad Sci 
U S A 104, 4506-4511 
310 Grabowski, G.A. (2008) Phenotype, diagnosis, and treatment of Gaucher's disease. 
Lancet 372, 1263-1271 
207 
 
311 Stern, G. (2014) Niemann-Pick's and Gaucher's diseases. Parkinsonism Relat Disord 20 
Suppl 1, S143-146 
312 Neudorfer, O., Giladi, N., Elstein, D., Abrahamov, A., Turezkite, T., Aghai, E., Reches, A., 
Bembi, B., and Zimran, A. (1996) Occurrence of Parkinson's syndrome in type I Gaucher 
disease. QJM 89, 691-694 
313 Tayebi, N., Walker, J., Stubblefield, B., Orvisky, E., LaMarca, M.E., Wong, K., Rosenbaum, 
H., Schiffmann, R., Bembi, B., and Sidransky, E. (2003) Gaucher disease with parkinsonian 
manifestations: does glucocerebrosidase deficiency contribute to a vulnerability to 
parkinsonism? Mol Genet Metab 79, 104-109 
314 Sidransky, E. (2005) Gaucher disease and parkinsonism. Mol Genet Metab 84, 302-304 
315 Wong, K., Sidransky, E., Verma, A., Mixon, T., Sandberg, G.D., Wakefield, L.K., Morrison, 
A., Lwin, A., Colegial, C., Allman, J.M., and Schiffmann, R. (2004) Neuropathology 
provides clues to the pathophysiology of Gaucher disease. Mol Genet Metab 82, 192-207 
316 Sidransky, E., Nalls, M.A., Aasly, J.O., Aharon-Peretz, J., Annesi, G., Barbosa, E.R., Bar-
Shira, A., Berg, D., Bras, J., Brice, A., Chen, C.M., Clark, L.N., Condroyer, C., De Marco, 
E.V., Durr, A., Eblan, M.J., Fahn, S., Farrer, M.J., Fung, H.C., Gan-Or, Z., Gasser, T., 
Gershoni-Baruch, R., Giladi, N., Griffith, A., Gurevich, T., Januario, C., Kropp, P., Lang, 
A.E., Lee-Chen, G.J., Lesage, S., Marder, K., Mata, I.F., Mirelman, A., Mitsui, J., Mizuta, I., 
Nicoletti, G., Oliveira, C., Ottman, R., Orr-Urtreger, A., Pereira, L.V., Quattrone, A., 
Rogaeva, E., Rolfs, A., Rosenbaum, H., Rozenberg, R., Samii, A., Samaddar, T., Schulte, C., 
Sharma, M., Singleton, A., Spitz, M., Tan, E.K., Tayebi, N., Toda, T., Troiano, A.R., Tsuji, S., 
Wittstock, M., Wolfsberg, T.G., Wu, Y.R., Zabetian, C.P., Zhao, Y., and Ziegler, S.G. (2009) 
Multicenter analysis of glucocerebrosidase mutations in Parkinson's disease. N Engl J 
Med 361, 1651-1661 
317 Nixon, R.A. (2004) Niemann-Pick Type C disease and Alzheimer's disease: the APP-
endosome connection fattens up. Am J Pathol 164, 757-761 
318 Yamazaki, T., Chang, T.Y., Haass, C., and Ihara, Y. (2001) Accumulation and aggregation 
of amyloid beta-protein in late endosomes of Niemann-pick type C cells. J Biol Chem 276, 
4454-4460 
319 Jin, L.W., Shie, F.S., Maezawa, I., Vincent, I., and Bird, T. (2004) Intracellular 
accumulation of amyloidogenic fragments of amyloid-beta precursor protein in neurons 
with Niemann-Pick type C defects is associated with endosomal abnormalities. Am J 
Pathol 164, 975-985 
320 Love, S., Bridges, L.R., and Case, C.P. (1995) Neurofibrillary tangles in Niemann-Pick 
disease type C. Brain 118 ( Pt 1), 119-129 
208 
 
321 Suzuki, K., Parker, C.C., Pentchev, P.G., Katz, D., Ghetti, B., D'Agostino, A.N., and Carstea, 
E.D. (1995) Neurofibrillary tangles in Niemann-Pick disease type C. Acta Neuropathol 89, 
227-238 
322 Poirier, J. (2003) Apolipoprotein E and cholesterol metabolism in the pathogenesis and 
treatment of Alzheimer's disease. Trends Mol Med 9, 94-101 
323 Treusch, S., Hamamichi, S., Goodman, J.L., Matlack, K.E., Chung, C.Y., Baru, V., Shulman, 
J.M., Parrado, A., Bevis, B.J., Valastyan, J.S., Han, H., Lindhagen-Persson, M., Reiman, 
E.M., Evans, D.A., Bennett, D.A., Olofsson, A., DeJager, P.L., Tanzi, R.E., Caldwell, K.A., 
Caldwell, G.A., and Lindquist, S. (2011) Functional links between Abeta toxicity, 
endocytic trafficking, and Alzheimer's disease risk factors in yeast. Science 334, 1241-
1245 
324 Sorrentino, P., Iuliano, A., Polverino, A., Jacini, F., and Sorrentino, G. (2014) The dark 
sides of amyloid in Alzheimer's disease pathogenesis. FEBS Lett 588, 641-652 
325 Kad, N.M., Thomson, N.H., Smith, D.P., Smith, D.A., and Radford, S.E. (2001) Beta(2)-
microglobulin and its deamidated variant, N17D form amyloid fibrils with a range of 
morphologies in vitro. J Mol Biol 313, 559-571 
326 Gill, S.C. and von Hippel, P.H. (1989) Calculation of protein extinction coefficients from 
amino acid sequence data. Anal Biochem 182, 319-326 
327 O'Nuallain, B. and Wetzel, R. (2002) Conformational Abs recognizing a generic amyloid 
fibril epitope. Proc Natl Acad Sci U S A 99, 1485-1490 
328 Xue, W.F., Homans, S.W., and Radford, S.E. (2009) Amyloid fibril length distribution 
quantified by atomic force microscopy single-particle image analysis. Protein Eng Des Sel 
22, 489-496 
329 Bolte, S. and Cordelieres, F.P. (2006) A guided tour into subcellular colocalization 
analysis in light microscopy. J Microsc 224, 213-232 
330 Dunn, K.W., Kamocka, M.M., and McDonald, J.H. (2011) A practical guide to evaluating 
colocalization in biological microscopy. Am J Physiol Cell Physiol 300, C723-742 
331 Costes, S.V., Daelemans, D., Cho, E.H., Dobbin, Z., Pavlakis, G., and Lockett, S. (2004) 
Automatic and quantitative measurement of protein-protein colocalization in live cells. 
Biophys J 86, 3993-4003 
332 Manders, E.M.M., Verbeek, F.J., and Aten, J.A. (1993) Measurement of co-localization of 
objects in dual-colour confocal images. Journal of Microscopy 169, 375-382 
333 Roodveldt, C., Bertoncini, C.W., Andersson, A., van der Goot, A.T., Hsu, S.T., Fernandez-
Montesinos, R., de Jong, J., van Ham, T.J., Nollen, E.A., Pozo, D., Christodoulou, J., and 
209 
 
Dobson, C.M. (2009) Chaperone proteostasis in Parkinson's disease: stabilization of the 
Hsp70/alpha-synuclein complex by Hip. EMBO J 28, 3758-3770 
334 Trinh, C.H., Smith, D.P., Kalverda, A.P., Phillips, S.E., and Radford, S.E. (2002) Crystal 
structure of monomeric human beta-2-microglobulin reveals clues to its amyloidogenic 
properties. Proc Natl Acad Sci U S A 99, 9771-9776 
335 Khan, A.R., Baker, B.M., Ghosh, P., Biddison, W.E., and Wiley, D.C. (2000) The structure 
and stability of an HLA-A*0201/octameric tax peptide complex with an empty conserved 
peptide-N-terminal binding site. J Immunol 164, 6398-6405 
336 Verdone, G., Corazza, A., Viglino, P., Pettirossi, F., Giorgetti, S., Mangione, P., Andreola, 
A., Stoppini, M., Bellotti, V., and Esposito, G. (2002) The solution structure of human 
beta2-microglobulin reveals the prodromes of its amyloid transition. Protein Sci 11, 487-
499 
337 Eichner, T. and Radford, S.E. (2011) Understanding the complex mechanisms of beta2-
microglobulin amyloid assembly. FEBS J 278, 3868-3883 
338 Jahn, T.R., Parker, M.J., Homans, S.W., and Radford, S.E. (2006) Amyloid formation under 
physiological conditions proceeds via a native-like folding intermediate. Nat Struct Mol 
Biol 13, 195-201 
339 Borbulevych, O.Y., Do, P., and Baker, B.M. (2010) Structures of native and affinity-
enhanced WT1 epitopes bound to HLA-A*0201: implications for WT1-based cancer 
therapeutics. Mol Immunol 47, 2519-2524 
340 Eichner, T., Kalverda, A.P., Thompson, G.S., Homans, S.W., and Radford, S.E. (2011) 
Conformational conversion during amyloid formation at atomic resolution. Mol Cell 41, 
161-172 
341 Platt, G.W. and Radford, S.E. (2009) Glimpses of the molecular mechanisms of beta2-
microglobulin fibril formation in vitro: aggregation on a complex energy landscape. FEBS 
Lett 583, 2623-2629 
342 Rosano, C., Zuccotti, S., Mangione, P., Giorgetti, S., Bellotti, V., Pettirossi, F., Corazza, A., 
Viglino, P., Esposito, G., and Bolognesi, M. (2004) beta2-microglobulin H31Y variant 3D 
structure highlights the protein natural propensity towards intermolecular aggregation. J 
Mol Biol 335, 1051-1064 
343 Esposito, G., Ricagno, S., Corazza, A., Rennella, E., Gumral, D., Mimmi, M.C., Betto, E., 
Pucillo, C.E., Fogolari, F., Viglino, P., Raimondi, S., Giorgetti, S., Bolognesi, B., Merlini, G., 
Stoppini, M., Bolognesi, M., and Bellotti, V. (2008) The controlling roles of Trp60 and 
Trp95 in beta2-microglobulin function, folding and amyloid aggregation properties. J Mol 
Biol 378, 887-897 
210 
 
344 Calabrese, M.F., Eakin, C.M., Wang, J.M., and Miranker, A.D. (2008) A regulatable switch 
mediates self-association in an immunoglobulin fold. Nat Struct Mol Biol 15, 965-971 
345 Kihara, M., Chatani, E., Iwata, K., Yamamoto, K., Matsuura, T., Nakagawa, A., Naiki, H., 
and Goto, Y. (2006) Conformation of amyloid fibrils of beta2-microglobulin probed by 
tryptophan mutagenesis. J Biol Chem 281, 31061-31069 
346 Iwata, K., Matsuura, T., Sakurai, K., Nakagawa, A., and Goto, Y. (2007) High-resolution 
crystal structure of beta2-microglobulin formed at pH 7.0. J Biochem 142, 413-419 
347 Ricagno, S., Colombo, M., de Rosa, M., Sangiovanni, E., Giorgetti, S., Raimondi, S., 
Bellotti, V., and Bolognesi, M. (2008) DE loop mutations affect beta2-microglobulin 
stability and amyloid aggregation. Biochem Biophys Res Commun 377, 146-150 
348 Santambrogio, C., Ricagno, S., Colombo, M., Barbiroli, A., Bonomi, F., Bellotti, V., 
Bolognesi, M., and Grandori, R. (2010) DE-loop mutations affect beta2 microglobulin 
stability, oligomerization, and the low-pH unfolded form. Protein Sci 19, 1386-1394 
349 Eakin, C.M., Berman, A.J., and Miranker, A.D. (2006) A native to amyloidogenic transition 
regulated by a backbone trigger. Nat Struct Mol Biol 13, 202-208 
350 Eakin, C.M. and Miranker, A.D. (2005) From chance to frequent encounters: origins of 
beta2-microglobulin fibrillogenesis. Biochim Biophys Acta 1753, 92-99 
351 Yamamoto, S., Hasegawa, K., Yamaguchi, I., Tsutsumi, S., Kardos, J., Goto, Y., Gejyo, F., 
and Naiki, H. (2004) Low concentrations of sodium dodecyl sulfate induce the extension 
of beta 2-microglobulin-related amyloid fibrils at a neutral pH. Biochemistry 43, 11075-
11082 
352 Yamamoto, S., Yamaguchi, I., Hasegawa, K., Tsutsumi, S., Goto, Y., Gejyo, F., and Naiki, H. 
(2004) Glycosaminoglycans enhance the trifluoroethanol-induced extension of beta 2-
microglobulin-related amyloid fibrils at a neutral pH. J Am Soc Nephrol 15, 126-133 
353 Smith, D.P., Jones, S., Serpell, L.C., Sunde, M., and Radford, S.E. (2003) A systematic 
investigation into the effect of protein destabilisation on beta 2-microglobulin amyloid 
formation. J Mol Biol 330, 943-954 
354 Kozhukh, G.V., Hagihara, Y., Kawakami, T., Hasegawa, K., Naiki, H., and Goto, Y. (2002) 
Investigation of a peptide responsible for amyloid fibril formation of beta 2-
microglobulin by achromobacter protease I. J Biol Chem 277, 1310-1315 
355 Jones, S., Manning, J., Kad, N.M., and Radford, S.E. (2003) Amyloid-forming peptides 
from beta2-microglobulin-Insights into the mechanism of fibril formation in vitro. J Mol 
Biol 325, 249-257 
211 
 
356 Platt, G.W., Routledge, K.E., Homans, S.W., and Radford, S.E. (2008) Fibril growth 
kinetics reveal a region of beta2-microglobulin important for nucleation and elongation 
of aggregation. J Mol Biol 378, 251-263 
357 Routledge, K.E., Tartaglia, G.G., Platt, G.W., Vendruscolo, M., and Radford, S.E. (2009) 
Competition between intramolecular and intermolecular interactions in an amyloid-
forming protein. J Mol Biol 389, 776-786 
358 Ivanova, M.I., Sawaya, M.R., Gingery, M., Attinger, A., and Eisenberg, D. (2004) An 
amyloid-forming segment of beta2-microglobulin suggests a molecular model for the 
fibril. Proc Natl Acad Sci U S A 101, 10584-10589 
359 Esposito, G., Michelutti, R., Verdone, G., Viglino, P., Hernandez, H., Robinson, C.V., 
Amoresano, A., Dal Piaz, F., Monti, M., Pucci, P., Mangione, P., Stoppini, M., Merlini, G., 
Ferri, G., and Bellotti, V. (2000) Removal of the N-terminal hexapeptide from human 
beta2-microglobulin facilitates protein aggregation and fibril formation. Protein Sci 9, 
831-845 
360 Bellotti, V., Stoppini, M., Mangione, P., Sunde, M., Robinson, C., Asti, L., Brancaccio, D., 
and Ferri, G. (1998) Beta2-microglobulin can be refolded into a native state from ex vivo 
amyloid fibrils. Eur J Biochem 258, 61-67 
361 Giorgetti, S., Rossi, A., Mangione, P., Raimondi, S., Marini, S., Stoppini, M., Corazza, A., 
Viglino, P., Esposito, G., Cetta, G., Merlini, G., and Bellotti, V. (2005) Beta2-microglobulin 
isoforms display an heterogeneous affinity for type I collagen. Protein Sci 14, 696-702 
362 Eichner, T. and Radford, S.E. (2009) A generic mechanism of beta2-microglobulin 
amyloid assembly at neutral pH involving a specific proline switch. J Mol Biol 386, 1312-
1326 
363 Stoppini, M., Mangione, P., Monti, M., Giorgetti, S., Marchese, L., Arcidiaco, P., Verga, L., 
Segagni, S., Pucci, P., Merlini, G., and Bellotti, V. (2005) Proteomics of beta2-
microglobulin amyloid fibrils. Biochim Biophys Acta 1753, 23-33 
364 Monti, M., Amoresano, A., Giorgetti, S., Bellotti, V., and Pucci, P. (2005) Limited 
proteolysis in the investigation of beta2-microglobulin amyloidogenic and fibrillar states. 
Biochim Biophys Acta 1753, 44-50 
365 McParland, V.J., Kad, N.M., Kalverda, A.P., Brown, A., Kirwin-Jones, P., Hunter, M.G., 
Sunde, M., and Radford, S.E. (2000) Partially unfolded states of beta(2)-microglobulin 
and amyloid formation in vitro. Biochemistry 39, 8735-8746 
366 Jahn, T.R., Tennent, G.A., and Radford, S.E. (2008) A common beta-sheet architecture 
underlies in vitro and in vivo beta2-microglobulin amyloid fibrils. J Biol Chem 283, 17279-
17286 
212 
 
367 Myers, S.L., Jones, S., Jahn, T.R., Morten, I.J., Tennent, G.A., Hewitt, E.W., and Radford, 
S.E. (2006) A systematic study of the effect of physiological factors on beta2-
microglobulin amyloid formation at neutral pH. Biochemistry 45, 2311-2321 
368 Radford, S.E., Gosal, W.S., and Platt, G.W. (2005) Towards an understanding of the 
structural molecular mechanism of beta(2)-microglobulin amyloid formation in vitro. 
Biochim Biophys Acta 1753, 51-63 
369 Biancalana, M. and Koide, S. (2010) Molecular mechanism of Thioflavin-T binding to 
amyloid fibrils. Biochim Biophys Acta 1804, 1405-1412 
370 Zhang, C., Jackson, A.P., Zhang, Z.R., Han, Y., Yu, S., He, R.Q., and Perrett, S. (2010) 
Amyloid-like aggregates of the yeast prion protein ure2 enter vertebrate cells by specific 
endocytotic pathways and induce apoptosis. PLoS One 5 
371 Cecchi, C., Nichino, D., Zampagni, M., Bernacchioni, C., Evangelisti, E., Pensalfini, A., 
Liguri, G., Gliozzi, A., Stefani, M., and Relini, A. (2009) A protective role for lipid raft 
cholesterol against amyloid-induced membrane damage in human neuroblastoma cells. 
Biochim Biophys Acta 1788, 2204-2216 
372 Menaa, C., Esser, E., and Sprague, S.M. (2008) Beta2-microglobulin stimulates osteoclast 
formation. Kidney Int 73, 1275-1281 
373 Mosmann, T. (1983) Rapid colorimetric assay for cellular growth and survival: application 
to proliferation and cytotoxicity assays. J Immunol Methods 65, 55-63 
374 Acerra, N., Kad, N.M., Cheruvara, H., and Mason, J.M. (2014) Intracellular selection of 
peptide inhibitors that target disulphide-bridged Abeta oligomers. Protein Sci  
375 Cipriani, S., Bakshi, R., and Schwarzschild, M.A. (2014) Protection by inosine in a cellular 
model of Parkinson's disease. Neuroscience 274C, 242-249 
376 Zhao, Y., Zhao, H., Lobo, N., Guo, X., Gentleman, S.M., and Ma, D. (2014) Celastrol 
Enhances Cell Viability and Inhibits Amyloid-beta Production Induced by 
Lipopolysaccharide In Vitro. J Alzheimers Dis  
377 Berridge, M.V., Herst, P.M., and Tan, A.S. (2005) Tetrazolium dyes as tools in cell biology: 
new insights into their cellular reduction. Biotechnol Annu Rev 11, 127-152 
378 Liu, Y., Peterson, D.A., Kimura, H., and Schubert, D. (1997) Mechanism of cellular 3-(4,5-
dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide (MTT) reduction. J Neurochem 
69, 581-593 
379 Liu, Y. and Schubert, D. (1997) Cytotoxic amyloid peptides inhibit cellular 3-(4,5-
dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide (MTT) reduction by enhancing 
MTT formazan exocytosis. J Neurochem 69, 2285-2293 
213 
 
380 Isobe, I., Michikawa, M., and Yanagisawa, K. (1999) Enhancement of MTT, a tetrazolium 
salt, exocytosis by amyloid beta-protein and chloroquine in cultured rat astrocytes. 
Neurosci Lett 266, 129-132 
381 Liu, M.L. and Hong, S.T. (2005) Early phase of amyloid beta42-induced cytotoxicity in 
neuronal cells is associated with vacuole formation and enhancement of exocytosis. Exp 
Mol Med 37, 559-566 
382 Wogulis, M., Wright, S., Cunningham, D., Chilcote, T., Powell, K., and Rydel, R.E. (2005) 
Nucleation-dependent polymerization is an essential component of amyloid-mediated 
neuronal cell death. J Neurosci 25, 1071-1080 
383 Hertel, C., Hauser, N., Schubenel, R., Seilheimer, B., and Kemp, J.A. (1996) Beta-amyloid-
induced cell toxicity: enhancement of 3-(4,5-dimethylthiazol-2-yl)-2,5-
diphenyltetrazolium bromide-dependent cell death. J Neurochem 67, 272-276 
384 Xue, W.F. and Radford, S.E. (2013) An imaging and systems modeling approach to fibril 
breakage enables prediction of amyloid behavior. Biophys J 105, 2811-2819 
385 Shorter, J. and Lindquist, S. (2004) Hsp104 catalyzes formation and elimination of self-
replicating Sup35 prion conformers. Science 304, 1793-1797 
386 Hellewell, A. (2011) The Cytotoxicity of Amyloid Fibrils. In Faculty of Biological Sciences, 
University of Leeds 
387 Crouch, S.P., Kozlowski, R., Slater, K.J., and Fletcher, J. (1993) The use of ATP 
bioluminescence as a measure of cell proliferation and cytotoxicity. J Immunol Methods 
160, 81-88 
388 Ghavami, S., Shojaei, S., Yeganeh, B., Ande, S.R., Jangamreddy, J.R., Mehrpour, M., 
Christoffersson, J., Chaabane, W., Moghadam, A.R., Kashani, H.H., Hashemi, M., Owji, 
A.A., and Los, M.J. (2014) Autophagy and apoptosis dysfunction in neurodegenerative 
disorders. Prog Neurobiol 112, 24-49 
389 McBrayer, M. and Nixon, R.A. (2013) Lysosome and calcium dysregulation in Alzheimer's 
disease: partners in crime. Biochem Soc Trans 41, 1495-1502 
390 Garcia-Garcia, M., Argiles, Gouin-Charnet, A., Durfort, M., Garcia-Valero, J., and Mourad, 
G. (1999) Impaired lysosomal processing of beta2-microglobulin by infiltrating 
macrophages in dialysis amyloidosis. Kidney Int 55, 899-906 
391 Kornfeld, S. and Mellman, I. (1989) The biogenesis of lysosomes. Annu Rev Cell Biol 5, 
483-525 
392 Macdonald, P.M. (1992) The Drosophila pumilio gene: an unusually long transcription 
unit and an unusual protein. Development 114, 221-232 
214 
 
393 Zhang, T., Maekawa, Y., Hanba, J., Dainichi, T., Nashed, B.F., Hisaeda, H., Sakai, T., Asao, 
T., Himeno, K., Good, R.A., and Katunuma, N. (2000) Lysosomal cathepsin B plays an 
important role in antigen processing, while cathepsin D is involved in degradation of the 
invariant chain inovalbumin-immunized mice. Immunology 100, 13-20 
394 Hardy, J., Bogdanovic, N., Winblad, B., Portelius, E., Andreasen, N., Cedazo-Minguez, A., 
and Zetterberg, H. (2014) Pathways to Alzheimer's disease. J Intern Med 275, 296-303 
395 Hoang, Q.Q. (2014) Pathway for Parkinson disease. Proc Natl Acad Sci U S A 111, 2402-
2403 
396 Tanida, I., Ueno, T., and Kominami, E. (2008) LC3 and Autophagy. Methods Mol Biol 445, 
77-88 
397 Lorincz, M., Herzenberg, L.A., Diwu, Z., Barranger, J.A., and Kerr, W.G. (1997) Detection 
and isolation of gene-corrected cells in Gaucher disease via a fluorescence-activated cell 
sorter assay for lysosomal glucocerebrosidase activity. Blood 89, 3412-3420 
398 Boot, R.G., Verhoek, M., Donker-Koopman, W., Strijland, A., van Marle, J., Overkleeft, 
H.S., Wennekes, T., and Aerts, J.M. (2007) Identification of the non-lysosomal 
glucosylceramidase as beta-glucosidase 2. J Biol Chem 282, 1305-1312 
399 Zong, D., Zielinska-Chomej, K., Juntti, T., Mork, B., Lewensohn, R., Haag, P., and 
Viktorsson, K. (2014) Harnessing the lysosome-dependent antitumor activity of 
phenothiazines in human small cell lung cancer. Cell Death Dis 5, e1111 
400 Li, Y., Cheng, D., Cheng, R., Zhu, X., Wan, T., Liu, J., and Zhang, R. (2014) Mechanisms of 
U87 astrocytoma cell uptake and trafficking of monomeric versus protofibril Alzheimer's 
disease amyloid-beta proteins. PLoS One 9, e99939 
401 Borghi, R., Marchese, R., Negro, A., Marinelli, L., Forloni, G., Zaccheo, D., Abbruzzese, G., 
and Tabaton, M. (2000) Full length alpha-synuclein is present in cerebrospinal fluid from 
Parkinson's disease and normal subjects. Neurosci Lett 287, 65-67 
402 Visanji, N.P., Brooks, P.L., Hazrati, L.N., and Lang, A.E. (2013) The prion hypothesis in 
Parkinson's disease: Braak to the future. Acta Neuropathol Commun 1, 2 
403 Yu, W.H., Cuervo, A.M., Kumar, A., Peterhoff, C.M., Schmidt, S.D., Lee, J.H., Mohan, P.S., 
Mercken, M., Farmery, M.R., Tjernberg, L.O., Jiang, Y., Duff, K., Uchiyama, Y., Naslund, J., 
Mathews, P.M., Cataldo, A.M., and Nixon, R.A. (2005) Macroautophagy--a novel Beta-
amyloid peptide-generating pathway activated in Alzheimer's disease. J Cell Biol 171, 87-
98 
404 Howell, G.J., Holloway, Z.G., Cobbold, C., Monaco, A.P., and Ponnambalam, S. (2006) Cell 
biology of membrane trafficking in human disease. Int Rev Cytol 252, 1-69 
215 
 
405 Palade, G. (1975) Intracellular aspects of the process of protein synthesis. Science 189, 
347-358 
406 Sollner, T., Whiteheart, S.W., Brunner, M., Erdjument-Bromage, H., Geromanos, S., 
Tempst, P., and Rothman, J.E. (1993) SNAP receptors implicated in vesicle targeting and 
fusion. Nature 362, 318-324 
407 Bennett, M.K. (1995) SNAREs and the specificity of transport vesicle targeting. Curr Opin 
Cell Biol 7, 581-586 
408 Hutagalung, A.H. and Novick, P.J. (2011) Role of Rab GTPases in membrane traffic and 
cell physiology. Physiol Rev 91, 119-149 
409 Dalfo, E., Gomez-Isla, T., Rosa, J.L., Nieto Bodelon, M., Cuadrado Tejedor, M., Barrachina, 
M., Ambrosio, S., and Ferrer, I. (2004) Abnormal alpha-synuclein interactions with Rab 
proteins in alpha-synuclein A30P transgenic mice. J Neuropathol Exp Neurol 63, 302-313 
410 Cooper, A.A., Gitler, A.D., Cashikar, A., Haynes, C.M., Hill, K.J., Bhullar, B., Liu, K., Xu, K., 
Strathearn, K.E., Liu, F., Cao, S., Caldwell, K.A., Caldwell, G.A., Marsischky, G., Kolodner, 
R.D., Labaer, J., Rochet, J.C., Bonini, N.M., and Lindquist, S. (2006) Alpha-synuclein blocks 
ER-Golgi traffic and Rab1 rescues neuron loss in Parkinson's models. Science 313, 324-
328 
411 Gitler, A.D., Bevis, B.J., Shorter, J., Strathearn, K.E., Hamamichi, S., Su, L.J., Caldwell, K.A., 
Caldwell, G.A., Rochet, J.C., McCaffery, J.M., Barlowe, C., and Lindquist, S. (2008) The 
Parkinson's disease protein alpha-synuclein disrupts cellular Rab homeostasis. Proc Natl 
Acad Sci U S A 105, 145-150 
412 MacLeod, D.A., Rhinn, H., Kuwahara, T., Zolin, A., Di Paolo, G., McCabe, B.D., Marder, 
K.S., Honig, L.S., Clark, L.N., Small, S.A., and Abeliovich, A. (2013) RAB7L1 interacts with 
LRRK2 to modify intraneuronal protein sorting and Parkinson's disease risk. Neuron 77, 
425-439 
413 Matlack, K.E., Tardiff, D.F., Narayan, P., Hamamichi, S., Caldwell, K.A., Caldwell, G.A., and 
Lindquist, S. (2014) Clioquinol promotes the degradation of metal-dependent amyloid-
beta (Abeta) oligomers to restore endocytosis and ameliorate Abeta toxicity. Proc Natl 
Acad Sci U S A 111, 4013-4018 
414 Yu, A., Shibata, Y., Shah, B., Calamini, B., Lo, D.C., and Morimoto, R.I. (2014) Protein 
aggregation can inhibit clathrin-mediated endocytosis by chaperone competition. Proc 
Natl Acad Sci U S A 111, E1481-1490 
415 Pols, M.S. and Klumperman, J. (2009) Trafficking and function of the tetraspanin CD63. 
Exp Cell Res 315, 1584-1592 
216 
 
416 Eskelinen, E.L., Tanaka, Y., and Saftig, P. (2003) At the acidic edge: emerging functions 
for lysosomal membrane proteins. Trends Cell Biol 13, 137-145 
417 Akasaki, K., Michihara, A., Mibuka, K., Fujiwara, Y., and Tsuji, H. (1995) Biosynthetic 
transport of a major lysosomal membrane glycoprotein, lamp-1: convergence of 
biosynthetic and endocytic pathways occurs at three distinctive points. Exp Cell Res 220, 
464-473 
418 Medina, D.L., Fraldi, A., Bouche, V., Annunziata, F., Mansueto, G., Spampanato, C., Puri, 
C., Pignata, A., Martina, J.A., Sardiello, M., Palmieri, M., Polishchuk, R., Puertollano, R., 
and Ballabio, A. (2011) Transcriptional activation of lysosomal exocytosis promotes 
cellular clearance. Dev Cell 21, 421-430 
419 Reddy, A., Caler, E.V., and Andrews, N.W. (2001) Plasma membrane repair is mediated 
by Ca(2+)-regulated exocytosis of lysosomes. Cell 106, 157-169 
420 van der Sluijs, P., Zibouche, M., and van Kerkhof, P. (2013) Late steps in secretory 
lysosome exocytosis in cytotoxic lymphocytes. Front Immunol 4, 359 
421 Khalikova, E., Susi, P., and Korpela, T. (2005) Microbial dextran-hydrolyzing enzymes: 
fundamentals and applications. Microbiol Mol Biol Rev 69, 306-325 
422 Ben-Yoseph, Y., Potier, M., Mitchell, D.A., Pack, B.A., Melancon, S.B., and Nadler, H.L. 
(1987) Altered molecular size of N-acetylglucosamine 1-phosphotransferase in I-cell 
disease and pseudo-Hurler polydystrophy. Biochem J 248, 697-701 
423 Settembre, C. and Ballabio, A. (2013) New targets for old diseases: lessons from 
mucolipidosis type II. EMBO Mol Med 5, 1801-1803 
424 Braulke, T. and Bonifacino, J.S. (2009) Sorting of lysosomal proteins. Biochim Biophys 
Acta 1793, 605-614 
425 Dell'Angelica, E.C., Shotelersuk, V., Aguilar, R.C., Gahl, W.A., and Bonifacino, J.S. (1999) 
Altered trafficking of lysosomal proteins in Hermansky-Pudlak syndrome due to 
mutations in the beta 3A subunit of the AP-3 adaptor. Mol Cell 3, 11-21 
426 Doherty, G.J. and McMahon, H.T. (2009) Mechanisms of endocytosis. Annu Rev Biochem 
78, 857-902 
427 Turturici, G., Sconzo, G., and Geraci, F. (2011) Hsp70 and its molecular role in nervous 
system diseases. Biochem Res Int 2011, 618127 
428 Uversky, V.N. (2011) Flexible nets of malleable guardians: intrinsically disordered 
chaperones in neurodegenerative diseases. Chem Rev 111, 1134-1166 
429 Fink, A.L. (1999) Chaperone-mediated protein folding. Physiol Rev 79, 425-449 
430 Ingemann, L. and Kirkegaard, T. (2014) Lysosomal Storage Diseases and the Heat Shock 
Response: Convergences and Therapeutic Opportunities. J Lipid Res  
217 
 
431 Warrick, J.M., Chan, H.Y., Gray-Board, G.L., Chai, Y., Paulson, H.L., and Bonini, N.M. 
(1999) Suppression of polyglutamine-mediated neurodegeneration in Drosophila by the 
molecular chaperone HSP70. Nat Genet 23, 425-428 
432 Cummings, C.J., Sun, Y., Opal, P., Antalffy, B., Mestril, R., Orr, H.T., Dillmann, W.H., and 
Zoghbi, H.Y. (2001) Over-expression of inducible HSP70 chaperone suppresses 
neuropathology and improves motor function in SCA1 mice. Hum Mol Genet 10, 1511-
1518 
433 Adachi, H., Katsuno, M., Minamiyama, M., Sang, C., Pagoulatos, G., Angelidis, C., 
Kusakabe, M., Yoshiki, A., Kobayashi, Y., Doyu, M., and Sobue, G. (2003) Heat shock 
protein 70 chaperone overexpression ameliorates phenotypes of the spinal and bulbar 
muscular atrophy transgenic mouse model by reducing nuclear-localized mutant 
androgen receptor protein. J Neurosci 23, 2203-2211 
434 Klucken, J., Shin, Y., Masliah, E., Hyman, B.T., and McLean, P.J. (2004) Hsp70 Reduces 
alpha-Synuclein Aggregation and Toxicity. J Biol Chem 279, 25497-25502 
435 Guzhova, I., Kislyakova, K., Moskaliova, O., Fridlanskaya, I., Tytell, M., Cheetham, M., and 
Margulis, B. (2001) In vitro studies show that Hsp70 can be released by glia and that 
exogenous Hsp70 can enhance neuronal stress tolerance. Brain Res 914, 66-73 
436 Hightower, L.E. and Guidon, P.T., Jr. (1989) Selective release from cultured mammalian 
cells of heat-shock (stress) proteins that resemble glia-axon transfer proteins. J Cell 
Physiol 138, 257-266 
437 Kakimura, J., Kitamura, Y., Takata, K., Umeki, M., Suzuki, S., Shibagaki, K., Taniguchi, T., 
Nomura, Y., Gebicke-Haerter, P.J., Smith, M.A., Perry, G., and Shimohama, S. (2002) 
Microglial activation and amyloid-beta clearance induced by exogenous heat-shock 
proteins. FASEB J 16, 601-603 
438 Gifondorwa, D.J., Robinson, M.B., Hayes, C.D., Taylor, A.R., Prevette, D.M., Oppenheim, 
R.W., Caress, J., and Milligan, C.E. (2007) Exogenous delivery of heat shock protein 70 
increases lifespan in a mouse model of amyotrophic lateral sclerosis. J Neurosci 27, 
13173-13180 
439 Vitner, E.B., Platt, F.M., and Futerman, A.H. (2010) Common and uncommon pathogenic 
cascades in lysosomal storage diseases. J Biol Chem 285, 20423-20427 
440 Yang, C., Swallows, C.L., Zhang, C., Lu, J., Xiao, H., Brady, R.O., and Zhuang, Z. (2014) 
Celastrol increases glucocerebrosidase activity in Gaucher disease by modulating 
molecular chaperones. Proc Natl Acad Sci U S A 111, 249-254 
441 Kirkegaard, T., Roth, A.G., Petersen, N.H., Mahalka, A.K., Olsen, O.D., Moilanen, I., Zylicz, 
A., Knudsen, J., Sandhoff, K., Arenz, C., Kinnunen, P.K., Nylandsted, J., and Jaattela, M. 
218 
 
(2010) Hsp70 stabilizes lysosomes and reverts Niemann-Pick disease-associated 
lysosomal pathology. Nature 463, 549-553 
442 Mambula, S.S. and Calderwood, S.K. (2006) Heat shock protein 70 is secreted from 
tumor cells by a nonclassical pathway involving lysosomal endosomes. J Immunol 177, 
7849-7857 
443 Hirel, P.H., Schmitter, M.J., Dessen, P., Fayat, G., and Blanquet, S. (1989) Extent of N-
terminal methionine excision from Escherichia coli proteins is governed by the side-
chain length of the penultimate amino acid. Proc Natl Acad Sci U S A 86, 8247-8251 
444 Nylandsted, J., Gyrd-Hansen, M., Danielewicz, A., Fehrenbacher, N., Lademann, U., 
Hoyer-Hansen, M., Weber, E., Multhoff, G., Rohde, M., and Jaattela, M. (2004) Heat 
shock protein 70 promotes cell survival by inhibiting lysosomal membrane 
permeabilization. J Exp Med 200, 425-435 
445 Petersen, N.H., Kirkegaard, T., Olsen, O.D., and Jaattela, M. (2010) Connecting Hsp70, 
sphingolipid metabolism and lysosomal stability. Cell Cycle 9, 2305-2309 
446 Goodchild, S.C., Sheynis, T., Thompson, R., Tipping, K.W., Xue, W.F., Ranson, N.A., 
Beales, P.A., Hewitt, E.W., and Radford, S.E. (2014) beta2-Microglobulin Amyloid Fibril-
Induced Membrane Disruption Is Enhanced by Endosomal Lipids and Acidic pH. PLoS One 
9, e104492 
447 Dedmon, M.M., Christodoulou, J., Wilson, M.R., and Dobson, C.M. (2005) Heat shock 
protein 70 inhibits alpha-synuclein fibril formation via preferential binding to prefibrillar 
species. J Biol Chem 280, 14733-14740 
448 Huang, C., Cheng, H., Hao, S., Zhou, H., Zhang, X., Gao, J., Sun, Q.H., Hu, H., and Wang, 
C.C. (2006) Heat shock protein 70 inhibits alpha-synuclein fibril formation via 
interactions with diverse intermediates. J Mol Biol 364, 323-336 
449 Pemberton, S., Madiona, K., Pieri, L., Kabani, M., Bousset, L., and Melki, R. (2011) Hsc70 
protein interaction with soluble and fibrillar alpha-synuclein. J Biol Chem 286, 34690-
34699 
450 Singh, L.R., Gupta, S., Honig, N.H., Kraus, J.P., and Kruger, W.D. (2010) Activation of 
mutant enzyme function in vivo by proteasome inhibitors and treatments that induce 
Hsp70. PLoS Genet 6, e1000807 
451 Kalmar, B., Lu, C.H., and Greensmith, L. (2014) The role of heat shock proteins in 
Amyotrophic Lateral Sclerosis: The therapeutic potential of Arimoclomol. Pharmacol 
Ther 141, 40-54 
452 Cleren, C., Calingasan, N.Y., Chen, J., and Beal, M.F. (2005) Celastrol protects against 
MPTP- and 3-nitropropionic acid-induced neurotoxicity. J Neurochem 94, 995-1004 
219 
 
453 Wang, J., Gines, S., MacDonald, M.E., and Gusella, J.F. (2005) Reversal of a full-length 
mutant huntingtin neuronal cell phenotype by chemical inhibitors of polyglutamine-
mediated aggregation. BMC Neurosci 6, 1 
454 Kiaei, M., Kipiani, K., Petri, S., Chen, J., Calingasan, N.Y., and Beal, M.F. (2005) Celastrol 
blocks neuronal cell death and extends life in transgenic mouse model of amyotrophic 
lateral sclerosis. Neurodegener Dis 2, 246-254 
455 Riedel, M., Goldbaum, O., Schwarz, L., Schmitt, S., and Richter-Landsberg, C. (2010) 17-
AAG induces cytoplasmic alpha-synuclein aggregate clearance by induction of 
autophagy. PLoS One 5, e8753 
456 Waza, M., Adachi, H., Katsuno, M., Minamiyama, M., Sang, C., Tanaka, F., Inukai, A., 
Doyu, M., and Sobue, G. (2005) 17-AAG, an Hsp90 inhibitor, ameliorates polyglutamine-
mediated motor neuron degeneration. Nat Med 11, 1088-1095 
457 Kieran, D., Kalmar, B., Dick, J.R., Riddoch-Contreras, J., Burnstock, G., and Greensmith, L. 
(2004) Treatment with arimoclomol, a coinducer of heat shock proteins, delays disease 
progression in ALS mice. Nat Med 10, 402-405 
458 Kalmar, B., Novoselov, S., Gray, A., Cheetham, M.E., Margulis, B., and Greensmith, L. 
(2008) Late stage treatment with arimoclomol delays disease progression and prevents 
protein aggregation in the SOD1 mouse model of ALS. J Neurochem 107, 339-350 
459 Malik, B., Nirmalananthan, N., Gray, A.L., La Spada, A.R., Hanna, M.G., and Greensmith, 
L. (2013) Co-induction of the heat shock response ameliorates disease progression in a 
mouse model of human spinal and bulbar muscular atrophy: implications for therapy. 
Brain 136, 926-943 
460 Sims, N.A. and Gooi, J.H. (2008) Bone remodeling: Multiple cellular interactions required 
for coupling of bone formation and resorption. Semin Cell Dev Biol 19, 444-451 
461 Motley, A., Bright, N.A., Seaman, M.N., and Robinson, M.S. (2003) Clathrin-mediated 
endocytosis in AP-2-depleted cells. J Cell Biol 162, 909-918 
462 Kirkegaard, T. (2013) Emerging therapies and therapeutic concepts for lysosomal storage 
diseases. Expert Opinion on Orphan Drugs 1, 385-404 
463 Tsunemi, T., Ashe, T.D., Morrison, B.E., Soriano, K.R., Au, J., Roque, R.A., Lazarowski, E.R., 
Damian, V.A., Masliah, E., and La Spada, A.R. (2012) PGC-1alpha rescues Huntington's 
disease proteotoxicity by preventing oxidative stress and promoting TFEB function. Sci 
Transl Med 4, 142ra197 
 
 
